



100 वर्षों तक स्वस्थ,  
सुखी व सम्पन्न जीने के लिए



# JEENA SIKHO LIFECARE LIMITED

REGD OFFICE: ZIRAKPUR, SCO 11, Kalgidhar Enclave, Baltana, 98283-91602, 98764-03632

DELHI, NEW MULTAN NAGAR : B-26, Opp. Metro Pillar No. 223, Rohtak Road, 98554-87770, 95554-61115

CIN NO.: U52601PB2017PLC046545

Email ID.: contact@jeenasikho.co.in

Ref. No. ....

Dated .....

To,

The Manager,  
Listing Compliance Department  
National Stock Exchange of India Ltd.  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai-400051

SYMBOL: JSLL  
ISIN: INE0J5801011

SUB: INTIMATION FOR 5<sup>th</sup> ANNUAL REPORT FOR THE YEAR ENDED 31<sup>ST</sup> MARCH, 2022 REGULATION 34(1) OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015.

Dear Sir/Ma'am,

In reference to captioned subject, we would like to submit the 5<sup>th</sup> Annual Report for the year ended on 31<sup>st</sup> March, 2022 as per Regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

You are requested to take the same in your kind record.


Thanks & Regards

For and on behalf of JEENA SIKHO LIFECARE LIMITED

Auth. Sign.

Nikita Juneja  
Compliance Officer

Encl: 5<sup>th</sup> Annual Report of Jeena Sikho Lifecare Limited



# **JEENA SIKHO LIFECARE LIMITED**

**5<sup>TH</sup> ANNUAL REPORT  
2021-2022**

**Building the Balance of Science with Tradition**

SCO 11 FIRST FLOOR, KALGIDHAR  
ENCLAVE  
ZIRAKPUR, MOHALI  
PUNJAB 140604

01762-513185  
[cs@jeenasikho.co.in](mailto:cs@jeenasikho.co.in)

## CONTENT

<b>S. No.</b>	<b>Particulars</b>	<b>Page No.</b>
1	Corporate Information	3
2	Chairman Letter	4
3	About company	5
4	Our Presence	6
5	HIIMS and Panchkarma in India	7
6	Our Clinics	8
7	Top 10 selling products	12
8	Notice of AGM	13
9	Board Report and Annexures	26
10	Certification by CFO	59
11	Management Discussion and Analysis Report	60
12	Standalone Financials	68
13	Consolidated Financials	101

## CORPORATE INFORMATION

### **BOARD OF DIRECTORS**

Manish Grover  
(Managing Director,  
Chairman)  
Bhavna Grover  
(Whole-Time Director)  
Shreya Grover  
(Director)  
Suraj Prakash Choudhary  
(Independent Director)  
Karan Vir Bindra  
(Independent Director)

### **KEY MANAGERIAL PERSONNEL**

Manish Grover  
(Managing Director,  
Nanak Chand  
(Chief Financial Officer)  
Nikita Juneja  
(Company Secretary)

### **COMMITTEES**

#### **AUDIT COMMITTEES**

Suraj Kumar Choudhary  
Karan Vir Bindra  
Manish Grover

#### **NOMINATION & REMUNERATION COMMITTEE**

Karan Vir Bindra  
Suraj Kumar Choudhary  
Shreya Grover

#### **STAKEHOLDER RELATIONSHIP COMMITTEE**

Suraj Kumar Choudhary  
Manish Grover  
Bhavna Grover

#### **CSR COMMITTEE**

Karan Vir Bindra  
Manish Grover  
Bhavna Grover

### **STATUTORY AUDITOR**

M/s KRA & Co.  
Chartered Accountants

### **BANKERS**

AXIS Bank Ltd  
Yes Bank Ltd  
HDFC Bank Ltd  
Kotak Mahindra Bank

### **REGISTRAR AND TRANSFER AGENTS**

Skyline Financial Services Private  
Limited

## CHAIRMAN'S LETTER



**Dear Stakeholders,**

Dear Shareholders,



It brings me immense pleasure to put forth the 5<sup>th</sup> Annual Report of your Company, Jeena Sikho Lifecare Limited for the Financial Year 2021-2022. I would like to thank all our shareholders who have reposed their trust in the Company during the Initial Public Offering.

We are coming back to our normal life after two years of Covid19 pandemic. Whatever happened is in past, we have to look towards the future and build a great society consist of good-hearted people who look for each other. I would like to place on record my appreciation on behalf of the Board of Directors of the entire Jeena Sikho family who has worked tirelessly even in exceptional circumstances for the greater good of the society.

Our company also suffered due to this global pandemic and now we are in transition period, collecting our pieces together and held our head high. While the Indian economy is still struggling to overcome the rippling effects of the COVID-19 pandemic, we have reported another year of steady revenue growth.

While we are applying our learnings from the last two years of the pandemic to enhance the efficiencies of our operations and build robust supply chains to function with minimum disruption in such exceptional circumstances, we also plan on reassessing our business continuity plan this year to come up with better synergies.

Our people are our most valuable asset, with their commitment and dedication, I am confident that we will continue to meet the demands of our consumers, live up to their expectations by providing long-term value, and generate sustainable long-term growth. While we acknowledge the progress that has been made, we also understand that we still have a long way to go.

I would like to take this opportunity to thank the Board of Directors and our advisors for their continued guidance and trust. I would also like to thank our shareholders and customers for their unwavering support and faith in us and for making Jeena Sikho, India's most trusted name. I look forward to your continued support while we remain committed to delivering quality.

We look forward to the future with excitement. We are at an early stage but we are very optimistic. Take care.

Sincerely  
Manish Grover  
Chairman

## ABOUT THE COMPANY

Jeena Sikho Lifecare Limited is ayurvedic healthcare company headquartered in Zirakpur, Punjab. The company is founded by Mr. Manish Grover (popularly known as Acharya Manish) in the year 2017, with a motive to build a healthy India through preventive measures by providing authentic and good quality ayurvedic products.

Ayurveda is an alternative medical system with historical roots in Indian subcontinent. The origin of Ayurveda dates back to the Vedic era. It was developed more than 3,000 years ago in India. It's based on the belief that health and wellness depend on a delicate balance between the mind, body, and spirit.

The main goal is to promote good health, not fight disease. Ayurvedic theory states that all areas of life impact one's health, so it follows that the Vedas cover a wide variety of topics, including health and health care techniques, astrology, spirituality, government and politics, art, and human behaviour.

The promoters of our company have been engaged in ayurvedic healthcare product & services since last ten years. The company has portfolio of over a wide range of Ayurvedic products. And engaged in health check-up camps and yoga sessions free of cost to make people aware of their health problems.

### **Our Brand "SHUDDHI"**

Shuddhi Ayurveda is an essential and authentic Ayurveda brand that believes in delivering natural care to your body, mind and soul with the methodologies of ancient Ayurveda. Shuddhi Ayurveda has become a quintessential brand that combines ancient Ayurveda with modern aesthetics to provide effective and purifying remedies for improving health. We research and gather learning of ancient methodologies for crafting naturally extracted healing remedies for health's benefit.

Shuddhi, is crafted with threads of knowledge and a practice in Ayurveda, Acharya Manish Ji. The distinct therapy at Shuddhi is based not just on ayurvedic products, but a holistic practice of complete change of lifestyle. It allows you to make significant changes in life that is kept close to nature by adopting a disciplined lifestyle.

We use the finest quality herbs to craft exceptional quality ayurvedic remedies for enhancing good health. Every remedy is infused with 100% pure nutrients extracted from nature to nourish your body uniquely.

## OUR PRESENCE

As you know JEENA SIKHO is an organization where we teach people to live and for this, we initiated many campaigns and services. And after the establishment of specialized organizations like **Shuddhi Ayurveda Clinics and Panchkarma and HIIMS Hospital** by Acharya Manish Ji, people took immense benefits. Today, people have started adopting Ayurveda not only in India but also abroad and have started moving ahead with it. And to make this possible Acharya Ji and his organizations have contributed a lot.

At the same time, the way people's serious illness is being cured in HIIMS in a very natural way without any modern medicine remains a matter of surprise for the people. There was a time when an organ transplant was the last option for someone having Kidney or liver failure. But HIIMS Hospital and its branches have proved such concepts completely wrong.

Even patients with kidney failure who are undergoing dialysis thrice a week, are getting rid of their problems. In addition to this, their same kidney is also getting healthy again and their dialysis is being stopped. And for these all not a single modern medicine or modern technology is being utilized, but ancient medical systems like Ayurveda, Naturopath and Panchkarma are being used.

HIIMS is a hospital where every problem related to health is treated from the root. Even serious, incurable and life-threatening diseases like BP, Sugar, Cancer, Asthma, Liver Failure, and Kidney Failure are also being cured naturally at HIIMS.

So, if you are also suffering from any health-related problem and want to heal yourself without any additional harm. Then the specialized medical system of HIIMS and its natural therapies can help you entirely. In daily routine and treatment procedures food, lifestyle, yoga and meditation are as much important as natural therapies and Ayurvedic medicines are! So without any extra worries, you can directly contact HIIMS for your healthy and long life.

### **Shuddhi Ayurveda Panchkarma Hospital (HIIMS)**

Shuddhi Ayurveda Panchkarma Hospital is a unit of Jeena Sikho Lifecare Limited. It is accredited by NABH, a constituent Board of Quality Council of India. It is established to deliver effective traditional treatments that not only improve the health but also the quality of life.

It is an integrated hospital and has taken the task of providing superior treatment in a variety of ways to reduce the disease's fundamental causes. It develops natural remedies for health-related problems. Furthermore, our specialised medical team, provides the care facilities, medications, therapies, and nutritional meals to ensure that the patient has a positive vibe to help them overcome their negative feelings.

It provides treatment by different methods such as Ayurveda, Allopathy, Homeopathy and Naturopathy.

## HIIMS and Panchkarma in India

### HIIMS and Panchkarma in India

Sr. No.	Hospital	Location
1	<b>HIIMS-Zirakpur</b>	SCO 11, Kalgidhar Enclave, Shimla-Kalka Highway Landmark-Near K-Area Light Point, Baltana Zirakpur, Punjab 140603
2	<b>HIIMS-Derabassi</b>	Land Khata Ni. 9/11, Devinagar, Punjab 140507
3	<b>HIIMS-JAIPUR</b>	E-19, New Light Colony, Under Bhaskar Flyover, Jaipur, Rajasthan 302018, Landmark- Gopalpura mod
4	<b>HIIMS-Gurgaram</b>	S.C.O No. 42, Old Judicial Complex, Gurugram-122001
5	<b>HIIMS-Amritsar</b>	B-13, Block-B, Ranjeet Avenue, Landmark-Near Green Avenue, Golden Sarovar Portico Amritsar, Punjab 143001
6	<b>HIIMS-Delhi</b>	Plot-B-26, Opposite to Metro Pillar No. 223, Rohtak Road, New Multan Nagar, New Delhi, Delhi 110063
7	<b>HIIMS-Lucknow</b>	Revathy Resorts, located at Sewa Nagar, Khasra No. 1039, Kamlabad Badhauli, Sitapur Road, Lucknow, Uttar Pradesh- 226201
8	<b>Panchkarma - Sangrur</b>	No.157-D, Street-4, Mehal, Mubarak Colony , Sangrur, Pincode - 148001
9	<b>HIIMS-Ludhiana</b>	SCO.12-13, Lajpat Nagar, Landmark-Beneath the Flyover, Opposite Bus Stand, Ludhiana, Punjab 141001
10	<b>HIIMS-KOTA</b>	1-C-3, SFS, Sheela Choudhary Road Talwandi Kota, Rajasthan 324005
11	<b>Panchkarma - GOA</b>	H.No 882, Ground Floor, lane no 1 Provorim, Near Sanjay School Pundalik Nagar Goa, 403521
12	<b>HIIMS-Faridabad</b>	Shop No.2, 3 & 4 Sushma Complex Near Ajronda Chwak,Sector -20B Near Neelam Flyover, Faridabad- 121001
13	<b>Panchkarma - Noida</b>	Awana complex Ground floor , Sector-49, Main Dadri Road, Barola, New Yamaha Vihar, Noida 201301
14	<b>Panchkarma - Ghaziabad</b>	C-34 Ground Floor, RDC Raj Nagar, Old Ghaziabad, 201002
15.	<b>Panchkarma - Patiala</b>	House No. 54-B, Vikas Colony, Near Sarhandi Gate &SBI Sewa Kendra, Rajpura Road, Patiala-147001
16.	<b>Panchkarma - Vaishali</b>	Plot -640, Ground Floor, Sector 5, Vaishali Ghaziabad, 201014

## Our Clinics

Sr. No.	Name	Location	State	Remarks
1	Jeena Sikho Lifecare Ltd-Laxminagar	Laxminagar	Delhi	Owned Clinic
2	Jeena Sikho Lifecare Limited-Faridabad	Faridabad	Haryana	Owned Clinic
3	Jeena Sikho Lifecare Limited-Abohar	Abohar	Punjab	Owned Clinic
4	Jeena Sikho Lifecare Limited-Moga	Moga	Punjab	Owned Clinic
5	Jeena Sikho Lifecare Limited-Hyderabad	Hyderabad	Telangana	Owned Clinic
6	Jeena Sikho Lifecare Limited-Allahabad	Allahabad	Uttar Pradesh	Owned Clinic
7	Jeena Sikho Lifecare Limited - Noida	Noida	Uttar Pradesh	Owned Clinic
8	M/s Shri Ganesha Enterprises	Guwahati	Assam	Franchised Clinic
9	Ayurveda Health Care Centre	Gopalganj	Bihar	Franchised Clinic
10	Balaji Unique Sky - Clinic	Sasaram	Bihar	Franchised Clinic
11	Jeetendra Medicine House-Hajipur	Hajipur	Bihar	Franchised Clinic
12	Kanhaiya Trading	Begusarai	Bihar	Franchised Clinic
13	M/s Shivshakti Aayurvedic Sansthan	Bhagalpur	Bihar	Franchised Clinic
14	M/s Shivshakti Aayurvedic Sansthan-Purnia Clinic	Purnia	Bihar	Franchised Clinic
15	Sai Ayurved Sansthan	Gaya	Bihar	Franchised Clinic
16	Sanjivani Lifecare	Madhubani	Bihar	Franchised Clinic
17	Shivani Ayurved Kendra	Raxaul	Bihar	Franchised Clinic
18	Tele Trend - Clinic	Patna	Bihar	Franchised Clinic
19	Jeena Seekho Seva Kalyan Kendra - Raipur	Raipur	Chattishgarh	Franchised Clinic
20	M/s H.K Global-Durg	Durg	Chattishgarh	Franchised Clinic
21	Jai Shree Shyam Pharmacy	Pritampura	Delhi	Franchised Clinic
22	Jindal Pharmacy	Dwarka	Delhi	Franchised Clinic
23	Madhav Health Care	Rajnendra Nagar	Delhi	Franchised Clinic
24	M/S Ghunawat Health Care	New Friend Colony	Delhi	Franchised Clinic
25	Radhey Radhey Pharmacy	Rohini	Delhi	Franchised Clinic
26	Shri Kunj Bihari Pharmacy	Shastri Nagar	Delhi	Franchised Clinic
27	MG Pharma & Equipments	Hauz Khas	Delhi	Franchised Clinic
28	Gold Care - Clinic	Ahmedabad	Gujarat	Franchised Clinic
29	Gold Care-Rajkot	Rajkot	Gujarat	Franchised Clinic
30	Gold Care-Surat Clinic	Surat	Gujarat	Franchised Clinic
31	Gold Care-Vadodara Clinic	Vadodra	Gujarat	Franchised Clinic
32	Jai Vijay Agency-Clinic	Mehsana	Gujarat	Franchised Clinic

33	Shree Namdev Healthcare-Gandhinagar	Gandhinagar	Gujarat	Franchised Clinic
34	D S Healthcare	Panipat	Haryana	Franchised Clinic
35	Industrial Distributors-New Sirsa	Sirsa	Haryana	Franchised Clinic
36	Life Coach	Jind	Haryana	Franchised Clinic
37	Life Coach-Rohtak Clinic	Rohtak	Haryana	Franchised Clinic
38	Mishvi Enterprises	Sonipat	Haryana	Franchised Clinic
39	M/s Shri Balaji Ayurvedic	Hisar	Haryana	Franchised Clinic
40	M/S Uma Ayurvedic	Bhiwani	Haryana	Franchised Clinic
41	Nidhi Enterprise-Jamnagar	Jamnagar	Haryana	Franchised Clinic
42	Preet Enterprises	Yamunanagar	Haryana	Franchised Clinic
43	Radhey Health Care Centre	Ambala	Haryana	Franchised Clinic
44	Shri Mahadev Ayurvedic	Karnal	Haryana	Franchised Clinic
45	Divya Jyoti Chikitsalaya	Shimla	Himachal Pradesh	Franchised Clinic
46	M M Agency-Clinic	Una	Himachal Pradesh	Franchised Clinic
47	M/S Dev Bhoomi Nirog Sanstha	Hamirpur	Himachal Pradesh	Franchised Clinic
48	M/s Shiv Clinic	Dharamshala	Himachal Pradesh	Franchised Clinic
49	Narang Ayur Care	Solan	Himachal Pradesh	Franchised Clinic
50	Ram Chander Sharma -Kangra Clinic	Kangra	Himachal Pradesh	Franchised Clinic
51	Telexpress-New Bilaspur	Bilaspur	Himachal Pradesh	Franchised Clinic
52	D.S Enterprises-Clinic	Jammu	J & K	Franchised Clinic
53	Gaurav Enterprises-Clinic	Ramgarh	Jharkhand	Franchised Clinic
54	Jeetendra Medicine House-Hazaribag	Hazaribhag	Jharkhand	Franchised Clinic
55	M G Pharma and Equipments	Ranchi	Jharkhand	Franchised Clinic
56	M/s Jeetendra Medicine House	Bokaro	Jharkhand	Franchised Clinic
57	Rudraex - Clinic	Dhanwad	Jharkhand	Franchised Clinic
58	Shivaaex	Jamshedpur	Jharkhand	Franchised Clinic
59	Aarogyam Enterprises- Indore Clinic	Indore	Madhya Pradesh	Franchised Clinic
60	Nimansh Ayurveda	Bhopal	Madhya Pradesh	Franchised Clinic
61	Yashi Healthcare	Gwalior	Madhya Pradesh	Franchised Clinic
62	Ayushi Marketing-Nanded	Nanded	Maharashtra	Franchised Clinic
63	Ekdant Agency-Chandrapur Clinic	Chanderpur	Maharashtra	Franchised Clinic
64	Gaonkar Dot Ecom	Solapur	Maharashtra	Franchised Clinic
65	Lakhan Traders-Buldhana Clinic	Buldana	Maharashtra	Franchised Clinic
66	Manish Enterprises	Jalgaon	Maharashtra	Franchised Clinic

67	Shree Agencies - Clinic	Nagpur	Maharashtra	Franchised Clinic
68	Twin Industries-Aurangabad	New Aurangabad	Maharashtra	Franchised Clinic
69	Twin Industries-Clinic	Pune	Maharashtra	Franchised Clinic
70	Twin Industries-Nashik Clinic	Nasik	Maharashtra	Franchised Clinic
71	Bidwan Engicon Trade and Service Pvt Ltd-Cuttack	Cuttack	Odisha	Franchised Clinic
72	Bidwan Engicon Trade and Services Pvt.Ltd-Clinic	Bhubaneshwar	Odisha	Franchised Clinic
73	Bidwan Engicon Trade and Services Pvt.Ltd-Sambalpur	Sambalpur	Odisha	Franchised Clinic
74	Aarogyam Enterprises-Hoshiarpur	Hoshiarpur	Punjab	Franchised Clinic
75	DN Enterprises	Jalandhar	Punjab	Franchised Clinic
76	Industrial Distributors	Bathinda	Punjab	Franchised Clinic
77	N.K Pharmaceuticals	Gurdaspur	Punjab	Franchised Clinic
78	Sainison Enterprises	Pathankot	Punjab	Franchised Clinic
79	Saraswati Impex-Clinic	Firozpur	Punjab	Franchised Clinic
80	Sukhman Enterprises	Kapurthla	Punjab	Franchised Clinic
81	Aarogyam Enterprises	Alwar	Rajasthan	Franchised Clinic
82	C T Square Ventures	Ajmer	Rajasthan	Franchised Clinic
83	Jai Shree Balaji Enterprises	Jodhpur	Rajasthan	Franchised Clinic
84	Kochar Enterprises-Clinic	Ganga Nagar	Rajasthan	Franchised Clinic
85	OM Health Care	Udaypur	Rajasthan	Franchised Clinic
86	Vanshika Enterprises-Bikaner	Bikaner	Rajasthan	Franchised Clinic
87	Balaji Health Care	Agartala	Tripura	Franchised Clinic
88	Dheeraj Enterprises-Clinic	Agra	Uttar Pradesh	Franchised Clinic
89	Dheeraj Enterprises-Kanpur Clinic	Kanpur	Uttar Pradesh	Franchised Clinic
90	Dheeraj Enterprises-Mathura	Mathura	Uttar Pradesh	Franchised Clinic
91	Dheeraj Enterprises-Saharanpur	Saharanpur	Uttar Pradesh	Franchised Clinic
92	Divya Arogya Kendra Tirhut Mandal	Mujaffarpur	Uttar Pradesh	Franchised Clinic
93	Kritika Healthcare	Moradabad	Uttar Pradesh	Franchised Clinic
94	Kritika Healthcare-Muzaffarnagar	Mujaffarnagar	Uttar Pradesh	Franchised Clinic
95	Mahi Ayurveda Healthcare-Ghazipur	Gazipur	Uttar Pradesh	Franchised Clinic
96	M/S Chahal Traders	Meerut	Uttar Pradesh	Franchised Clinic
97	M/s Madhu Enterprises	Bulandshahar	Uttar Pradesh	Franchised Clinic
98	Sainison Enterprises	Pathankot	Punjab	Franchised Clinic
99	M/s Saurabh Sky World-Azamgarh	Azamgarh	Uttar Pradesh	Franchised Clinic
100	Om Point	Faizabad	Uttar Pradesh	Franchised Clinic
101	Shanti Healthcares	Jhansi	Uttar Pradesh	Franchised Clinic
102	Shivam Ayurved Kendra	Varanashi	Uttar Pradesh	Franchised Clinic
103	Shyam Jee Enterprises	Bareilly	Uttar Pradesh	Franchised Clinic
104	Shyam Jee Enterprises-Aligarh	Aligarh	Uttar Pradesh	Franchised Clinic
105	Ajay Ayurveda	Rishikesh	Uttarakhand	Franchised Clinic
106	Shavks Distributor-Clinic	Dehradun	Uttarakhand	Franchised Clinic

107	Shavks Distributor-Haridwar	Haridwar	Uttarakhand	Franchised Clinic
108	Shreya Traders	Rudarpur	Uttarakhand	Franchised Clinic
109	Shyam Jee Enterprises-Haldwani	Haldwani	Uttarakhand	Franchised Clinic
110	Rudraex-Bardhaman	BARDHAMAN	West Bengal	Franchised Clinic
111	Rudraex-North Kolkata	North Kolkata	West Bengal	Franchised Clinic
112	Satyam Communication-Malda	Malda	West Bengal	Franchised Clinic
113	Shree Siddhi Vinayak Ayurvedic Sansthan	Siliguri	West Bengal	Franchised Clinic



**Our Top 10 Selling Products across India**

Sr no.	Product Name
1	Dr Suddhi Powder 100 gm
2	Dr. Immune Tablet 80 Tab
3	Dm Capsule 60 Cap
4	Divya Liver Tonic 450ML Black
5	Dhatu Poshak Vati
6	Divya Chander Vati 60 tab
7	Divya CKD 500ml
8	Kidney Care 450ml Black
9	Nefron Plus Capsule
10	Divya Brahm Vati 60 Tab



## NOTICE

**NOTICE IS HEREBY GIVEN THAT THE 05<sup>TH</sup> ANNUAL GENERAL MEETING OF THE MEMBERS OF JEENA SIKHO LIFECARE LIMITED WILL BE HELD ON THURSDAY, SEPTEMBER 29, 2022 AT SHUDDHI AYURVEDA PANCHKARMA HOSPITAL, PIND DEVINAGAR, HADBAST NO. 18 TEHSIL, DERABASSI DIST, PUNJAB 140507 AT 12 NOON TO TRANSACT THE FOLLOWING BUSINESS :-**

### **ORDINARY BUSINESS**

To consider and if thought fit, to pass with or without modification(s), the following resolution as Ordinary Resolution:

1. To receive, consider and adopt
  - a. the Audited Standalone Financial Statements of the Company for the financial period ended on 31<sup>st</sup> March 2022 together with the reports of Directors and Auditors thereon.
  - b. the Audited Consolidated Financial Statements of the Company for the financial period ended on 31<sup>st</sup> March 2022 together with the reports Auditors thereon.
2. To re-appoint Mr. Manish Grover as a Director who retires by rotation & being eligible offers himself for re-appointment.

### **SPECIAL BUSINESS**

To consider and if thought fit, to pass with or without modification(s), the following resolution as Special Resolution:

3. To Fix remuneration of Mr. Manish Grover, Managing Director of the company.

**“RESOLVED THAT** pursuant to the recommendation of Nomination and Remuneration Committee and pursuant to the provision of section 197, 198, 203 and other applicable provisions, if any of the Companies Act, 2013 and Companies (Appointment and remuneration of managerial personnel) Rules, 2014 (including rules notifications, any statutory modification, amendment or re-enactment thereof for the time being in force and as may enacted from time to time) read with schedule V of the said Act, and such other approval permissions and sanctions of such authorities and/or agencies as may be required in this regard and subject to the provisions of Article of Association of the Company, the approval of the Members be and is hereby accorded for fixation of limit of remuneration of Mr. Manish Grover (DIN : 07557886), Managing Director of the Company with effect from April 1, 2022 to March 31, 2023 as mentioned below:

Basic Salary and Allowances upto Rs 240.00 Lakhs.

**RESOLVED FURTHER THAT** notwithstanding anything contained in Section 197, 198 and Schedule V of the Companies Act, 2013 or any amendment/re-enactment thereof or any revised/new schedule thereof, in the event of absence of profits or inadequate profits in any

financial year, the salary, perquisites and statutory benefits, as set out in the explanatory statement forming part of this resolution be paid as minimum remuneration to Mr. Manish Grover, Managing Director.

**RESOLVED FURTHER THAT** the Board of Directors of the Company be and is hereby authorized to do all such acts, deeds and things, to enter into such agreement(s), deed(s) of amendment(s) or any such document(s), as the Board may, in its absolute discretion, consider necessary, expedient or desirable including power to sub-delegate, in order to give effect to this resolution or as otherwise considered by the Board to be in the best interest of the Company, as it may deem fit.”

4. To Fix remuneration of Mrs. Bhavna Grover, Whole-Time Director of the company.

**“RESOLVED THAT** pursuant to the recommendation of Nomination and Remuneration Committee and pursuant to the provision of section 197, 198, 203 and other applicable provisions, if any of the Companies Act, 2013 and Companies (Appointment and remuneration of managerial personnel) Rules, 2014 (including rules notifications, any statutory modification, amendment or re-enactment thereof for the time being in force and as may enacted from time to time) read with schedule V of the said Act, and such other approval permissions and sanctions of such authorities and/or agencies as may be required in this regard and subject to the provisions of Article of Association of the Company, the approval of the Members be and is hereby accorded for fixation of limit of remuneration of Mrs. Bhavna Grover (DIN: 07557913), Whole-Time Director of the Company with effect from April 1, 2022 to March 31, 2023 as mentioned below:

Basic Salary and Allowances upto Rs 180.00 Lakhs.

**RESOLVED FURTHER THAT** notwithstanding anything contained in Section 197, 198 and Schedule V of the Companies Act, 2013 or any amendment/re-enactment thereof or any revised/new schedule thereof, in the event of absence of profits or inadequate profits in any financial year, the salary, perquisites and statutory benefits, as set out in the explanatory statement forming part of this resolution be paid as minimum remuneration to Mrs. Bhavna Grover, Whole-Time Director.

**RESOLVED FURTHER THAT** the Board of Directors of the Company be and is hereby authorized to do all such acts, deeds and things, to enter into such agreement(s), deed(s) of amendment(s) or any such document(s), as the Board may, in its absolute discretion, consider necessary, expedient or desirable including power to sub-delegate, in order to give effect to this resolution or as otherwise considered by the Board to be in the best interest of the Company, as it may deem fit.”

5. To approve related party transactions.  
To consider and if thought fit, to pass with or without modification(s), the following resolution as Ordinary Resolution:

**“RESOLVED THAT**, pursuant to the provisions of Section 188 of the Companies Act, 2013 and Rule 15 of the Companies (Meetings of Board and its Powers) Rules, 2014 and other applicable provisions and rules thereto, and Regulation 23 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, if applicable and subject to such amendments as may be made therein, the approval of the Members of the Company be and is hereby accorded to the Board of Directors of the Company to enter into transactions as detailed hereunder with following Related Parties as defined under the Act for purchase/sale of goods, services and/or any other business activities during the financial year 2022-23.

<b>Name of Related Party</b>	<b>Maximum Amount of Transaction</b>	<b>Type of Transaction</b>
Divya Upchar Sansthan	10 crore	Sale/Purchase of goods or services
Finest Tech Solution Pvt Ltd	2 crore	Sale/Purchase of goods or services

**By Order of the Board of Directors  
For JEENA SIKHO LIFECARE LIMITED**

Sd/-

**(Nikita Juneja)  
(Company Secretary)**

**Dated: 05/09/2022**

**Place: Chandigarh**

**ANNEXURE TO ITEM NO. 2**

**DETAILS OF DIRECTORS SEEKING APPOINTMENT / RE-APPOINTMENT AS REQUIRED UNDER REGULATION 36(3) OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 ('SEBI LISTING REGULATIONS')**

<b>Name of Director</b>	<b>Mr. Manish Grover</b>
<b>DIN</b>	07557886
<b>Date Of Birth</b>	May 06, 1974
<b>Age</b>	48
<b>Date of Appointment on Board of company</b>	May 29, 2017 as Director August 25, 2021 as Managing Director
<b>Education Qualification</b>	B.Com
<b>Relationship with KMP and Directors</b>	Father of Shreya Grover, Spouse of Bhavna Grover
<b>Shareholding in company</b>	9005360 shares (Promoter)
<b>Experience (in years)</b>	Ten Years
<b>Area of Expertise</b>	Preacher Of Ayurvedic Healthcare
<b>Directorship in other public/ private company</b>	<ul style="list-style-type: none"> <li>• Jeena Sikho Foundation,</li> <li>• Sab Kuch Tera Foundation</li> <li>• Divya Seva Sanstha LLP</li> <li>• Shuddhi Green Charcoal Private Limited</li> <li>• Dvm Goa Developers Associates Private Limited</li> </ul>
<b>Membership in committee of other public company</b>	Audit Committee Stakeholder's Committee

Notes:

1. The respective Explanatory Statements, pursuant to Section 102 of the Companies Act 2013, in respect of the business under Item No. 3, 4 and 5 of accompanying notice is annexed hereto.
2. A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE INSTEAD OF HIMSELF AND THE PROXY NEED NOT BE A MEMBER OF THE COMPANY. INSTRUMENT APPOINTING THE PROXY IS ANNEXED HEREWITH AS **ANNEXURE-A**.
3. Proxy forms, in order to be effective, must be deposited at the Registered Office of the Company not later than 48 hours before the time fixed for the meeting, duly completed and signed. A proxy does not have the right to speak at the meeting and cast votes only on a poll. A proxy form is annexed to this report. Proxies submitted on behalf of limited companies, societies, etc. must be supported by an appropriate resolution/ authority, as applicable.
4. A person can act as proxy on behalf of members not exceeding fifty in number and holding in the aggregate not more than 10% of the total share capital of the company carrying voting rights. However, a member holding more than 10% of the total share capital of the company carrying voting rights may appoint a single person as proxy and such person shall not act as proxy for any other person or shareholder.
5. Members are requested to notify immediately any change in their addresses to the Company at its Registered Office.
6. Corporate members intending to send their authorized representative to attend the Meeting pursuant to section 113 of the companies act 2013 are requested to send to the company, a certified true copy of the relevant Board of Director resolution together with their respective specimen signatures authorizing their representative (s) to attend and vote on their behalf at the meeting.
7. Members/proxies should bring duly filled Attendance Slip to attend the annual general meeting. Attendance slip is annexed herewith as **ANNEXURE-B**.
8. In case of joint holders attending the meeting, only such joint holders who are first holders/ higher in order of names will be entitled to vote.
9. The voting rights of members shall be in proportion to their shares in the paid-up equity share capital of the Company as on cut-off date. A person, whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on cut-off date i.e September 22, 2022, only shall be entitled to avail facility of voting at the venue of the meeting. A person who is not a member as on the cutoff date should treat this notice for information purpose only.
10. Any person, who acquires shares of the Company and becomes a member of the Company after dispatch of the Notice and holding shares as on cut-off date, may cast vote as provided in the Notice convening the Meeting, which is available on the website of the Company.

11. Shareholders may be aware that the Companies Act, 2013, permits service of the Notice of the Annual General Meeting through electronic mode. In view of this the Company would communicate the important and relevant information, events and send the documents including the intimations, notices, annual reports, financial statements etc. in electronic form, to the email address of the respective Member. Members who have not registered their e-mail addresses, so far, are requested to register their e-mail addresses in the following manner:

The shareholders who are holding shares in demat form and have not yet registered their e-mail IDs with their Depository Participant are requested to register their e-mail address at the earliest. Electronic copy of the Annual Report including Notice of the 5th Annual General Meeting of the Company inter-alia indicating the manner of voting along with Attendance Slip, Proxy Form is being sent to all the members whose email IDs are registered with the Company/Depository Participant(s) for communication purposes.

However, those members who desire to have a physical copy may request for the same to Company. For members who have not registered their email IDs, physical copies of the Annual Report are being sent in the permitted mode. The Annual Report of the Company will also be made available on the Company's website [www.jeenasikho.co.in](http://www.jeenasikho.co.in).

The company or its Registrar and Transfer Agents, Accurate Securities & Registry Private Limited, can not act on any request received directly from the Members holding shares in electronic form for any change of bank particulars or bank mandates, such changes are to be advised only to the Depository Participants.

12. The Securities and Exchange Board of India (SEBI) has mandated the submission of a Permanent Account Number (PAN) by every participant in the securities market. Members holding shares in electronic form are , therefore, requested to submit their PAN to the Depository Participants with whom they maintain their Demat accounts.
13. Members seeking clarifications on the Annual Report are requested to send in writing through email at [Investors@jeenasikho.co.in](mailto:Investors@jeenasikho.co.in) at least 7 days before the date of meeting. This would enable the company to compile the information and provide replies in the meeting.
14. To prevent fraudulent transactions, members are advised to exercise due diligence and notify the company/ Registrar of any change in address or demise of any member as soon as possible. Members are also advised not to leave their demat account(s) dormant for long. A periodic statement of holding should be obtained from the concerned Depository Participant and holding should be verified.
15. With reference to the Section 180 of Companies Act 2013 and Companies (Management and Administration) Rules, 2014, Companies covered under Chapter XB as per SEBI (ICDR) Regulations, 2009 are exempted from e-voting provisions. Your Company is listed on the Emerge platform of NSE. Therefore, Company is not providing an e-voting facility to its shareholders.
16. MEMBERS HOLDING EQUITY SHARES IN ELECTRONIC FORM, AND PROXIES THEREOF, ARE REQUESTED TO BRING THEIR DP ID AND CLIENT ID FOR IDENTIFICATION. Members are requested to bring their attendance along with copies of their Annual Report at the meeting.
17. Route-map to the venue of the Meeting is provided in this Notice.
18. During the period beginning 24 hours before the time fixed for the commencement of the Meeting and ending with the conclusion of meeting, a Member would be entitled to inspect the proxies lodged at any time during the business hours of the Company. All documents

referred to in the notice and the explanatory statement and other statutory registers shall be available for inspection by the Members at the registered office of the Company during office hours on all working days between 11.00 a.m. and 4.00 p.m. on all days except Saturdays, Sundays and public holidays, from the date hereof up to the date of the Meeting and at the venue of the Meeting for the duration of the Meeting.

19. Pursuant to Section 91 of the Companies Act, 2013, The Register of Members and Share Transfer Books of the Company will be closed from September 23, 2022 to September 28, 2022 (both days inclusive).

**EXPLANATORY STATEMENTS PURSUANT TO SECTION 102(1) OF THE COMPANIES ACT, 2013**

**Item No. 3**

The members of the company have appointed Mr. Manish Grover as Managing Director in Extra-Ordinary General Meeting held on August 25, 2021. It is proposed to fix their remuneration for financial year 2022-2023.

<b>Particulars</b>	<b>Details</b>
1. Terms of Remuneration	One (1) year
2. Monthly gross salary	Rs. 20,00,000/- p.m.

The total managerial remuneration payable to its directors, in respect to its financial year is exceeding eleven percent of the net profits of the company for the Company to be calculated as per the provisions of section 198 of the Companies Act, 2013 ("the Act") and accordingly an approval of shareholders through a special resolution is being sought.

It is hereby confirmed that the Company has not committed any default in payment of dues to any bank or public financial institution or any other secured creditor.

None of the Directors and Key Managerial Personnel of the company/ and their relatives, except Mr. Manish Grover and his relatives, are in any way concerned or interested, financially or otherwise, in the Special Resolution.

The Board of Directors accordingly commends the resolution for your approval.

**Item No. 4**

The members of the company have appointed Mrs. Bhavna Grover as Whole-Time Director in Extra-Ordinary General Meeting held on August 25, 2021. It is proposed to fix their remuneration for financial year 2022-2023.

<b>Particulars</b>	<b>Details</b>
1. Terms of Remuneration	One (1) year
2. Monthly gross salary	Rs. 15,00,000/- p.m.

The total managerial remuneration payable to its directors, in respect to its financial year is exceeding eleven percent of the net profits of the company for the Company to be calculated as per the provisions of section 198 of the Companies Act, 2013 ("the Act") and accordingly an approval of shareholders through a special resolution is being sought.

It is hereby confirmed that the Company has not committed any default in payment of dues to any bank or public financial institution or any other secured creditor.

None of the Directors or Key Managerial Personnel of the company/ and their relatives, except Mrs. Bhavna Grover and her relatives, are in any way concerned or interested, financially or otherwise, in the Special Resolution.

The Board of Directors accordingly commends the resolution for your approval.

**Item No. 5**

The company enters into various related party transactions with Divya Upchar Sanstan and Finest Tech Solution Private Limited. The Board of Directors intends to enter into various related party transactions with these parties in financial year 2022-2023.

As per Section 188 of the Companies Act 2013, the company shall not enter into a contract or arrangement with any related party except with the prior approval of the company by a resolution if they are not in the ordinary course of business and not on arm's basis. However, the above transactions are in ordinary course of business and on arm length basis.

The Board of Directors recommends this resolution for the approval of the shareholders through Ordinary Resolution.

None of the Directors or Key Managerial Personnel of the company/ and their relatives, except Mrs. Bhavna Grover and her relatives, are in any way concerned or interested, financially or otherwise, in the Ordinary Resolution.

**Form No. MGT-11**

**ANNEXURE-A**

**Proxy form**

*[Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of the Companies (Management and Administration) Rules, 2014]*

**CIN:** U52601PB2017PLC046545

**NAME OF THE COMPANY:** JEENA SIKHO LIFECARE LIMITED

**REGISTERED OFFICE:** SCO 11 First Floor, Kalgidhar Enclave, Zirakpur, Mohali, Punjab-140604

**VENUE FOR MEETING:** Shuddhi Ayurveda Panchkarma Hospital, Pind Devinagar, Hadbast No. 18 Tehsil Derabassi Dist, Punjab 140507

Name of the members (s):.....

Registered address:.....

E-Mail Id:.....

Folio No/Client Id:.....

DP ID:.....

I/We, being the member (s) of ..... shares of the above named company, hereby appoint

1. Name: .....  
 Address:.....  
 E-mail Id:.....  
 Signature: ....., or failing him.

2. Name: .....  
 Address:.....  
 E-mail Id:.....  
 Signature: ....., or failing him

3. Name: .....  
 Address:.....  
 E-mail Id:.....  
 Signature: .....,

as my proxy to attend and vote (on a poll) for me and on my behalf at the 05<sup>TH</sup> Annual General Meeting of the company, to be held on Thursday, September 29, 2022 at 12 Noon at Shuddhi Ayurveda Panchkarma Hospital, Pind Devinagar, Hadbast No. 18 Tehsil Derabassi Dist, Punjab 140507 and at any adjournment thereof in respect of such resolutions as are indicated below:

S. No.	Resolution(s)	Vote	
		For	Against
1	1. To receive, consider and adopt the Audited Accounts of the Company for the financial period ended on 31 <sup>st</sup> March 2022 together with the reports of Directors and Auditors thereon.		

	<p>2. To re-appoint Mr. Manish Grover as a Director who retires by rotation &amp; being eligible offers himself for re-appointment.</p> <p>3. To Fix remuneration of Mr. Manish Grover, Managing Director of the company.</p> <p>4. To Fix remuneration of Mrs. Bhavna Grover, Whole-Time Director of the company.</p> <p>5. To approve related party transactions.</p>		
--	---	--	--

Signed this \_\_\_\_\_ day of \_\_\_\_\_ 2022  
 Signature of shareholder: \_\_\_\_\_  
 Signature of Proxy holder(s) \_\_\_\_\_

Signature of the shareholder across the Revenue Stamp

**ANNEXURE-B**

**ATTENDANCE SLIP**

05<sup>th</sup> Annual General Meeting of "JEENA SIKHO LIFECARE LIMITED"

Registered Office: SCO 11 First Floor, Kalgidhar Enclave, Zirakpur, Mohali Punjab-140604

Reg. Folio: .....

No. of Shares Held: .....

Full Name of Shareholder: .....

Full Name of Proxy/ Authorised Representative: .....

Regd Folio No. : .....

DP Id: .....

No. of Shares Held: .....

Client Id: .....

I hereby record my presence at the 05<sup>th</sup> Annual General Meeting of the Company held on Thursday, September 29, 2022 at 12 Noon at Shuddhi Ayurveda Panchkarma Hospital, Pind Devinagar, Hadbast No. 18 Tehsil Derabassi Dist, Punjab 140507


.....  
Name of the member/ Proxy/ Authorised Representative  
(In BLOCK LETTERS)

.....  
Signature of member/ Proxy/ Authorised Representative

Note : Please fill in this attendance slip and hand it over at the venue.

\* Strike out whichever is not applicable.

**ROUTE MAP TO THE AGM VENUE**



(<https://maps.app.goo.gl/sxNJRNXp7cgQZScm9>)

**JEENA SIKHO LIFECARE LIMITED**

**Shuddhi Ayurveda Panchkarma Hospital,  
PIND DEVINAGAR, HADBAST NO. 18 TEHSIL DERABASSI DIST, PUNJAB 140507**

**5<sup>th</sup> Annual General Meeting  
29<sup>th</sup> Day, September, 2022, at 12 Noon.**

## Board Report and Annexures

To,

The Members,

Your Directors have pleasure in presenting the 5<sup>th</sup> Annual Report on the business and operations of the Company, together with the audited standalone and consolidated financial statements for the financial year ended March 31, 2022 ("FY 2021-22").

### FINANCIAL RESULTS

The standalone and consolidated financial performance of the Company is summarised in the table below:

Particulars	Consolidated		Standalone	
	2021-2022	2020-2021	2021-2022	2020-2021
Revenue from Operations including other Income	14,804.35	-	14,794.22	13,687.45
Less: Expenses				
Purchase of Stock in Trade	1,226.97	-	1,159.16	1,492.04
Changes in Inventories of Stock in Trade	292.24	-	351.96	127.68
Employee Benefit Expenses	3,379.64	-	3,374.66	3,038.25
Finance Cost	113.97	-	113.97	130.15
Depreciation and Amortization Expenses	331.09	-	330.59	246.09
Other Expenses	7,951.16	-	7,947.09	7,234.61
<b>Total Expenses</b>	<b>13,295.07</b>	-	<b>13,277.43</b>	<b>12,268.82</b>
Profit before exceptional items and tax	1,509.28	-	1,516.79	1,418.63
Exceptional and Extraordinary items	-	-	-	-
Profit Before Tax	1,509.28	-	1,516.79	1,418.63
Tax Expenses	389.89	-	389.55	389.21
Net Profit for the Year	1,119.39	-	1,127.24	1,029.42

### FINANCIAL PERFORMANCE

#### STANDALONE:

During the current period, your company has shown an increase in total revenue of Rs. 14,794.22 Lakhs as against Rs. 13,687.45 Lakhs in the previous year. The Company has earned a net profit of Rs. 1127.24 Lakhs as compared to a profit of Rs. 1029.42 Lakhs in the previous year. The company will continue to pursue expansion in the domestic market, to achieve sustained and profitable growth.

#### **CONSOLIDATED:**

Pursuant to the provisions of section 129 and 134 136 of the Companies Act, 2013 read with rules framed there under and pursuant to Regulation 33 of SEBI (Regulations, 2015 your Company had prepared consolidated financial statements of the Company and its subsidiary i.e., Shuddhi Green Charcoal Private Limited (CIN: U37200HR2021PTC099839). Shuddhi Green Charcoal Private Limited became our subsidiary on January 05, 2022.

During the current period, your company has shown the total revenue of Rs. 14804.35 Lakhs. The company has earned a net profit of Rs. 1123.24 Lakhs.

As per Rule 8 of Companies (Accounts) Amendments Rules, 2016, a report on the highlights of performance of subsidiaries, associates and joint venture companies and their contributions to the overall performance of the company during the period under report is attached as **Annexure 1**.

Any member intending to have a copy of Balance Sheet and other Financial Statement of these Companies shall be made available on the website of the Company at [www.jeenasikho.co.in](http://www.jeenasikho.co.in).

It shall also be kept for inspection during business hours by any shareholder in the registered office of the Company and the respective offices of its subsidiary companies.

#### **SHARE CAPITAL**

##### **Authorised Share Capital**

During the year under review, the Authorized Share Capital was increased from Rs. 20,00,000/- (Rupees Twenty Lakhs Only) divided into 2,00,000 (Two Lakh) Equity shares of Rs.10 each to Rs. 15,00,00,000/- (Rupees Fifteen Crore Only) divided into 1,50,00,000 (One Crore Fifteen lakh) Equity Shares of Rs. 10/- each by creation of additional 1,48,00,000 (One Crore Forty-Eight Lakhs) Equity Shares of Rs.10/- each ranking pari-passu in all respect with the existing Equity shares of the Company.

##### **Paid Up Share Capital**

The paid up share capital of the Company as on March 31, 2022 is Rs. 13,81,11,920/- divided into 1,38,11,192 equity shares of Rs.10/- each.

During the Year the Company has issued 1,00,00,080 fully paid up Equity Shares as Bonus to the shareholders of the Company on August 25, 2021.

#### **LISTING WITH STOCK EXCHANGES**

After the year into consideration, the equity shares of the company were listed on Emerge Platform of National Stock Exchange of India Limited w.e.f. April 19, 2022 and the Company confirms that it has paid the Annual Listing Fees for the year 2021-22 to NSE Limited.

#### **DEMATERIALISATION OF EQUITY SHARES**

All the Equity shares of the Company are in dematerialized form with either of the depositories viz NSDL and CDSL. The ISIN No. allotted is INE0J5801011.

#### **DIVIDEND**

In order to conserve the resources for future requirements & plans for future expansion, the Board has decided to retain the profits generated and consequently, Board is unable to recommend distribution of dividend.

#### **TRANSFER TO GENERAL RESERVE**

The Company has transferred Rs. 1127.24 Lakhs to its Reserves during the year.

#### **DEPOSITS**

During the year under review, the Company has not accepted or renewed any deposit from the public falling within the ambit of section 73 of the Companies Act, 2013 and the Companies (Acceptance of Deposits) Rules, 2014.

#### **CORPORATE GOVERNANCE**

The Company has got listed on 19/04/2022 on SME Emerge Platform of NSE, by virtue of Regulation 15 of SEBI (Listing obligations and disclosure requirements) Regulations, 2015 (" the compliance with the corporate governance provisions as specified in Regulation 17 to 27 and clauses ( i to i of sub regulation 2 of Regulation 46 and Para C, D and E of Schedule V are not applicable to the Company Hence, the Corporate Governance Report does not form part of this Annual Report.

#### **SUBSIDIARIES/ASSOCIATES/JOINT VENTURE**

Your Company has One Subsidiary Company, namely Shuddhi Green Charcoal Private Limited. Shuddhi Green Charcoal Private Limited became subsidiary on January 05, 2022. Your company has acquired 5100 equity shares of the company, holding a stake of 51.00%.

Pursuant to Section 129 (3) of the Act and Ind - AS 110 issued by the Institute of Chartered Accountants of India, Consolidated Financial Statements presented by the Company include the financial statements of its subsidiaries.

Further, a separate statement containing the salient features of the financial statements of subsidiaries of the company in the prescribed form AOC-1 has been disclosed in **Annexure 1**.

The Financial Statements, as required, of the subsidiary companies shall be available on website of the Company at [www.jeenasikho.co.in](http://www.jeenasikho.co.in).

#### **DIRECTORS**

Pursuant to Section 149, 152 and other applicable provisions of the Companies Act, 2013, one-third of such of the Directors as are liable to retire by rotation, shall retire every year and, if eligible, offer themselves for re-appointment at every AGM. Consequently, Mr. Manish Grover

(DIN: 07557886), director will retire by rotation at the ensuing AGM, and being eligible, offers himself for re-appointment in accordance with provisions of the Act.

During the Year, Mr. Manish Grover (DIN: 07557886) who was serving as the Director in the Company appointed as a Managing Director for a period of 5 years w.e.f. August 25, 2021, and his tenure shall end on August 24, 2026. Mrs. Bhavna Grover (DIN: 07557913) who was serving as Director in the Company appointed as a Whole time Director for a period of 5 years w.e.f. August 25, 2021, and his tenure shall end on August 24, 2026.

Further, During the Year Board of Directors in its meeting held on June 10, 2021 proposed to appoint Ms. Shreya Grover (DIN: 09199495), as a Non- Executive Director of the Company, which was approved by shareholders in Extra-Ordinary General Meeting held on June 12, 2021.

Further, pursuant to Section 149, 152, 161 read with Schedule IV and other applicable provisions of the Companies Act, 2013, Companies (Appointment and Qualification of Directors) Rules, 2014 and Listing Regulations, the Company at their Extra-Ordinary General meeting held on August 25, 2021, had appointed Mr. Karan Vir Bindra (DIN: 09283623) and Mr. Suraj Prakash Choudhary (DIN: 09241286) as Non-Executive Independent Directors of the Company, for a period of 5 consecutive years from the date of appointment. Mr. Karan Vir Bindra and Mr. Suraj Prakash Choudhary have given consent for his appointment and have also submitted necessary disclosures with respect to his appointment.

The Company has received necessary declaration from all the Independent Directors under Section 149(7) of the Act confirming that they meet the criteria of independence as laid down in Section 149(6) of the Act and Regulation 16(1)(b) of the Listing Regulations. The Company has also received from them declaration of compliance of Rule 6 (1) & (2) of the Companies (Appointment and Qualifications of Directors) Rules, 2014, regarding online registration with the Indian Institute of Corporate Affairs, Manesar, for inclusion/ renewal of name in the data bank of Independent Directors. With regard to integrity, expertise and experience (including the proficiency) of the Independent Director appointed during FY 2021-22, the Board of Directors have taken on record the declarations and confirmations submitted by the Independent Director and is of the opinion that he is a person of integrity and possesses relevant expertise and experience and his continued association as Director will be of immense benefit and in the best interest of the Company. With regard to proficiency of the independent Director, ascertained from the online proficiency self-assessment test conducted by the Institute, as notified under Section 150(1) of the Act, the Board of Directors have taken on record the information submitted by Independent Director that he has complied with the applicable laws.

Further, in the opinion of the Board, the independent directors appointed during the financial year are the person of integrity and possesses relevant expertise and experience (including the proficiency).

None of the Directors of the Company, except following, are related inter-se, in terms of section 2(77) of the Act including rules made thereunder.

S No.	Name of Director	Relationship with other Director
1.	Manish Grover	Spouse of Bhavna Grover Father of Shreya Grover
2.	Bhavna Grover	Spouse of Manish Grover Mother of Shreya Grover
3.	Shreya Grover	Daughter of Manish Grover and Bhavna Grover

During the Year, Ms. Nikita Juneja was appointed as a Company secretary and Compliance Officer of the Company w.e.f. August 25, 2021, and Mr. Nanak Chand was appointed as Chief Financial Officer of the Company w.e.f. August 25, 2021.

#### **FAMILIARIZATION PROGRAMME OF INDEPENDENT DIRECTORS**

Periodic presentations are made at the Board and Committee meetings on business and performance updates of the Company and business strategy. The Company has done various programmes to familiarize Independent Directors with the Company, responsibilities in the Company, nature of the industry in which the Company operates, business model of the Company and related matters.

Details of the familiarization programme for Independent Directors are explained in the Corporate Governance Report.

#### **REMUNERATION OF DIRECTORS**

The details of remuneration/Sitting fees paid during the financial year 2021-22 to Executive Directors/ Non-Executive Directors of the Company is provided in Form MGT-9 which is the part of this report.

#### **POLICY ON CODE OF CONDUCT FOR DIRECTORS AND SENIOR MANAGEMENT**

The policy on appointment of Board members including criteria for determining qualifications, positive attributes, independence of a director and the policy on remuneration of directors, KMP and other employees is enclosed as "Annexure 2" respectively to this report. The same are also available on the website of the Company at [www.jeenasikho.co.in](http://www.jeenasikho.co.in) at weblink <https://www.jeenasikho.co.in/policies>.

#### **COMMITTEES OF THE BOARD**

The Committees of the Board focus on certain specific areas and make an informed decisions in line with the delegated authority.

The following Committees constituted by the Board function according to their respective roles and defined scope:

1. Audit Committee
2. Nomination and Remuneration Committee
3. Stakeholder relationship Committee

During the year under review, all recommendations made by the various committees have been accepted by the Board.

The Composition of the Said Committees are as Under:

**Audit Committee:**

The Audit Committee was constituted vide Board resolution dated September 3rd, 2021, pursuant to Section 177 of the Companies Act, 2013. As on date, the Audit Committee comprises of:

Name of Director	Designation of Committee	Nature of Directorship
Mr. Suraj Kumar Choudhary	Chairperson	Independent Director
Mr. Karan Vir Bindra	Member	Independent Director
Mr. Manish Grover	Member	Managing Director

Our Company Secretary and Compliance officer will act as the secretary of the Committee.

**Nomination And Remuneration Committee:**

The Nomination and Remuneration Committee was constituted at a meeting of the Board of Directors held on September 3rd, 2021, As on date the Nomination and Remuneration Committee comprises of:

Name of Director	Designation of Committee	Nature of Directorship
Mr. Karan Vir Bindra	Chairperson	Independent Director
Mr. Suraj Kumar Choudhary	Member	Independent Director
Ms. Shreya Grover	Member	Non- Executive Director

Our Company Secretary and Compliance officer will act as the secretary of the Committee.

**Stakeholders' Relationship Committee:**

The Stakeholders' Relationship Committee has been formed by the Board of Directors, at the meeting held on September 3rd, 2021. As on date the Stakeholders' Relationship Committee comprises of:

Name of Director	Designation of Committee	Nature of Directorship
Mr. Suraj Kumar Choudhary	Chairperson	Independent Director
Ms. Bhavna Grover	Member	Whole Time Director
Ms. Manish Grover	Member	Managing Director

Our Company Secretary and Compliance officer will act as the secretary of the Committee.

**Corporate Social Responsibility Committee:**

The Company has constituted CSR Committee. As on date CSR committee comprises of:

<b>Name</b>	<b>Designation</b>	<b>Nature of Directorship</b>
Karan Vir Bindra	Chairman	Independent Director
Manish Grover	Member	Managing Director
Bhavna Grover	Member	Whole Time Director

#### **VIGIL MECHANISM / WHISTLE BLOWER POLICY:**

Pursuant to the provisions of Section 177(9) & (10) of the Companies Act, 2013, a Vigil Mechanism/Whistle Blower Policy for directors and employees to report genuine concerns has been established. The Vigil Mechanism / Whistle Blower Policy has been uploaded on the website of the Company at <https://www.jeenasikho.co.in/policies> under 'Investor Section'.

The Policy is an extension of the Code of Conduct for Directors & Senior Management Personnel and covers any unethical and improper actions or malpractices and events which have taken place/suspected to take place:

As per the policy all Protected Disclosures should be addressed to the Vigilance Officer / Company Secretary or to the Chairman of the Audit Committee in exceptional cases.

#### **RISK MANAGEMENT POLICY**

The Company has in place a mechanism to identify, assess, monitor and mitigate various risks to key business objectives. Major risks identified by the businesses and functions are systematically addressed through mitigating actions on a continuing basis. Major elements of risk/threats for Ayurveda Industry are regulatory concerns, consumer perceptions and competition. These are discussed at the meetings of the Audit Committee and the Board of Directors of the Company. The Board of Directors has adopted a risk management policy for the company outlining the parameters of identification, assessment, monitoring and mitigation of various risks which is available on the website of the company.

#### **AUDITORS & AUDITOR'S REPORT**

The Company in its Annual General Meeting held on November 15, 2021, has appointed M/s KRA & Co., Chartered Accountants (Firm Registration No. 020266N), holding a valid certificate issued by the Peer Review Board (Certificate No. 012550) of the Institute of Chartered Accountants of India (ICAI), as statutory auditors of the company from the conclusion of 4th Annual General Meeting of the Company till the conclusion of the 09th Annual General Meeting.

M/s KRA & Co., Chartered Accountants, have submitted their Report on the Financial Statements of the Company for the FY 2021-22, which forms part of the Annual Report 2021-22. There are no observations (including any qualification, reservation, adverse remark or disclaimer) of the Auditors in the Audit Reports issued by them which call for any explanation from the Board of Directors.

The Auditors have also confirmed that they have subjected themselves to the peer review process of Institute of Chartered Accountants of India (ICAI) and hold a valid certificate issued by the Peer Review Board of the ICAI.

The Auditors of the Company have not reported any fraud as specified under Section 143(12) of the Companies Act, 2013.

#### **SECRETARIAL AUDITORS AND THEIR REPORT**

The requirement of appointing secretarial auditors under section 204(1) of the Companies Act, 2013 read with rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 didn't apply on the Company for financial year 2021-2022.

#### **MEETINGS OF BOARD OF DIRECTORS**

During the financial year 2021-2022, 24 (Twenty Four) Board Meetings were held.

The details of meeting & attendance are given hereunder. The intervening gap between the Meetings was within the period prescribed under the Companies Act, 2013 and the SEBI (LODR) Regulations, 2015 and pursuant to the relaxations provided. During the financial year 2021-22, the Board of Directors of the Company met on the following dates.

<b>S. No.</b>	<b>Date of Board Meeting</b>	<b>No. of Directors eligible to attend</b>	<b>No. of Directors attended meeting</b>
1	May 04, 2021	2	2
2	June 02, 2021	2	2
3	June 10, 2021	2	2
4	June 25, 2021	3	3
5	July 21, 2021	3	3
6	July 27, 2021	3	3
7	August 03, 2021	3	3
8	August 09, 2021	3	3
9	August 25, 2021	3	3
10	September 01, 2021	5	5
11	September 03, 2021	5	5
12	September 22, 2021	5	5
13	October 11, 2021	5	5
14	October 19, 2021	5	5
15	December 02, 2021	5	5
16	December 04, 2021	5	5
17	December 10, 2021	5	5
18	December 13, 2021	5	5
19	January 03, 2022	5	5
20	January 14, 2022	5	5
21	February 04, 2022	5	5
22	February 08, 2022	5	5
23	February 22, 2022	5	5
24	March 21, 2022	5	5

Further, separate meeting of Independent Directors of the Company was held on August 25, 2021 where the prescribed items enumerated under Schedule IV to the Companies Act, 2013 and clause 25(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 were discussed.

#### **ANNUAL REPORT**

Pursuant to Section 92 (3) read with Section 134 (3) (of the Act, the Annual Return as on March 31<sup>st</sup>, 2022 is available on the Company's website on <https://www.jeenasikho.co.in/>.

#### **CSR COMMITTEE**

The Company comes under the criteria as mentioned in section 135 of the Companies Act, 2013 i.e Corporate Social Responsibility and accordingly the amount has been spent on CSR activities in the financial year 2021-2022 to comply with the requirements of necessary social expenditure which is Rs. 20,38,500 Lakhs (2% of the average net profit of the immediate preceding financial years). The constitution of CSR Committee was applicable for FY 2021-22, subsequently the CSR Committee is formulated and the composition is also given. The CSR Report is annexed as **Annexure 3**.

#### **BOARD EVALUATION**

Pursuant to the provisions of The Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has carried out an annual performance evaluation of its own performance, the directors individually as well as the working of its Committees.

#### **NATURE OF BUSINESS**

There has been no change in business of the Company.

Jeena Sikho has a diverse portfolio consisting of a number of brands and sub-brands including "Shuddhi". The Company offers a variety of Ayurvedic Products and services through Shuddhi clinics and HIIMS, all over the Country. The Company has presence across various channels such as general groceries, chemists, organized retail and ecommerce.

#### **COMPANIES WHICH HAVE BECOME OR CEASED TO BE ITS SUBSIDIARIES DURING THE YEAR**

During the financial year ended 31<sup>st</sup> March, 2022, no entity has become or ceased to be a joint venture or associate of the Company. However, Shuddhi Green Charcoal Private Limited became our subsidiary on January 5, 2022, the details of which are given in **Annexure 1**.

#### **MANAGEMENT DISCUSSION AND ANALYSIS REPORT**

A detailed review of operations, performance and future outlook of your company and its businesses is given in the Management Discussion and Analysis Report, which forms part of this report.

#### **EXTRACT OF ANNUAL RETURN**

As required under Section 92(3) of the Companies Act, 2013, an extract of Annual Return in Form MGT-9 is provided as **Annexure 4** and is uploaded on the website of the Company at [www.jeenasikho.co.in](http://www.jeenasikho.co.in).

#### **PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS UNDER SECTION 186**

The details of loans and Investments and guarantees covered under the provisions of Section 186 of the Act are given in the Notes to the Financial Statements forming a part of Annual Report.

Current borrowings of the company are compliant with Section 180(1)(c) of the Companies Act, 2013.

#### **PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES:**

The particulars of contracts or arrangements entered into by the Company with related parties referred to in sub section (1) of Section 188 of the Companies Act, 2013 including certain arm's length transactions under that proviso attached as **Annexure 5** in Form AOC-2 forms an integral part of this report. All related party transactions are presented to the Audit Committee and the Board. Omnibus approval is obtained before the commencement of the new financial year, for the transactions which are repetitive in nature and also for the transactions which are not foreseen.

In line with the requirements of the applicable laws, the Company has formulated a policy on related party transactions which is uploaded on the website of the Company at: <https://www.jeenasikho.co.in/policies>.

#### **DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013**

The Company has zero tolerance towards sexual harassment at the workplace and has adopted a policy on prevention, prohibition and redressal of sexual harassment at workplace in line with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules thereunder. As required under law, an Internal Compliance Committee has been constituted for reporting and conducting inquiry into the complaints made by the victim on the harassments at the workplace.

During the year, no complaint of sexual harassment has been received by the Committee.

#### **SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS IMPACTING THE GOING CONCERNS STATUS AND COMPANY'S OPERATIONS IN FUTURE**

The Company has not received any significant or material orders passed by any regulatory authority, court or tribunal which shall impact the going concern status and Company's operations in future, during the financial year.

However, after the end of financial year 2021-2022, the company has been imposed fine and penalty by the stock exchange (“NSE”) for non compliance of Regulation 33 of SEBI (LODR) Regulations 2018, which has been duly paid and complied.

## **HUMAN RESOURCES**

Your Company treats its “human resources” as one of its most important assets. Your Company continuously invests in attraction, retention and development of talent on an ongoing basis. A number of programs that provide focused people attention are currently underway. Your Company’s thrust is on the promotion of talent internally through job rotation and job enlargement.

## **PARTICULARS OF EMPLOYEES**

In terms of the provisions of Section 197 (12) of the Companies Act, 2013 read with Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, disclosure pertaining to remuneration and other details are provided in the **Annexure 6** to this Report.

## **TRANSFER OF AMOUNTS TO INVESTOR EDUCATION AND PROTECTION FUND**

Your Company did not have any funds lying in unpaid or unclaimed dividend for a period of seven years. Therefore, there were no funds which were required to be transferred to Investor Education and Protection Fund (IEPF) under Section 124 of the Companies Act, 2013.

## **COMPLIANCE WITH SECRETARIAL STANDARDS**

During the year under review, the Company was in compliance with the Secretarial Standards. i.e. SS-1 and SS-2 relating to “Meetings of the Board of Directors” and “General Meetings” respectively.

## **INDUSTRIAL RELATIONS**

The Company maintained healthy, cordial and harmonious industrial relations at all levels. The enthusiasm and unstinting efforts of employees have enabled the Company to remain at the leadership position in the industry. It has taken various steps to improve productivity across organization.

## **REMUNERATION POLICY**

The Board has on the recommendation of the Nomination & Remuneration Committee, formulated criteria for determining, qualifications, positive attributes and independence of directors and also a policy for the remuneration of directors, key managerial personnel, and senior management. The policy is updated on the website of the company at <https://www.jeenasikho.co.in/>.

## **DIRECTORS’ RESPONSIBILITY STATEMENT**

Pursuant to the provisions under Section 134(5) of the Act, with respect to Directors’ Responsibility Statement, the Directors confirm:

- a) That in the preparation of the annual accounts, the applicable accounting standards have been followed and no material departures have been made from the same;
- b) That they had selected such accounting policies and applied them consistently, and made judgements and estimates that are reasonable and prudent, so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit and loss of the Company for that period;
- c) That they had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013, for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- d) That they had prepared the annual accounts on a going concern basis;
- e) That they had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively; and
- f) That they had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

#### **ACKNOWLEDGMENTS**

The Board places on record its appreciation for the continued patronage, support and co-operation extended by its shareholders, customers, bankers and all Government and statutory agencies with whose help, cooperation and hard work the Company was able to achieve the results. Your directors would further like to record appreciation to the efforts of all the employees for their valuable contribution to the Company.

**Date:** 05/09/2022

**Place:** Chandigarh

For and on behalf of Board

**Jeena Sikho Lifecare Limited**

Sd/-

**Manish Grover**

Managing Director

DIN: 07557886

Sd/-

**Bhavna Grover**

Whole Time Director

DIN: 07557913

**ANNEXURE 1****AOC-1**

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)

**(Information in respect of each subsidiary to be presented with amounts in Rs.)**

Name of the subsidiary	Shuddhi Green Charcoal Private Limited
The date since when subsidiary was acquired	January 05,2022
Reporting period for the subsidiary concerned, if different from the holding company's reporting period.	NA
Reporting currency and Exchange rate as on the last date of the relevant Financial year in the case of foreign subsidiaries.	NA
Share capital	1,00,000.00
Reserves and surplus	(7,86,182.27)
Total assets	1,37,89,207.73
Total Liabilities	72,37,695.00
Investments	0.00
Turnover	10,13,064.00
Profit before taxation	(7,51,793.00)
Provision for taxation	34,390.00
Profit after taxation	(7,86,182.00)
Proposed Dividend	0.00
Extent of shareholding (in percentage)	51.00%

<b>Name of Associates or Joint Ventures</b>	<b>Name 1</b>	<b>Name 2</b>	<b>Name 3</b>
1. Latest audited Balance Sheet Date			
2. Date on which the Associate or Joint Venture was associated or acquired			
3. Shares of Associate or Joint Ventures held by the company on the year end			
No.			
Amount of Investment in Associates or Joint Venture			
Extent of Holding (in percentage)			
4. Description of how there is significant influence			
5. Reason why the associate/Jointventure is not consolidated.			
6. Net worth attributable to shareholding as per latest audited Balance Sheet			
7. Profit or Loss for the year			
i. Considered in Consolidation			
ii. Not Considered in Consolidation			

## ANNEXURE 2

### CODE OF CONDUCT FOR DIRECTORS AND SENIOR MANAGEMENT

#### 1. BACK GROUND

The Securities and Exchange Board of India (SEBI), on September 2, 2015, notified the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulations").

As per Regulation 17(5)(a) of the Regulations, Jeena Sikho Lifecare Limited (the "Company") has adopted the code namely "Code of Conduct for Directors and Senior Management" ("the Code") by passing a Board resolution on September 03, 2021. The Company has formulated the Code to ensure that the business of the Company is conducted in accordance with the applicable laws, the Regulations and with the highest standard of integrity, ethics and values.

#### 1. APPLICABILITY

This Code shall be applicable to the following persons:

- Board of Directors.
- Senior Management Personnel.

The Directors both executive and non-executive, are obliged to carry out their duties in an honest, fair, diligent and ethical manner, within the scope of the authority conferred upon them and in accordance with the laws, rules, regulations, agreements, guidelines, standards and internal policies and procedures. The Board of Directors of the Company is entrusted with the fiduciary responsibility of oversight of the affairs of the Company. As Directors of the Company, they have a duty to make decisions and implement policies in the best interests of the Company and its stakeholders.

Senior Management team comprising of members of Management one level below the Executive Directors, including all functional heads.

#### 3. DEFINITIONS

In this Code, unless repugnant to the meaning or context thereof, the following expressions, wherever used in this Code, shall have the meaning as defined below:

- "Act" shall mean the Companies Act, 2013, rules framed there under and any amendments thereto.
- "Associate Company" shall have the same meaning as defined under sub-section (6) of Section 2 of the Act.
- "Board" shall mean Board of Directors of the Company, as constituted from time to time.
- "Body Corporate" shall have the same meaning as defined under sub-section (11) of Section 2 of the Act.
- "Compliance Officer" shall mean the Company Secretary under Section 203 of the Act and Regulation 6 of Regulations.
- "Directors" shall mean all Directors, including Independent Directors of the Company.

- "Independent Director" shall mean a Director as defined under sub-section (6) of Section 149 of the Act.
- "Key Managerial Personnel" shall have the same meaning as defined under sub-section (51) of Section 2 of the Act.
- "Relative" shall mean relative as defined under sub-section (77) of Section 2 of the Act, read with the Companies (Specification of definitions details) Rules, 2014.
- "Securities" shall mean the securities as defined in clause (h) of Section 2 of the Securities Contracts (Regulation) Act, 1956.
- "Senior Management" shall mean officers/personnel of the listed entity who are members of its core management team excluding board of directors and normally this shall comprise all members of management one level below the executive directors, including all functional heads.
- "Stock Exchange" shall mean the stock exchange where securities of the Company are listed.
- "Subsidiary" shall mean a subsidiary as defined under sub-section (87) of Section 2 of the Act.
- "Unpublished Price Sensitive Information" shall mean any information, relating to a Company or its Securities, directly or indirectly, that is not generally available which upon becoming generally available, is likely to materially affect the price of the Securities and shall, ordinarily including but not restricted to, information relating to the following:
  - i. financial results;
  - ii. dividends;
  - iii. change in capital structure;
  - iv. mergers, de-mergers, acquisitions, delisting(s), disposals and expansion of business and such other transactions;
  - v. changes in key managerial personnel; and
  - vi. material events in accordance with the listing agreement.

All other words and expressions used but not defined in this Code but defined in the SEBI Act, 1992, the Act, the Securities Contracts (Regulation) Act, 1956, the Depositories Act, 1996 and/ or the rules and regulations made there under shall have the same meaning as respectively assigned to them in such Acts or rules or regulations or any statutory modification or re-enactment thereto, as the case may be

This Code is applicable to all the members of the Board of Directors and Senior Management of the Company and its Subsidiaries.

#### **4. COMPLIANCE WITH APPLICABLE LAWS**

The Directors and Senior Management shall comply with all applicable laws, rules, regulations and guidelines, in all areas and geographies where the Company operates, both in letter and spirit. It is therefore desirable that Directors and Senior Management acquire appropriate knowledge of the legal requirements relating to their roles and duties to enable them to be in compliance thereof and to recognize potential risks, and to know when to seek advice from the legal department.

#### **5. CODE OF CONDUCT**

The following are the code of Conduct adopted by the Company-

1. Every Director / Executive shall discharge his / her responsibilities at all times and in such manner so as to ensure that there is compliance with all the laws, rules, regulations as may be applicable to the company or to the transaction or to the person.
2. Every Director / Executive shall avoid being in situations that give rise to conflict between the personal interests of the person and the interest of the Company. Where such a situation is not avoidable, the person shall disclose the matter in writing to his /her superior and in the case of any Director; such disclosure should be made to the Board.
4. Every Director / Executive shall treat any data or information of the Company which has not been published or disclosed previously as confidential information and shall not disclose or transmit the same to any person who is not an employee or Director of the Company, without permission of his/her superior or the Chairman of the Board, unless such disclosure is as per the requirements of any law, or any lawful agreement to which the company is a party.
5. Every Director / Executive shall strictly adhere to the policy of the company.
6. Every Director / Executive shall at all-time ensure proper use of Company's funds, assets and property.
7. No Director / Executive shall knowingly suppress from the company a material fact, which can be detrimental to the interest of the Company.
8. Every Director / Executive shall ensure maintenance of a healthy and safe work environment in the company.
9. Every Director / Executive shall avoid discrimination and harassment in any form, on the basis of race, religion and gender.
10. Every Director / Executive shall adhere to fair and lawful competitive practices pertaining to the operations of the company.
11. Every Director / Executive must ensure that he / she does not exploit opportunities arising out of the place of work or in course of work, for personal gain.
12. Every Director / Executive shall ensure that no political contribution is made whether directly or indirectly on behalf of the Company, without permission of the Board of the Company.
13. Every Director / Executive shall ensure that no statement is given to the press or any other form of media without due authorization by the person's superior or the Vice Chairman or the Board of the Company.
14. Every Director / Executive must at all times ensure to conduct him / her, so as to give respect to human beings and human values.

Guidelines of professional conduct, Role, Function and Duties as an Independent Director (As provided in Schedule IV of the Companies Act, 2013)

***Guidelines for Professional conduct***

1. To uphold ethical standards of integrity and probity;
2. To act objectively and constructively while exercising your duties;
3. To exercise their responsibilities in a bona fide manner in the interest of the Company;
4. To devote sufficient time and attention towards your professional obligations for informed and balanced decision making;

5. To not allow any extraneous considerations that will vitiate their exercise of objective independent judgment in the paramount interest of the Company as a whole, while concurring in or dissenting from the collective judgment of the Board in its decision making;
6. To not abuse their position to the detriment of the Company or its shareholders or for the purpose of gaining direct or indirect personal advantage or advantage for any associated person;
7. To refrain from any action that would lead to loss of their independence;
8. Where circumstances arise which make an independent Director lose his independence, the Independent Director must immediately inform the Board accordingly;
9. To assist the Company in implementing the best corporate governance practices.

***Role and Functions***

1. Assist in bringing an independent judgment to bear on the Board's deliberations especially on issues of strategy, performance, risk management, resources, key appointments and standards of conduct.
2. Bring an objective view in the evaluation of the performance of Board and management.
3. Scrutinize the performance of management in meeting with respect to agreed goals and objectives and monitor the reporting of performance.
4. Satisfy yourself on the integrity of financial information and that financial controls and systems of risk management are robust and defensible.
5. Safeguard the interests of all stakeholders, particularly the minority shareholders.
6. Balance the conflicting interest of the stakeholders.
7. Determine appropriate levels of remuneration of executive directors, key managerial personnel and senior management and have a prime role in appointing and where necessary recommend removal of executive directors, key managerial personnel and senior management.
8. Moderate and arbitrate in the interest of the company as a whole, in situations of conflict between management and shareholder's interest

***Duties:***

1. Undertake appropriate induction and regularly update and refresh your skills, knowledge and familiarity with the Company.
2. Seek appropriate clarification or amplification of information and, where necessary, take and follow appropriate professional advice and opinion of outside experts at the expense of the Company.
3. Strive to attend all meetings of the Board including a Separate meeting of the independent director and of the Board committees of which you are a member.
4. Participate constructively and actively in the committees of the Board in which you are chairperson or member.
5. Strive to attend the general meetings of the Company.
6. Where you have concerns about the running of the Company or a proposed action, ensure that these are addressed by the Board and, to the extent that they are not resolved, insist that your concerns are recorded in the minutes of the Board meeting.
7. Keep yourself well informed about the Company and the external environment in which it operates.

8. Not to unfairly obstruct the functioning of an otherwise proper Board or committee of the Board.
9. Pay sufficient attention and ensure that adequate deliberations are held before approving related party transactions and assure yourself that the same are in the interest of the Company.
10. Ascertain and ensure that the Company has an adequate and functional vigil mechanism and to ensure that the interests of a person who uses such mechanism are not prejudicially affected on account of such use.
11. Report concerns about unethical behavior, actual or suspected fraud or violation of the Company's code of conduct or ethics policy.
12. Acting within your authority, assist in protecting the legitimate interests of the Company, shareholders and its employees.
13. Not disclose confidential information, including commercial secrets, technologies, advertising and sales promotion plans, unpublished price sensitive information, unless such disclosure is expressly approved by the Board or required by law.

However, in case of any person serving on the Board of the Company as a nominee of any institution or organization, this code shall apply to such person during his / her tenure as Director of the Company, subject to anything contained herein which is repugnant to the Code of Conduct or the service rules of the institution or organisation who have appointed such persons as its nominee on the Board.

#### **1. AMENDMENT TO THE CODE**

The provisions of this Code can be amended or modified by the Board of Directors from time to time and all such amendments/modifications shall take effect from the date stated therein.

#### **2. COMPLIANCE OFFICER**

The Company Secretary shall act as a Compliance Officer and shall monitor compliances with the Chairman and Managing Director of the Company.

#### **3. PUBLICATION OF THE CODE**

This Code and any amendments thereto shall be published / posted on the website of the Company i.e. <https://www.jeenasikho.co.in/>

**CORPORATE SOCIAL RESPONSIBILITY (CSR) REPORT**

**[Pursuant to clause (o) of sub-section (3) of section 134 of the Act and Rule 9 of the Companies (Corporate Social Responsibility) Rules, 2014]**

1. A brief outline of the Company's CSR policy, including overview of projects or programs proposed to be undertaken and a reference to the web-link to the CSR policy and projects or programs.

The Company, through its Corporate Social Responsibility initiatives, shall strive to enrich the quality of life in different segments of the society."

2. The Composition of the CSR Committee.

The Committee constituted of following members:

- |                         |   |                      |
|-------------------------|---|----------------------|
| 1. Mr. Manish Grover    | : | Director             |
| 2. Mrs. Bhavna Grover   | : | Director             |
| 3. Mr. Karan Vir Bindra | : | Independent Director |

3. Average net profit of the company for last three financial years:

- |     |   |                    |
|-----|---|--------------------|
| (a) | Profit for the financial year ended on 31.03.2019:                | Rs. 8,39,03,198/-  |
| (b) | Profit for the financial year ended on 31.03.2020:                | Rs. 7,86,81,364/-  |
| (c) | Profit for the financial year ended on 31.03.2021:                | Rs.14,31,90,870/-  |
| (d) | Average net profit of the company for last three financial years: | Rs. 10,19,25,144/- |

4. Prescribed CSR Expenditure (two per cent of the amount as in item 3 above)

Prescribed CSR Expenditure: Rs. 20,38,502.88 (2% of Average Net Profit)

5. Details of CSR spent during the financial year.

(a) Total amount to be spent for the financial year 21-22: Rs. 20,38,502.88 /-

(b) Amount spent for the financial year 21-22: Rs. 21,00,000.00/-

(c) Amount unspent, if any at the end of the year 2020-2021; Rs. 1,23,609.62/-

(d) Amount unspent, if any at the end of the year 2021-2022; Rs. 62,112.50/-

(The unspent amount has been transferred to the Fund as specified in Schedule VII of the Companies Act within six months of the end of financial year)

(e) Manner in which the amount spent during the financial year is detailed below:

(1) S.No	(2) CSR project or activity identified	(3) Sector in which the Project is covered	(4) Projects or programs (1) Local area or other (2) Specify the State and district where projects or programs	(5) Amount outlay (budget) project for programs wise	(6) Amount spent on the projects or programs Sub - heads: (1) Direct expenditure on	(7) Cumulative expenditure upto to the reporting period	(8) Amount spent: Direct or through implementing agency*
-------------	---	---	---	---	--	--	---

			was undertaken		projects or programs (2) Overheads		
1	By giving donation to "Capri Foundation" engaged in promoting health, education for unprivileged children and livelihood initiatives for women.	Education and Health	Donation to "Capri Foundation" engaged in promoting health, education for unprivileged children and livelihood initiatives for women.	Amount to be spent in Total: Rs. 20,38,502.88 /-	21,00,000	Rs. 43,50,000/-	Direct Donation to "Capri Foundation"
	<b>TOTAL</b>			<b>Rs. 20,38,502</b>	<b>Rs. 21,00,000</b>	<b>Rs. 44,12,112.50/-</b>	

6. In case the Company has failed to spend the two per cent of the average net profit of the last three financial years or any part thereof, the company shall provide the reasons for not spending the amount in its Board report.: Not Applicable

7. A responsibility statement of the CSR Committee that the implementation and monitoring of CSR Policy, is in compliance with CSR objectives and Policy of the Company.

We the Members of Corporate Social Responsibility Committee hereby confirm that the implementation and monitoring of CSR Policy is in compliance with CSR objectives and Policy of the Company.

**ANNEXURE 4**

**FORM NO. MGT 9  
EXTRACT OF ANNUAL RETURN  
As on the financial year ended 31<sup>st</sup> March 2022**

Pursuant to Section 92 (3) of the Companies Act, 2013 and rule 12(1) of the Company (Management & Administration) Rules, 2014.

**I. REGISTRATION AND OTHER DETAILS:**

1	<b>CIN</b>	U52601PB2017PLC046545
2	<b>Registration Date</b>	29-05-2017
3	<b>Name of the Company</b>	Jeena Sikho Lifecare Limited
4	<b>Category/Sub-category of the Company</b>	Company Limited By Shares Indian-Non Government Company
5	<b>Whether listed company</b>	Yes
6	<b>Name, Address &amp; contact details of the Registrar &amp; Transfer Agent, if any.</b>	<b>SKYLINE FINANCIAL SERVICES PRIVATE LIMITED</b> D-153 A, 1st Floor, Okhla Industrial Area, Phase - I, New Delhi-110020 Tel No: +91-11-40450193-97; Fax No: +91-11-26812683

**II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY**

All the business activities contributing 10 % or more of the total turnover of the company shall be stated:-

S.No.	Name and Description of main products/ services	NIC Code of the product/ Service	% to total turnover of the Company
1.	Ayurvedic Healthcare activities	86909	100%

**III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES -**

S.No.	Name and Address of the Company	CIN/GLN	Address	Holding/ Subsidiary / Associate	% of shares held
1	Shuddhi Green Charcoal Private Limited	U37200HR2021PTC099839	MultiTherm India Building, Nr. HSIDC Plot No 82-83, Phase-7 Sector-35, Gurgaon Haryana 122004	Subsidiary	100.00

#### IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

##### i) Category-wise Share Holding

Category of Shareholders	No. of Shares held at the beginning of the year [As on 1-April-2021]				No. of Shares held at the end of the year [As on 31-March-2022]				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
<b>A. Promoters</b>									
<b>(1) Indian</b>									
a) Individual/HUF	-	1,00,000	1,00,000	90.00%	91,00,000	-	91,00,000	90.00%	9000.00%
b) Central Govt	-	-	-	0.00%	-	-	-	0.00%	0.00%
c) State Govt(s)	-	-	-	0.00%	-	-	-	0.00%	0.00%
d) Bodies Corp.	-	-	-	0.00%	-	-	-	0.00%	0.00%
e) Banks / FI	-	-	-	0.00%	-	-	-	0.00%	0.00%
f) Any other	-	-	-	0.00%	-	-	-	0.00%	0.00%
<b>Sub Total (A) (1)</b>	-	1,00,000	1,00,000	<b>90.00%</b>	91,00,000	-	91,00,000	<b>90.00%</b>	<b>9000.00%</b>
<b>(2) Foreign</b>									
a) NRI Individuals	-	-	-	0.00%	-	-	-	0.00%	0.00%
b) Other Individuals	-	-	-	0.00%	-	-	-	0.00%	0.00%
c) Bodies Corp.	-	-	-	0.00%	-	-	-	0.00%	0.00%
d) Any other	-	-	-	0.00%	-	-	-	0.00%	0.00%
<b>Sub Total (A) (2)</b>	-	-	-	<b>0.00%</b>	-	-	-	<b>0.00%</b>	<b>0.00%</b>
<b>TOTAL (A)= (A)(1)+(A)(2)</b>	-	1,00,000	1,00,000	<b>90.00%</b>	91,00,000	-	91,00,000	<b>90.00%</b>	<b>9000.00%</b>
<b>B. Public Shareholding</b>									
<b>1. Institutions</b>									
a) Mutual Funds	-	-	-	-	-	-	-	0.00%	0.00%
b) Banks / FI	-	-	-	0.00%	-	-	-	0.00%	0.00%
c) Central Govt	-	-	-	0.00%	-	-	-	0.00%	0.00%
d) State Govt(s)	-	-	-	0.00%	-	-	-	0.00%	0.00%
e) Venture Capital Funds	-	-	-	0.00%	-	-	-	0.00%	0.00%
f) Insurance Companies	-	-	-	0.00%	-	-	-	0.00%	0.00%
g) FIs	-	-	-	0.00%	-	-	-	0.00%	0.00%
h) Foreign Venture Capital Funds	-	-	-	0.00%	-	-	-	0.00%	0.00%
i) Others (specify)	-	-	-	0.00%	-	-	-	0.00%	0.00%
<b>Sub-total (B)(1):-</b>	-	-	-	<b>0.00%</b>	-	-	-	<b>0.00%</b>	<b>0.00%</b>

<b>2. Non-Institutions</b>									
a) Bodies Corp.									
i) Indian		11,112	11,112	10.00%	10,11,192	-	10,11,192	10.00%	9000.00%
ii) Overseas		-	-	0.00%	-	-	-	0.00%	0.00%
b) Individuals		-	-		-	-	-		
i) Individual shareholders holding nominal share capital upto Rs. 1 lakh		-	-	0.00%	-	-	-	0.00%	0.00%
ii) Individual shareholders holding nominal share capital in excess of Rs 1 lakh		-	-	0.00%	-	-	-	0.00%	0.00%
c) Others (specify)		-	-		-	-	-		
Non Resident Indians		-	-	0.00%	-	-	-	0.00%	0.00%
Overseas Corporate Bodies		-	-	0.00%	-	-	-	0.00%	0.00%
Foreign Nationals		-	-	0.00%	-	-	-	0.00%	0.00%
Clearing Members		-	-	0.00%	-	-	-	0.00%	0.00%
Trusts		-	-	0.00%	-	-	-	0.00%	0.00%
Foreign Bodies - D R		-	-	0.00%	-	-	-	0.00%	0.00%
<b>Sub-total (B)(2):-</b>	-	11,112	11,112	10.00%	10,11,192	-	10,11,192	10.00%	9000.00%
<b>Total Public (B)</b>	-	11,112	11,112	10.00%	10,11,192	-	10,11,192	10.00%	9000.00%
<b>C. Shares held by Custodian for GDRs &amp; ADRs</b>				0.00%	-	-	-	0.00%	0.00%
<b>Grand Total (A+B+C)</b>	-	1,11,112	1,11,112	100.00%	1,01,11,192	-	1,01,11,192	100.00%	9000.00%

### (ii) Shareholding of Promoters

SN	Shareholder's Name	Shareholding at the beginning of the year			Shareholding at the end of the year			% change in shareholding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged/encumbered to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	
1	Manish Grover	99000	89.10%	NIL	90,05,360	89.06%	NIL	8996.32%
2	Bhavna Grover	1000	0.90%	NIL	91,000	0.90%	NIL	9000.00%
3	Akansha Jain	0	0.00%	NIL		0.01%	NIL	0.01%

					910			
4	Sahil Jain	0	0.00%	NIL	910	0.01%	NIL	0.01%
5	Mukesh Grover	0	0.00%	NIL	910	0.01%	NIL	0.01%
6	Shreya Grover	0	0.00%	NIL	910	0.01%	NIL	0.01%

**(iii) Change in Promoters' Shareholding (please specify, if there is no change):**

SN	Particulars	Date	Reason	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
				No. of shares	% of total shares	No. of shares	% of total shares
<b>1</b>	<b>Mr. Manish Grover</b>						
	At the beginning of the year			99,000	89.10%	99,000	89.10%
	Changes during the year	June 02, 2021	Transfer	(40)	0.00%	(40)	0.00%
		August 25, 2021	Bonus	89,06,400	88.08%	89,06,400	88.08%
	At the end of the year			90,05,360	89.06%	90,05,360	89.06%
<b>2</b>	<b>Mrs. Bhavna Grover</b>						
	At the beginning of the year			1,000	0.90%	1,000	0.90%
	Changes during the year	August 25, 2021	Bonus	90,000	0.89%	90,000	0.89%
	At the end of the year			91,000	0.90%	91,000	0.90%
<b>3</b>	<b>Akansha Jain</b>						
	At the beginning of the year			-	-	-	-
	Changes during the year	June 02, 2021	Transfer	10	0.00%	10	0.00%
		August 25, 2021	Bonus	900	0.01%	900	0.01%
	At the end of the year			910	0.01%	910	0.01%
<b>4</b>	<b>Sahil Jain</b>						
	At the beginning of the year			-	-	-	-
	Changes during the year	June 02, 2021	Transfer	10	0.00%	10	0.00%
		August 25, 2021	Bonus	900	0.01%	900	0.01%
	At the end of the year			910	0.01%	910	0.01%

5	Mukesh Grover						
	At the beginning of the year			-	-	-	-
	Changes during the year	June 02, 2021	Transfer	10	0.00%	10	0.00%
		August 25, 2021	Bonus	900	0.01%	900	0.01%
	At the end of the year			910	0.01%	910	0.01%
6	Shreya Grover						
	At the beginning of the year			-	-	-	-
	Changes during the year	June 02, 2021	Transfer	10	0.00%	10	0.00%
		August 25, 2021	Bonus	900	0.01%	900	0.01%
	At the end of the year			910	0.01%	910	0.01%

**(iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs):**

SN	For each of the Top 10 shareholders	Date	Reason	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
				No. of shares	% of total shares	No. of shares	% of total shares
1	Oregano Life Private Limited						
	At the beginning of the year			11,112	10.00%	11,112	10.00%
	Changes during the year	August 25, 2021	Bonus	10,00,080	9.89%	10,00,080	9.89%
	At the end of the year			10,11,192	10.00%	10,11,192	10.00%

**(v) Shareholding of Directors and Key Managerial Personnel:**

SN	Shareholding of each Directors and each Key Managerial Personnel	Date	Reason	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
				No. of shares	% of total shares	No. of shares	% of total shares
1	Mr. Manish Grover						
	At the beginning of the year			99,000	89.10%	99,000	89.10%
	Changes during the year	June 02, 2021	Transfer	(40)	0.00%	(40)	0.00%

		August 25, 2021	Bonus	89,06,400	88.08%	89,06,400	88.08%
	At the end of the year			90,05,360	89.06%	90,05,360	89.06%
<b>2</b>	<b>Mrs. Bhavna Grover</b>						
	At the beginning of the year			1,000	0.90%	1,000	0.90%
	Changes during the year	August 25, 2021	Bonus	90,000	0.89%	90,000	0.89%
	At the end of the year			91,000	0.90%	91,000	0.90%
<b>6</b>	<b>Shreya Grover</b>						
	At the beginning of the year			-	-	-	-
	Changes during the year	June 02, 2021	Transfer	10	0.00%	10	0.00%
		August 25, 2021	Bonus	900	0.01%	900	0.01%
	At the end of the year			910	0.01%	910	0.01%

## V. INDEBTEDNESS

### Indebtedness of the Company including interest outstanding/accrued but not due for payment

(Amount in lakhs)

Particulars	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
<b>Indebtedness at the beginning of the financial year</b>				
i) Principal Amount	23.34	1,180.00	-	1,203.34
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	-	-	-	-
<b>Total (i+ii+iii)</b>	<b>23.34</b>	<b>1,180.00</b>	<b>-</b>	<b>1,203.34</b>
<b>Change in Indebtedness during the financial year</b>				
* Addition	85.15	-	-	-
* Reduction	-	-	-	-
Net Change	85.15	-	-	-
<b>Indebtedness at the end of the financial year</b>				
i) Principal Amount	108.49	635.00	-	743.49
ii) Interest due but	-	-	-	-

not paid				
iii) Interest accrued but not due	-	-	-	-
Total (i+ii+iii)	108.49	635.00	-	743.49

## VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

### A. Remuneration to Managing Director, Whole-time Directors and/or Manager:

SN.	Particulars of Remuneration	Name of MD/WTD/ Manager		Total Amount (Rs/Lac)
		Name	Manish Grover	
	Designation	Managing Director		
1	Gross salary			
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	220.00		220.00
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	0.00		-
	(c) Profits in lieu of salary under section 17(3) Income- tax Act, 1961	0.00		-
2	Stock Option	0.00		-
3	Sweat Equity	0.00		-
4	Commission	0.00		-
	- as % of profit	0.00		-
	- others, specify	0.00		-
5	Others, please specify	0.00		-
	Total (A)	220.00	-	220.00
	Ceiling as per the Act (11% of net profits)	166.84		

SN.	Particulars of Remuneration	Name of MD/WTD/ Manager		Total Amount (Rs/Lac)
		Name	Bhavna Grover	
	Designation	Whole-Time Director		
1	Gross salary			
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	152.00		152.00
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	0.00		-
	(c) Profits in lieu of salary under section 17(3) Income- tax Act, 1961	0.00		-
2	Stock Option	0.00		-
3	Sweat Equity	0.00		-
4	Commission	0.00		-
	- as % of profit	0.00		-
	- others, specify	0.00		-

5	Others, please specify	0.00		-
	Total (A)	152.00	-	152.00
	Ceiling as per the Act (11% of net profits)	166.84		

Note: The overall ceiling for remuneration as per section 198 of Companies Act 2013, is Rs. 166.84 lakhs for financial year 2021-22. The remuneration payable to Managing Director and Whole time Director is exceeding the limits, i.e., 11% of net profits. The total remuneration paid in financial year 2021-2022 is 372.00 Lakhs. The approval of members by way of Special Resolution was taken in this respect.

#### B. Remuneration to other directors:

SN.	Particulars of Remuneration	Name of Directors			Total Amount (Rs/Lac)
1	Independent Directors	Karan Vir Bindra	Suraj Prakash Choudhary	-	-
	Fee for attending board committee meetings	0.84	0.84	-	1.68
	Commission	-	-	-	-
	Others, please specify	-	-	-	-
	Total (1)	-	-	-	-
2	Other Non-Executive Directors	-	-	-	-
	Fee for attending board committee meetings	-	-	-	-
	Commission	-	-	-	-
	Others, please specify	-	-	-	-
	Total (3)	-	-	-	-
	Total (B)=(1+2+3)	0.84	0.84	-	1.68
	Total Managerial Remuneration	-	-	-	-
	Overall Ceiling as per the Act	N.A.	N.A.		

#### C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD: NA

SN.	Particulars of Remuneration	Name of Key Managerial Personnel			Total Amount (Rs/Lac)
		Name	N.A.	Nanak Chand	
	Designation	CEO	CFO	CS	
1	Gross salary				
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	-	10.25	1.50	11.75
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	-	-	-	-
	(c) Profits in lieu of salary under section 17(3) Income- tax Act, 1961	-	-	-	-
2	Stock Option	-	-	-	-

3	Sweat Equity	-	-	-	-
4	Commission	-	-	-	-
	- as % of profit	-	-	-	-
	- others, specify	-	-	-	-
5	Others, please specify	-	-	-	-
	Total	-	10.25	1.50	11.75

**VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES: NIL**

Type	Section of the Companies Act	Brief Description	Details of Penalty / Punishment/ Compounding fees imposed	Authority [RD / NCLT/ COURT]	Appeal made, if any (give Details)
<b>A. COMPANY</b>					
Penalty		-	-	-	-
Punishment		-	-	-	-
Compounding		-	-	-	-
<b>B. DIRECTORS</b>					
Penalty		-	-	-	-
Punishment		-	-	-	-
Compounding		-	-	-	-
<b>C. OTHER OFFICERS IN DEFAULT</b>					
Penalty		-	-	-	-
Punishment		-	-	-	-
Compounding		-	-	-	-

**By Order of the Board of Directors  
For JEENA SIKHO LIFECARE LIMITED**

**Place: Chandigarh  
Date: 05/09/2022**

**Sd/-  
(Manish Grover)  
Managing Director  
DIN No. 07557886**

**Sd/-  
(Bhavna Grover)  
Whole Time Director  
DIN No. 07557913**

**ANNEXURE 5**

**AOC-02**

**PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES**

*[Pursuant to sub-section (1) of section 188 of companies Act,2013 including certain arms length transactions under third proviso thereto]*

**1. Details of contracts or arrangements or transactions not at arm's length basis**

Name of the Related Party	Nature of relationship	Nature of contracts /arrangements/ transactions	Duration of the contracts /arrangements/ transaction	Salient terms of the contracts /arrangements /transactions including the value, if any	Justification for entering into such contracts or arrangements or transactions	Date of approval by the Board	Amount paid as advances, if any:	Date on which the special resolution was passed
NA								

**2. Details of material contracts or arrangement or transactions at arm's length basis**

Name of the Related Party	Nature of relationship	Nature of contracts /arrangements/ transaction	Duration of the contracts /arrangements/ transaction	Salient terms of the contracts /arrangements /transactions including the value, if any	Date of approval by the Board If any	Amount paid as advances, if any:
NA						

**EMPLOYEES DETAILS**

Disclosures pertaining to remuneration and other details as required under Section 197(12) of the Companies Act, 2013 read with Rule 5(1) & 5(2) of Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, are mentioned below:

**(A) Information as per Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel Rules, 2014**

1. Remuneration of each Director and Key Managerial Personnel (KMP) along with particulars of increase in remuneration during the financial year, Ratio of remuneration of Directors to the Median Remuneration of employees.

Name of the Director/ and KMP	Designation	Remuneration (Rs.) 2021-2022	Remuneration (Rs.) 2020-2021	Increase (%)	Ratio of Director's Remuneration to Median remuneration**
Manish Grover	Managing Director	22000000	18000000	22.22	181.82
Bhawna Grover	Whole Time Director	15200000	9600000	58.33	136.36
Nanak Chand	CFO	1025500	447179*	129.32	9.09
Nikita Juneja	CS	150000*	0	N.A.	2.27

*\*The above-mentioned figures are not annualised. The period of employment was for part of the year.*

*\*\* The median is calculated for per month remuneration.*

*\*\*\* The last month directors' remuneration is taken while calculating its ratio to median remuneration.*

2. The median remuneration of the Company for all its employees is Rs. 11000/- p.m. for the financial year 2021-2022.
3. The Percentage Increase/ decrease in median remuneration of employees in the Financial Year: 6.90%
4. Number of permanent employees on the rolls of the Company: 1476 (As at March 31, 2022).
5. The average increase in the managerial remuneration is 36.82%.
6. The average increase in employees salary other than managerial remunerations is 13.94%.

7. We, hereby affirm that pursuant to Rule 5(1)(xii) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, it is affirmed that the remuneration paid to the Directors, Key Managerial Personnel is as per the remuneration policy of the Company.

**(B) Information relating to Top 10 employees as per Rule 5 (2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and amendments thereof:**

Name of Employee	Designation	Nature of Employment	Qualification	Age	Experience	Remuneration (2021-2022) (IN Rs.)	Relative of any director/manager
Manish Grover	Managing Director	Permanent	B.com	48	26 years	2,20,00,000	Yes
Bhavna Grover	Whole Time Director	Permanent	B.A.	47	20 years	1,52,00,000	Yes
Gaurav Mohan Garg	HOD	Permanent	B.com and Diploma in software engineering	44	22 Years	24,00,000	No
Nidhi Punia	Doctor	Permanent	B.A.M.S Pgd Panchkarma	37	6 Years	18,41,137	No
Sahil Jain	HOD	Permanent	MCA	33	12 Years	18,00,000	Yes
Pardeep Kumar Thakur	Manager Operations- Clinic	Permanent	Graduate	42	17 years	17,43,667	No
Kapil Dev	HOD	Permanent	Graduate	42	18 years	17,25,000	No
Vivek Sehgal	HOD	Permanent	B.E. in Electronics & Telecommunication, MBA in Operations	44	20 years	15,60,000	No
Namrta Chaudhary	HOD	Permanent	MBA HR	44	4 years	11,00,000	No
Nanak Chand	CFO	Permanent	B.com & Cost & Management Accountant (Executive)	34	13 years	10,25,500	No

**By Order of the Board of Directors  
For JEENA SIKHO LIFECARE LIMITED**

**Place: Chandigarh  
Date: 05/09/2022**

**Sd/-  
(Manish Grover)  
Managing Director  
DIN No. 07557886**

**Sd/-  
(Bhavna Grover)  
Whole Time Director  
DIN No. 07557913**

**CERTIFICATION BY CHIEF FINANCIAL OFFICER OF THE COMPANY**

I declare that all Board members and senior management personnel have affirmed compliance with the code of conduct for the financial year 2021-22.

Sd/-

Nanak Chand

**Chief Financial Officer**

Place: New Delhi

Date: 05/09/2022

## MANAGEMENT DISCUSSION AND ANALYSIS REPORT

### 1. ECONOMIC SCENARIO

Policy response, economic stimulus measures, relief packages, and roll-out of COVID-19 vaccinations have led to a gradual economic recovery, and a revised global growth at 6% in 2021, moderating to an anticipated 4.4% in 2022.

Food, pharma and chemicals were the first sectors to witness a recovery. Some measure of overall economic normalcy was attained in the September-December quarter. However, the resurgence of COVID-19, towards the end of FY2021, bodes uncertainty for the future.

The year 2021-22 was also characterised by high inflation, at levels which had not been seen before. This was further aggravated by the Russia-Ukraine crisis which began in February 2022 leading to a sharp increase in commodity and oil prices.

The Russia-Ukraine crisis unfolded while the global economy was on a mending path but had not yet fully recovered from the COVID-19 pandemic. Russia's invasion of Ukraine and the economic sanctions on Russia that have followed have put global energy supplies at risk. Russia supplies around 10% of the world's energy, including 17% of its natural gas and 12% of its oil. The jump in oil and gas prices will add to industry costs and reduce consumer real incomes.

In addition to the war, frequent and wider-ranging lockdowns in China—including in key manufacturing hubs—have also slowed activity there and could cause new bottlenecks in global supply chains. Higher, broader, and more persistent price pressures also led to a tightening of monetary policy in many countries. Overall risks to economic prospects have risen sharply and policy trade-offs have become evermore challenging.

In the April Outlook, IMF has further moderated its global growth outlook to 3.6% in 2022 and 2023, 0.8 and 0.2 percentage points respectively, lower than their January forecast. This growth forecast assumes that the conflict remains confined to Ukraine, further sanctions on Russia exempt the energy sector, and the impact of the pandemic abates over the course of 2022.

With the Russia-Ukraine crisis pushing up overall costs of production, including the cost of raw material, transportation and packaging material, Inflation continues to be the biggest concern as we enter the 2022-23 fiscal.

Downside surprises in the second half of 2021: Supply disruptions continued into the fourth quarter, hindering global manufacturing—especially in Europe and the United States. A resurgence in COVID cases (particularly in Europe) also held back a broader recovery. In China, disruptions from COVID outbreaks, interruptions to industrial production from power outages, declining real estate investment, and a faster than-expected withdrawal of public investment all contributed to a second-half slowdown. Although there were signs of a global turnaround in November—with a pickup in international trade and upside surprises for services activity and industrial production data—this only partially offset earlier declines.

## 2. INDIAN SCENARIO

India has emerged as the fastest growing major economy in the world and is expected to be one of the top three economic powers in the world over the next 10-15 years, backed by its robust democracy and strong partnerships.

According to data from the Department of Economic Affairs, as of August 27, 2021, foreign exchange reserves in India reached US\$ 633.5 billion mark.

The Government of India has taken several initiatives to improve the economic condition of the country. The past 12 months have seen the government announce an outlay of `1.97 Lakh Crores for the Production-Linked Incentive (PLI) Schemes across 13 key sectors, including Food Processing, to create national manufacturing champions and generate employment opportunities for the country's youth. This initiative and the emphasis on building infrastructure and promoting Make in India programmes along with resilient domestic demand and consumption are likely to help sustain growth in the Indian economy.

With an improvement in the economic scenario, there have been investments across various sectors of the economy. The private equity - venture capital (PE-VC) sector recorded investments worth US\$ 10.7 billion across 137 deals in August 2021, registering a 5x YoY growth.

In September 2021, Prime Minister Mr. Narendra Modi approved the production-linked incentive (PLI) scheme in the textiles sector—for man-made fibre (MMF) apparel, MMF fabrics and 10 segments/products of technical textiles—at an estimated outlay of Rs. 10,683 crore (US\$ 1.45 billion).

In September 2021, the government approved a production-linked incentive (PLI) scheme for automobile and drone industries with an outlay of Rs. 26,058 crore (US\$ 3.54 billion) to boost the country's manufacturing capabilities.

Ayurvedic products are increasing in popularity. Many Indians are turning to Ayurveda and other alternative medicine systems and treatments, such as unani, siddha, naturopathy, and homoeopathy. The industry is anticipated to almost triple in size in the coming years. By 2022, the market will reach US\$ 9.7 billion in size. India ayurvedic products market exhibited strong growth during 2015-2020 and is expanding at a CAGR of around 15% during 2021-2026.

The Indian wellness industry—estimated at Rs. 49,000 crore (US\$ 6.70 billion)—is gaining momentum on the back of government focus on building a healthy and fit India. Ayurveda is an alternative medicine system with historical roots in India. The Indian wellness and ayurveda industries go hand in hand. Ayurveda is globally acclaimed for its preventive healthcare properties and treatment of many chronic lifestyle disorders. The Indian ayurveda industry has several large players, with the micro, small and medium enterprises (MSMEs) capturing 80% market share. Ayurveda is witnessing a resurgence in India because people have accepted this as a way of life as opposed to the earlier notion of ayurveda as an alternative area of medicine.

### **Key Developments & Trends in India's Wellness and Ayurveda Sectors**

The Services Export Promotion Council, the Ministry of Commerce, estimates the global medical tourism market to be worth US\$ 46.6 billion in 2021, with Asia-Pacific accounting for the largest share (40%). In a bid to position India as the global wellness and ayurveda hub, the tourism ministry is planning to register all wellness centres in the country after the pandemic.

The number of hospitals falling under the international standards of Joint Commission International (JCI) so that tourists have more hospitals to choose from and also, upgrade hospitals under the National Accreditation Board for Hospitals & Healthcare Providers (NABH) and elevate them to the JCI level of hospital. Granting of medical visas are also under consideration.

Travel Firm reveal that travellers are now increasingly looking at destinations offering wellness experiences—Goa, Kerala, Meghalaya, Karnataka, etc. Most travel firms now offer wellness packages to their customers.

Many hotels have tie ups with ayurveda and wellness centres where guests can reside at hotels and avail wellness & ayurveda facilities in the hotel premises. Indian Hotels Company Limited (IHCL), which runs the Taj Group of Hotels, revealed that its guests are opting for wellness programmes to relieve themselves from stress, leading to an average 50% increase in demand for spa treatments every month.

The AYUSH ministry revealed that the Jamnagar institute was conferred the status of an Institution of National Importance (INI) by a parliamentary act and another college in Jaipur was designated an 'Institution Deemed to be University (De novo Category)' by the University Grants Commission (UGC).

### **3. OPPORTUNITIES**

We believe the following are our competitive opportunities:

- Strong R & D capability, many new products under development. Develop medicines which can provide relief to medical conditions for which allopathy medicines do not provide much relief.
- Have fully integrated GMP manufacturing facility to manufacture both classical and proprietary ayurvedic formulations in the most hygienic condition and strict adherence to prescribed norms.
- Have Competent and experienced team of experts for the standardization of treatments. Growing the well-established network of clinics and treatment centre and distribution centres.

### **4. RISK, CONCERNS AND THREATS**

The market has both organized and unorganized players and the capability and the strengths differ. But both are classified under Ayurveda industry. So, the organized sector has to work hard to

maintain the parameters so that the high standards are maintained, and customers should not lose faith in the practice. Major threats for Ayurveda industry are regulatory concerns, consumer perceptions and competition. The regulatory agencies all over the world are focusing on the

Quality, efficacy, safety and standardization of herbal medicines. We have demonstrated excellence in quality of our medicines and JJSI is well positioned in the market for quality products. We rely on repeat business based on the strength of our client relationship and a major portion of our revenue comes from key clients. Initiatives are focused on improving client relationship.

## **5. FUTURE OUTLOOK**

While the government is on a major drive to Promote Yoga and Ayurveda Globally as Key Wellness Initiative, inadequate scientific scrutiny and concerns regarding standards and quality is of major concern. This has prompted the Department of Ayush to enforce a stricter regime under 'National Ayush Mission'. The National Rural Health Mission has a declared policy of promoting 'Pluralistic Healthcare' by involving, alongside the allopathic system, the AYUSH systems, including local health traditions in its operational mission. Insurance companies have started accepting Ayurveda Treatments under insurance claims.

A report by 'Research and Markets' covered a government survey, revealing 45% Indians born between 1982 and 2000 aspire a healthy lifestyle, use fitness apps on their phones and are willing to pay a premium for good health. Millennials prioritising a healthy life is expected to drive sales in the Indian ayurveda market to ~US\$ 10 billion by 2024, from US\$ 4 billion in 2018. Besides fatigue caused by the lockdown, straining work-from-home models and constant fear of infection have boosted the demand for ayurvedic products and wellness packages from domestic and international consumers.

India has the potential to become a health and wellness hub, attracting investments and creating additional jobs. The government has set a target of increasing spending on healthcare from the current 1.3% to 3% of its GDP by 2022. With continuous support from the government and various industries shifting towards a healthy ayurveda-based approach, the Indian wellness & ayurveda market is on its way to touch the lives of millions of people at domestic and global levels.

## **6. INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY**

The company has strong internal controls systems commensurate with the nature of its business, the size and complexity of its operations. In order to ensure orderly and efficient conduct of business the company has put in place systems which include policies and procedures, IT systems, delegation of authority, segregation of duties, internal audit and review framework etc.

The team is cognizant of applicable laws and regulations particularly those related to protection of resources and assets, and the accurate reporting of financial transactions. The audit findings are reviewed by the audit committee.

## 7. OUR KEY PRODUCTS

Our top selling products includes:

1. Dr Suddhi Powder 100 gm
2. Dr. Immune Tablet 80 Tab
3. Dm Capsule 60 Cap
4. Divya Liver Tonic 450ML Black
5. Dhatu Poshak Vati
6. Divya Chander Vati 60 tab
7. Divya CKD 500ml
8. Kidney Care 450ml Black
9. Nefron Plus Capsule
10. Divya Brahm Vati 60 Tab

## 8. MATERIAL DEVELOPMENTS IN HUMAN RESOURCES/INDUSTRIAL RELATIONS FRONT

The company places great emphasis on its employees and believes that they are the core of the Corporate Purpose. The HR mission is to empower employees to make continuous improvements and enhance their professional skills. The company believes in respecting the individual rights and dignity of the people. The company believes that human resources are the most valuable assets and a major driver for achieving its goals.

Our company continues to invest in human resources to build new businesses while simultaneously improving the individual & organisational preparedness for future challenges.

We have a qualified and professional employee base of 1476 fulltime employees as on March 31, 2022. Many of our employees, particularly the senior management, have been working with our Company since long. Our manpower is a prudent mix of the experienced and young people which gives us the dual advantage of stability and growth, execution of services within time and quality. We believe human capital is one of the most valuable assets of our Company as their technical know-how and skill sets position us at a competitive advantage over our competitors in providing some of our services.

## 9. FINANCIAL REVIEW

Statement Of Standalone Financials Result For The Year Ended 31<sup>st</sup> March 2022

S.No.	Particulars	Year Ended 31.03.2022
1.	Income	
	a. Revenue from operations	14,645.32
	b. Other Income	148.90
	Total Income	14,794.22
2.	Expenses	
	a. Purchase of stock in trade	1,159.16
	b. Change in inventories	351.96

	c. Employee benefits expenses	3,374.66
	d. Finance Costs	113.97
	e. Depreciation and amortization expenses	330.59
	f. Other expenses	7,947.09
	<b>Total Expenses</b>	<b>13,277.43</b>
3.	Profit before exceptional and extraordinary items and tax	1,516.79
4.	Exceptional items and extraordinary items	-
5.	Profit before tax	<b>1,516.79</b>
6.	Tax Expenses	
	a. Current tax	386.83
	b. Tax for earlier period	3.60
	c. Deferred tax	(0.88)
	<b>Total tax expenses</b>	<b>389.55</b>
7.	Profit for the year	1,127.24
8.	Earnings per share (Face value of Rs. 10 each)	
	Basic (in Rs.)	11.15
	Diluted (in Rs.)	11.15

Statement Of Consolidated Financials Result For The Year Ended\*31 March 2022 (Amount in Rs. Lacs)

S.No.	Particulars	Year Ended 31.03.2022
1.	Income	
	c. Revenue from operations	14655.44
	d. Other Income	148.91
	<b>Total Income</b>	<b>14804.35</b>
2.	Expenses	
	g. Purchase of stock in trade	1226.97
	h. Change in inventories	292.24
	i. Employee benefits expenses	3379.64
	j. Finance Costs	113.97
	k. Depreciation and amortization expenses	331.09
	l. Other expenses	7951.16
	<b>Total Expenses</b>	<b>13295.07</b>
3.	Profit before exceptional and extraordinary items and tax	1509.28
4.	Exceptional items and extraordinary items	-
5.	Profit before tax	1509.28
6.	Tax Expenses	
	d. Current tax	386.83
	e. Tax for earlier period	3.60
	f. Deferred tax	(0.54)
	<b>Total tax expenses</b>	<b>389.89</b>
7.	Profit for the year	1119.39

8.	Less: Minority report	(3.85)
9.	Profit for the year attributed to the owner of the company	1123.24
10.	Paid up equity share capital (Face value of Rs. 10 each)	1011.12
11.	Reserve (excluding revaluation reserve) as shown in the audited balance sheet of the previous year	NA
12.	Earnings per share (Face value of Rs. 10 each)	
	Basic (in Rs.) (not annualised)	11.11
	Diluted (in Rs.) (not annualised)	11.11

## 10. MARKETING

Ms. Akansha Jain, head of marketing & Information technology is responsible for overall marketing of our Company's products and services. Further, the head of each division provides input for enhancing marketing of the services provided by his respective team.

Generally, we attract consumers by word of mouth of Acharya Manish ji and our Company also run advertisement campaigns of Acharya Manish Ji on Facebook, Instagram, YouTube & other social media platform. Other than that, we also advertise on TV channel. Also we have been focusing on creating awareness on health issues by way of webinars or by posts on social media like YouTube, Facebook, and Instagram etc.

## 11. BUSINESS STRATEGY

Strategies Reflect the Organization's Strengths, Vulnerabilities, Resources, and Opportunities. And, they also reflect the Organization's Competitors and its Market.

### a) Expansion of Domestic Market:

We intend to expand our geographical reach and enter the large domestic market for growth opportunities of our business. Currently we have limited presence and we plan to deepen our presence in the existing market and expand our reach and penetrate into the large available market by giving scale down low price solution and grab major market share.

### b) Promotion of our brand recognition:

We propose to increase the brand recognition through various brand building efforts, communication and various promotional initiatives. Such promotion would enhance the visibility of our brand and also enhance our business positioning and credibility as a serious long term service provider in the education sector.

### c) Moving up the Value Chain:

Our Company increasingly endeavors to move up the value chain in terms of our learning and experiences. We believe that the more value we create, the most we can grow our competitive

advantage. Through constant and focused efforts, we would keep improving our business model to bring the good services to our consumers and constantly move up their value chain as well.

**d) Further widening of our consumer base:**

Since inception of company, we have developed a long-standing relationship with our products end-users. We always focused on providing satisfactory grievances redressal mechanism to them. We believe that this gives us a competitive edge over competitors that we bring to our engagements, our market division also conduct timely scan to identify upcoming opportunity, with the growing opportunities available in the market, we will endeavor to continue to grow our business by adding new consumers in existing and new geographies and also new market segments & products. We are looking towards expanding consumers base in all over India. With the widening of the consumers base for our services, we will be leveraging our marketing skills and relationships and focusing on total consumers orientation.

**e) Focus on cost management:**

Apart from expanding business and revenues, we have to look for areas to reduce costs and achieve efficiencies in order to remain a cost competitive company. We are always in search of new and innovative concepts as per the needs of our consumers but while in the process we make sure of the fact that we perform the given task at the lowest possible cost through effective supervision and planning at back office.

**f) Focus on cordial relationship with our consumer and employees:**

We believe that developing and maintaining long-term sustainable relationships with our consumers and employees will help us in achieving the organizational goals, increasing turnover and entering into new markets.

**g) Experienced Promoter and Management Expertise:**

Our Company is managed by a team of competent personnel having knowledge of core aspects of our Business. Our promoter Mr. Manish Grover ji with his knowledge and experience as well as assisted by our Key Managerial Persons who have helped us to have long term relations with our consumers & vendors. Further, they have also facilitated us to entrench with new consumers. We believe that our experience, knowledge and human resources will enable us to drive the business in a successful and profitable manner.

**INDEPENDENT AUDITOR'S REPORT  
TO THE MEMBERS OF JEENA SIKHO LIFECARE LIMITED**

**Report on the Audit of the Standalone Financial Statements**

**Opinion**

We have audited the standalone financial statements of **JEENA SIKHO LIFECARE LIMITED** (“the Company”), which comprise the balance sheet as at March 31, 2022, the statement of profit and loss, and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2022, and its Profit, and its cash flows for the year ended on that date.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the “Auditor’s Responsibilities for the Audit of the Financial Statements” section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Key Audit Matters**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

<b>The Key Audit Matter</b>	<b>How the matter was addressed in our audit</b>
<p><b>Revenue Recognition</b> As the Company revenue is from trading of ayurvedic medicine consisting of large number of sales orders, there are risks related to completeness of revenue, improper sales cut off, timing</p>	<ul style="list-style-type: none"> <li>• Cut off procedures performed for year ended 31<sup>st</sup> March 2022.</li> <li>• Substantive verification of sales transactions.</li> <li>• Analytical review of sales transactions.</li> <li>• Debtors analysis to ensure that all sales reversal are recognized appropriately.</li> <li>• Review that the revenue has been recognized in accordance with the revenue recognition policy of the Company.</li> <li>• Review sales booked by Company for unusual items, if any.</li> </ul>

of recognitions, out of period sales etc.	<ul style="list-style-type: none"> <li>• Verification of existence and operating effectiveness of internal controls related to sales transactions.</li> </ul>
---	---



### Other Information

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the annual report but does not include the financial statements and our auditor's report thereon. The annual report is expected to be made available to us after the date of this auditor's report. Our opinion on the financial statements does not cover the other information and we will not express any form of assurance or conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

When we will read the annual report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance.

### Responsibilities of Management and Those Charged with Governance for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

### Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from

fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit

matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

### **Report on Other Legal and Regulatory Requirements**

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143(3) of the Act, we report that:
  - a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
  - b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books
  - c. The Balance Sheet, the Statement of Profit and Loss and the Cash Flow Statement dealt with by this Report are in agreement with the books of account
  - d. In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
  - e. On the basis of the written representations received from the directors as on March 31, 2022 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2022 from being appointed as a director in terms of Section 164(2) of the Act.
  - f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".
  - g. With respect to the matter to be included in the Auditor's Report under Section 197(16) of the Act:

In our opinion, the managerial remuneration for the year ended March 31, 2022 has been paid by the Company to its directors in accordance with the provisions of section 197 read with Schedule V to the Act;
  - h. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
    - i. There are no pending litigations on the Company
    - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
    - iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.

- iv. (a) The Management has represented that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity, including foreign entity (“Intermediaries”), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- (b) The Management has represented, that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the Company from any person or entity, including foreign entity (“Funding Parties”), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- (c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.

**For KRA & Co.**  
**Chartered Accountants**  
**(Firm Registration No.020266N)**

Saurabh Garg  
Partner  
Membership No.: 510541  
UDIN: 22510541ANOJAG3579  
Place: Delhi  
Date: July 25, 2022

**ANNEXURE - A TO THE INDEPENDENT AUDITORS' REPORT OF EVEN DATE ON THE STANDALONE FINANCIAL STATEMENTS OF JEENA SIKHO LIFECARE LIMITED (Referred to in Paragraph 1 under the heading of "Report on Other Legal and Regulatory Requirements" of our report of even date)**

- (i) (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.  
(B) The Company has maintained proper records showing full particulars of intangible assets.
- (b) In accordance with the phased programme for verification of Property, Plant and Equipment, certain items of Property, Plant and Equipment were physically verified by the management during the year and no material discrepancies were noticed on such verification.
- (c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of all the immovable properties (other than properties where the company is the lessee and the lease agreements are duly executed in favour of the lessee) disclosed in the financial statements are held in the name of the company
- (d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not revalued any Property, Plant and Equipment during the year. Consequently, clause (i)(d) of the Order is not applicable to the Company.
- (e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, no proceedings have been initiated or are pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder, if so. Consequently, clause (i)(e) of the Order is not applicable to the Company.
- (ii) (a) The management has conducted physical verification of inventories at reasonable interval during the year and no material discrepancies (10% or more in the aggregate for each class of inventory) were noticed on physical verification of inventories. In our opinion the coverage and procedure of such verification by the management is appropriate.
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the company has not been sanctioned with any working capital limits in excess of five crore rupees, in aggregate, from banks or financial institutions on the basis of security of current assets. Consequently, clause (ii)(b) of the Order is not applicable to the Company.
- (iii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the company has granted loan and advances in the nature of loan to a subsidiary.

- (a) The aggregate amount of such loan granted is Rs. 138.50 Lakhs and the balance outstanding at the Balance Sheet date as at 31.03.2022 is Rs. 138.50 Lakhs.
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the loan has been provided interest free to the subsidiary.
- (c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the loan is repayable on demand. Consequently, clause (iii)(c) of the Order is not applicable to the Company
- (d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no amount overdue for this loan
- (e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no loan or advance in the nature of loan granted which has fallen due during the year and has been renewed or extended or fresh loans granted to settle the overdue of existing loans given to the same parties. Consequently, clause (iii)(e) of the Order is not applicable to the Company.
- (f) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the company has only granted loans or advances in the nature of loans repayable on demand to a subsidiary company for a total amount of Rs. 138.50 Lakhs
- (iv) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has complied with the provisions of Sections 185 and 186 of the Companies Act, 2013 in respect of grant of loans, making investments and providing guarantees and securities, as applicable. Except for providing interest free loan to subsidiary company.
- (v) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not accepted any deposit during the year. Consequently, clause (v) of the Order is not applicable to the Company.
- (vi) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company is not required to maintain cost records under section 148(1) of the Companies Act, 2013. Consequently, clause (vi) of the Order is not applicable to the Company.
- (vii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, in respect of statutory dues:
  - (a) The Company has generally been regular in depositing undisputed statutory dues including Goods and Services Tax, Provident Fund, Employees State Insurance, Income-tax, Sales-tax, Service Tax, Custom Duty, Excise Duty, value added tax, cess and any other statutory dues, during the year, with the appropriate authorities and there are no material statutory dues in arrears as at March 31, 2022 for a period of more than six months from the date they became payable.
  - (c) There are no Dues of Goods and Services Tax, Provident Fund, Employees State Insurance, Income-tax, Sales-tax, Service Tax, Custom Duty, Excise Duty, value added tax, cess and any

other statutory dues which have not been deposited as on March 31, 2022, on account of disputes with the related authorities.

- (viii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no transactions which are not recorded in the books of account and have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961
- (ix)
  - (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not defaulted in the repayment of dues to financial institutions or banks.
  - (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been declared wilful defaulter by any bank or financial institution or other lender.
  - (c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not availed any term loan during the period. Consequently, clause (ix)(c) of the Order is not applicable to the Company.
  - (d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the funds raised on short term basis have not been utilized for long term purposes. Consequently, clause (ix)(d) of the Order is not applicable to the Company.
  - (e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries.
  - (f) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the company has not raised loans during the year on the pledge of securities held in its subsidiaries.
- (x)
  - (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not raised money during the year by way of Initial Public Offer (IPO). Consequently, clause (x)(a) of the Order is not applicable to the Company. The Company has started the process of issue of IPO in the financial year 2021-22. However, the money was raised during the financial year 2022-23.
  - (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or convertible debentures during the year. Consequently, clause (x)(b) of the Order is not applicable to the Company.
- (xi)
  - (a) To the best of our knowledge and according to the information and explanations given to us, no material fraud by the Company or on the Company has been noticed or reported during the year.

- (b) According to the information and explanations given to us, no report under sub-section (12) of section 143 of the Companies Act has been filed by the auditor in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.
- (c) According to the information and explanations given to us, no whistle blower complaints has been received during the year. Consequently, clause (xi)(c) of the Order is not applicable to the Company.
- (xii) According to the information and explanations given to us, the Company is not a Nidhi Company. Consequently, clause (xii) of the Order is not applicable to the Company.
- (xiii) In our opinion and according to the information and explanations given to us, all transactions with the related parties are in compliance with section 177 and 188 of Companies Act, 2013, and corresponding details have been disclosed in the financial statements, as required by the applicable Accounting Standards.
- (xiv)
  - (a) In our opinion and according to the information and explanations given to us, the Company has an internal audit system commensurate with the size and nature of its business
  - (b) The report of the Internal Auditor for the year were considered by us for statutory audit purposes.
- (xv) In our opinion and according to the information and explanations given to us, the Company has not entered into any non-cash transactions with directors or persons connected with him.
- (xvi) The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Consequently, clause (xvi)(a), (b), (c) of the Order is not applicable to the Company.
- (xvii) The Company has not incurred any cash losses in the financial year and in the immediately preceding financial year.
- (xviii) There is a resignation of the Statutory Auditor during the year and we have taken into consideration the issues, objections and concerns raised by the outgoing auditor.
- (xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that the Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

- (xx) In our opinion and according to the information and explanations given to us, the Company has not fully spent the amount of Rs. 20.39 Lakhs required to be spend under section 135 of the Companies Act, 2013. The Company intent to spend this amount within six months of the close of the financial year.

**For KRA & Co.**  
**Chartered Accountants**  
**(Firm Registration No.020266N)**

**Saurabh Garg**  
**Partner**  
**Membership No.: 510541**  
**UDIN: 22510541ANOJAG3579**  
**Place: Delhi**  
**Date: July 25, 2022**

## **ANNEXURE “B” TO THE INDEPENDENT AUDITORS’ REPORT OF EVEN DATE ON THE STANDALONE FINANCIAL STATEMENTS OF JEENA SIKHO LIFECARE LIMITED**

**(Referred to in Paragraph 2 point (f) under the heading of “Report on Other Legal and Regulatory Requirements” of our report of even date)**

### **Report on the Internal Financial Controls Over Financial Reporting under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)**

We have audited the internal financial controls over financial reporting of **JEENA SIKHO LIFECARE LIMITED** (“the Company”) as at March 31, 2022, in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

#### **Management’s Responsibility for Internal Financial Controls**

The Company’s management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company, considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

#### **Auditors’ Responsibility**

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) issued by Institute of Chartered Accountants of India and the Standards on Auditing prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.

### **Meaning of Internal Financial Controls over Financial Reporting**

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

### **Inherent Limitations of Internal Financial Controls Over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### **Opinion**

In our opinion, to the best of our information and according to the explanation given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2022, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

**For KRA & Co.**  
**Chartered Accountants**  
**(Firm Registration No.020266N)**

**Saurabh Garg**  
**Partner**  
**Membership No.: 510541**  
**UDIN: 22510541ANOJAG3579**  
**Place: Delhi**  
**Date: July 25, 2022**

<b>Jeena Sikho Lifecare Limited</b> <b>CIN: U52601PB2017PLC046545</b> <b>Balance Sheet as at 31.03.2022</b> <b>(All amounts in Indian Rupees in Lakhs, unless otherwise stated)</b>				
Particulars		Note No.	As at 31 March, 2022	As at 31 March, 2021
<b>A</b>	<b>EQUITY AND LIABILITIES</b>			
<b>1</b>	<b>Shareholders' funds</b>			
	(a) Equity Share capital	3	1,011.12	10.14
	(b) Reserves and surplus	4	2,644.40	2,385.24
<b>2</b>	<b>Non-current liabilities</b>			
	(a) Long-term borrowings	5	80.80	15.32
	(b) Deferred tax liabilities (net)	6	27.79	28.67
	(c) Long-term provisions	7	8.27	47.76
<b>3</b>	<b>Current liabilities</b>			
	(a) Short-term borrowings	8	662.69	1,188.02
	(b) Trade payables	9		
	(i) total outstanding dues of micro enterprises and small enterprises; and		-	-
	(ii) total outstanding dues of creditors other than micro enterprises and small enterprises		463.12	328.14
	(c) Other current liabilities	10	1,156.08	891.31
	(d) Short-term provisions	11	100.94	20.40
	<b>TOTAL</b>		<b>6,155.21</b>	<b>4,915.00</b>
<b>B</b>	<b>ASSETS</b>			
<b>1</b>	<b>Non-current assets</b>			
	(a) Property, Plant and Equipment and Intangible assets			
	(i) Property, Plant and Equipment	12	2,821.67	2,249.57
	(ii) Intangible assets	13	12.86	17.85
	(iii) Capital work in progress		504.10	-
	(b) Non-current investments	14	0.51	
	(c) Long-term loans and advances	15	507.82	12.66
	(d) Other non-current assets	16	104.04	26.19
<b>2</b>	<b>Current assets</b>			
	(a) Inventories	17	575.90	927.86
	(b) Trade receivables	18	897.39	323.74
	(c) Cash and cash equivalents	19	256.92	896.30
	(d) Short-term loans and advances	20	382.87	320.89
	(e) Other current assets	21	91.13	139.94
	<b>TOTAL</b>		<b>6,155.21</b>	<b>4,915.00</b>
Notes to Balance Sheet and Statement of Profit and Loss				
As per our report of even date		For and on behalf of the Board of Directors		
For <b>KRA &amp; Co.</b>		<b>JEENA SIKHO LIFECARE LIMITED</b>		
Chartered Accountants				
Firm Regd. No.020266N				
<b>Saurabh Garg</b>		Sd/-		Sd/-
<b>(Partner)</b>		<b>Manish Grover</b>		<b>Bhavna Grover</b>
M.No. 510541		Managing Director		Whole-Time Director
Place: New Delhi		DIN: 07557886		DIN: 07557913
UDIN: 22510541AN0JAG3579				
Dated: 25/07/2022		Sd/-		Sd/-
		<b>Nanak Chand</b>		<b>Nikita Juneja</b>
		<b>(Chief Financial Officer)</b>		<b>(Company Secretary)</b>
				(M No. - A65160)

<b>Jeena Sikho Lifecare Limited</b> <b>CIN: U52601PB2017PLC046545</b> <b>Statement of Profit and Loss</b> <b>(All amounts in Indian Rupees in Lakhs, unless otherwise stated)</b>				
Particulars		Note No.	For the year ended 31 March, 2022	For the year ended 31 March, 2021
<b>I</b>	Revenue from Operations	22	14,645.32	13,580.82
<b>II</b>	Other Income	23	148.90	106.63
<b>III</b>	<b>Total Income (I + II)</b>		<b>14,794.22</b>	<b>13,687.45</b>
<b>IV</b>	<b>Expenses</b>			
	(a) Purchases of stock-in-trade	24	1,159.16	1,492.04
	(b) Change in inventories of stock-in-trade	25	351.96	127.68
	(c) Employee benefits expenses	26	3,374.66	3,038.25
	(d) Finance costs	27	113.97	130.15
	(e) Depreciation and amortisation expenses	28	330.59	246.09
	(f) Other expenses	29	7,947.09	7,234.61
	<b>Total expenses</b>		<b>13,277.43</b>	<b>12,268.82</b>
<b>V</b>	<b>Profit before exceptional and extraordinary items and tax (III - IV)</b>		1,516.79	1,418.63
<b>VI</b>	Exceptional items & Extraordinary items		-	-
<b>VII</b>	<b>Profit before tax (V + VI)</b>		<b>1,516.79</b>	<b>1,418.63</b>
<b>VIII</b>	<b>Tax expense:</b>			
	(a) Current tax		386.83	381.79
	(b) Taxation for earlier years		3.60	-
	(c) Deferred tax		(0.88)	7.42
	<b>Total tax expense</b>		<b>389.55</b>	<b>389.21</b>
<b>IX</b>	<b>Profit for the year (VII - VIII)</b>		<b>1,127.24</b>	<b>1,029.42</b>
<b>X</b>	<b>Earnings per share (of Rs. 10 each):</b>			
	(a) Basic	30	11.15	10.19
	(b) Diluted	30	11.15	10.19

**Notes to Balance Sheet and Statement of Profit and Loss**

As per our report of even date

**For KRA & Co.**

Chartered Accountants

Firm Regd. No.020266N

**For and on behalf of the Board of Directors**
**JEENA SIKHO LIFECARE LIMITED**
**Saurabh Garg**
**(Partner)**

M.No. 510541

Place: New Delhi

UDIN: 22510541AN0JAG3579

Dated: 25/07/2022

Sd/-

**Manish Grover**

Managing Director

DIN: 07557886

Sd/-

**Bhavna Grover**

Whole-Time Director

DIN: 07557913

Sd/-

Nanak Chand

**(Chief Financial Officer)**

Sd/-

Nikita Juneja

**(Company Secretary)**

(M No. - A.65160)

<b>Jeena Sikho Lifecare Limited</b> <b>CIN: U52601PB2017PLC046545</b> <b>Statement of cash flow</b> <b>(All amounts in Indian Rupees in Lakhs, unless otherwise stated)</b>		
Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
<b>Profit before tax</b>	<b>1,516.79</b>	<b>1,418.63</b>
<b>Adjustments for:</b>		
Depreciation & amortization expense	330.59	246.09
Net (gain)/ loss on sale of Property Plant & Equipment	(79.70)	13.28
Interest expense on borrowings	113.97	130.15
Interest income	(22.26)	(13.54)
<b>Operating Profit before working capital changes</b>	<b>1,859.39</b>	<b>1,794.61</b>
<b>Movement in working capital:</b>		
Increase/(decrease) in provisions	41.05	13.95
Increase/(decrease) in trade payables	134.98	(237.23)
Increase/(decrease) in other current liabilities	274.95	320.72
Decrease/(increase) in loans and advances	76.52	(145.50)
Decrease/(increase) in trade receivables	(573.65)	114.40
Decrease/(increase) in inventories	351.95	127.68
Decrease/(increase) in other non current assets	(77.86)	4.72
Decrease/(increase) in other current assets	51.06	141.20
<b>Cash generated from operations</b>	<b>2,138.39</b>	<b>2,134.55</b>
Income taxes refunded/ (paid)	(390.43)	(381.79)
<b>Net cash flow from operations (A)</b>	<b>1,747.96</b>	<b>1,752.76</b>
<b>Cash flow from investing activities</b>		
Purchase of property, plant & equipment and Intangible assets	(1,683.52)	(883.27)
Increase in capital advances	(495.16)	-
Advance to related party	(138.50)	-
Sale of property, plant & equipment	361.42	22.83
Investment in subsidiary company	(0.51)	-
Interest received	20.01	13.54
<b>Net cash used in investing activities (B)</b>	<b>(1,936.26)</b>	<b>(846.90)</b>
<b>Cash flow from financing activities</b>		
Proceeds/(Repayment) of Short Term Borrowings	(525.33)	(8.57)
Proceeds from issue of equity shares	132.90	19.00
Repayment of Long Term Borrowings	65.48	(34.24)
Interest paid	(124.13)	(129.41)
<b>Net cash flow from/ (used in) financing activities (C)</b>	<b>(451.08)</b>	<b>(153.22)</b>
Net increase/(decrease) in cash and cash equivalents (A+B+C)	<b>(639.38)</b>	<b>752.64</b>
Cash and cash equivalents at the beginning of the year	896.30	143.66
<b>Cash and cash equivalents at the closing of the year</b>	<b>256.92</b>	<b>896.30</b>
a) Cash and Cash Equivalents included in Cash Flow Statement comprise of following (Refer Note 19):		
Particulars	As at 31 March, 2022	As at 31 March, 2021
Cash in hand	72.82	42.73
Balances with banks		
Current Account With Banks	144.60	330.51
Bank deposits with original maturity of less than 3 months	39.50	523.06
	<b>256.92</b>	<b>896.30</b>
<b>Notes to Balance Sheet and Statement of Profit and Loss</b>		
As per our report of even date <b>For KRA &amp; Co.</b> Chartered Accountants Firm Regd. No.020266N	<b>or and on behalf of the Board of Directors</b> <b>JEENA SIKHO LIFECARE LIMITED</b>	
<b>Saurabh Garg</b> (Partner) M.No. 510541 Place: New Delhi UDIN: 22510541ANQJAG3579 Dated: 25/07/2022	Sd/- <b>Manish Grover</b> Managing Director DIN: 07557886	Sd/- <b>Bhavna Grover</b> Whole-Time Director DIN: 07557913
	Sd/- Nanak Chand <b>(Chief Financial Officer)</b>	Sd/- Nikita Juneja <b>(Company Secretary)</b> (M No. - A65160)

<b>Notes to financial statement for the year ended March 31, 2022</b>	
<b>(All amounts in Indian Rupees in Lakhs, unless otherwise stated)</b>	
<b>1</b>	<b>Corporate information</b>
	Jeena Sikho Lifecare limited was incorporated in 2017. The Company is a trading concern. The company deals in trading of Ayurvedic Medicines across the PAN India basis.
<b>2</b>	<b>Basis of Preparation of financial statements (Significant Accounting Policies &amp; other explanatory Notes)</b>
<b>2.1</b>	<b>Basis of Preparation</b>
	The financial statements of the Company have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP), including the Accounting Standards notified under section 133 of the Companies Act, 2013. The financial statements have been prepared on accrual basis under the historical cost convention.
<b>2.2</b>	<b>Current versus non-current classification</b>
	The Company presents assets and liabilities in the balance sheet based on current/non-current classification. An asset is treated as current when it is: <ul style="list-style-type: none"> <li>- Expected to be realized or intended to be sold or consumed in normal operating cycle</li> <li>- Held primarily for purpose of trading</li> <li>- Expected to be realized within twelve months after the reporting period, or</li> <li>- cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period</li> </ul> All other assets are classified as non-current. A liability is current when: <ul style="list-style-type: none"> <li>- It is expected to be settled in normal operating cycle</li> <li>- It is held primarily for purpose of trading</li> <li>- It is due to be settled within twelve months after the reporting period, or</li> <li>- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period</li> </ul> All other liabilities are classified as non-current. Deferred tax assets and deferred tax liabilities are classified as non-current assets and liabilities. The operating cycle is the time between the acquisition of assets for processing and their realization in cash and cash equivalents. The Company has identified twelve months as its operating cycle.
<b>2.3</b>	<b>Use of estimates</b>
	The preparation of the financial statements requires the Management to make estimates and assumptions considered in the reported amounts of assets and liabilities (including contingent liabilities) and the reported income and expenses during the year. The Management believes that the estimates used in preparation of the financial statements are prudent and reasonable. Future results could differ due to these estimates and the differences between the actual results and the estimates are recognised in the periods in which the results are known / materialise.
<b>2.4</b>	<b>Inventories</b>
	The inventory are valued at lower of cost or net realizable value. The inventory costs are based on first in first out method. Cost includes all charges in bringing the goods to the point of sale, including octroi and other levies, transit insurance and receiving charges. Finished goods include appropriate proportion of overheads.
<b>2.5</b>	<b>Cash and cash equivalents</b>
	Cash and cash equivalents in the balance sheet comprise of cash at bank and in hand and short term investments with an original maturity of three months or less. Earmarked balances with bank, margin money or security against borrowings, guarantees and other commitments, if any shall be treated separately from cash and cash equivalent
<b>2.6</b>	<b>Cash flow statement</b>
	Cash flows are reported using the indirect method, whereby profit / (loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated based on the available information.

<b>2.7</b>	<b>Property, plant and equipment</b>
	Property, Plant and equipment including capital work in progress are stated at cost, less accumulated depreciation and accumulated impairment losses, if any. The cost comprises of purchase price, taxes, duties, freight and other incidental expenses directly attributable and related to acquisition and installation of the concerned assets and are further adjusted by the amount of input tax credit availed wherever applicable. Subsequent costs are included in asset's carrying amount or recognised as separate assets, as appropriate, only when it is probable that future economic benefit associated with the item will flow to the Company and the cost of item can be measured reliably.
<b>2.8</b>	<b>Depreciation and amortisation</b>
	Depreciation on property, plant and equipment is provided on prorata basis on straight line method using the useful lives of the assets estimated by the management and in the manner prescribed in Schedule II of the Companies Act 2013. The estimated life of various assets is as follows:
	Building 30 Years
	Motor Cycle 10 Years
	Electrical equipment's 10 Years
	Furniture and Fixture 10 Years
	Motor Car 8 Years
	Office Equipment 5 Years
	Computer and Software 3 Years
<b>2.9</b>	<b>Intangible assets</b>
	<b>Separately acquired intangible assets</b>
	Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less accumulated amortization and accumulated impairment losses, if any. Internally generated intangibles, excluding capitalized development cost, are not capitalized and the related expenditure is reflected in statement of Profit and Loss in the period in which the expenditure is incurred. Cost comprises the purchase price and any attributable cost of bringing the asset to its working condition for its intended use.
<b>2.10</b>	<b>Revenue recognition</b>
	<u>Sale of goods</u>
	Sales are recognised, net of returns and trade discounts, on transfer of significant risks and rewards of ownership to the buyer, which generally coincides with the delivery of goods to customers. Sales exclude GST. The company follows the mercantile system of accounting and recognizes the income and expenditures on accrual basis except in case of significant uncertainties.
<b>2.11</b>	<b>Other income</b>
	Interest income is recognised on time proportion basis. Rental income is recognized on accrual basis
<b>2.12</b>	<b>Foreign currency transactions and translations</b>
	<u>Initial recognition</u>
	Transactions in foreign currencies entered into by the Company are accounted at the exchange rates prevailing on the date of the transaction or at rates that closely approximate the rate at the date of the transaction.
	<u>Measurement of foreign currency monetary items at the Balance Sheet date</u>
	Foreign currency monetary items (other than derivative contracts) of the Company outstanding at the Balance Sheet date are restated at the year-end rates.
	Exchange differences arising out of these translations are charged to the Statement of Profit and Loss.

<b>2.13</b>	<b>Investments</b>
	Long-term investments, are carried individually at cost less provision for diminution, other than temporary, in the value of such investments. Current investments are carried individually, at the lower of cost and fair value. Cost of investments include acquisition charges such as brokerage, fees and duties.
<b>2.14</b>	<b>Employee benefits</b>
	The Company has adopted the Accounting Standard 15- Employee Benefits prescribed under the Companies (Accounting Standards) Rules, 2006. 'Employee benefits include provident fund, bonus and gratuity benefits. The Company's obligation towards various employee benefits has been recognized as follows:
	<b>Short Term Employee Benefits</b>
	All employee benefits payable wholly within twelve months of rendering the service are short-term employee benefits. Benefits such as salaries, wages and bonus wages, etc, are recognized in the Profit and Loss statement in the period in which the employee renders the related service.
	<b>Defined contribution plans</b>
	The Company's contribution to provident fund are considered as defined contribution plans and are charged as an expense as they fall due based on the amount of contribution required to be made.
	<b>Defined benefits plans</b>
	(i) For defined-benefit plans, the amount recognised in the Balance Sheet is the present value of the defined-benefit obligation less the fair value of any plan assets and any past service costs not yet recognised. The present value of the defined-benefit obligation is the present value of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. The discount rate used is the market yields on government bonds at the Balance Sheet date with remaining terms to maturity approximating those of the Company's obligations.
	(ii) Actuarial gains and losses in respect of post employment and other long-term benefits are charged to the Statement of Profit and Loss.
<b>2.15</b>	<b>Borrowing costs</b>
	Borrowing costs include interest, amortisation of ancillary costs incurred and exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost. Costs in connection with the borrowing of funds to the extent not directly related to the acquisition of qualifying assets are charged to the Statement of Profit and Loss over the tenure of the loan. Borrowing costs, allocated to and utilised for qualifying assets, pertaining to the period from commencement of activities relating to construction / development of the qualifying asset up to the date of capitalisation of such asset is added to the cost of the assets. Borrowing cost attributable to the fixed assets during construction/ exploration, renovation and modernization are capitalized. Such borrowing costs are apportioned on the average balance of capital work in progress for the year. Other borrowing costs are recognized as an expense in the period in which they are incurred.
<b>2.16</b>	<b>Segment reporting</b>
	The Company identifies primary segments based on the dominant source, nature of risks and returns and the internal organisation and management structure. The operating segments are the segments for which separate financial information is available and for which operating profit/loss amounts are evaluated regularly by the executive
<b>2.17</b>	<b>Taxes on income</b>

	<p>Tax expense comprises current and deferred tax. Current income tax is measured at the amount expected to be paid to the tax authorities in accordance with Income Tax Act, 1961. Deferred income tax reflects the impact of current year timing differences between taxable income that originates in one period and are capable of reversal in one or more subsequent periods.</p> <p>Minimum Alternate Tax (MAT) paid in accordance with the tax laws, which gives future economic benefits in the form of adjustment to future income tax liability, is considered as an asset if there is convincing evidence that the Company will pay normal income tax. Accordingly, MAT is recognised as an asset in the Balance Sheet when it is probable that future economic benefit associated with it will flow to the Company.</p> <p>Deferred tax is recognised on timing differences, being the differences between the taxable income and the accounting income that originate in one period and are capable of reversal in one or more subsequent periods. Deferred tax is measured using the tax rates and the tax laws enacted or substantially enacted as at the reporting date. Deferred tax liabilities are recognised for all timing differences. Deferred tax assets in respect of unabsorbed depreciation and carry forward of losses are recognised only if there is virtual certainty that there will be sufficient future taxable income available to realise such assets. Deferred tax assets are recognised for timing differences of other items only to the extent that reasonable certainty exists that sufficient future taxable income will be available against which these can be realised. Deferred tax assets and liabilities are offset if such items relate to taxes on income levied by the same governing tax laws and the Company has a legally enforceable right for such set off. Deferred tax assets are reviewed at each Balance Sheet date for their realisability.</p>
<b>2.18</b>	<b>Impairment of assets</b>
	<p>The carrying values of assets / cash generating units are reviewed at each Balance Sheet date for impairment. If any indication of impairment exists, the recoverable amount of such assets is estimated and impairment is recognised if the carrying amount of these assets exceeds their recoverable amount. The recoverable amount is the greater of the net selling price and their value in use. Value in use is arrived at by discounting the future cash flows to their present value based on an appropriate discount factor. When there is indication that an impairment loss recognised for an asset in earlier accounting periods no longer exists or may have decreased, such reversal of impairment loss is recognised in the Statement of Profit and Loss.</p>
<b>2.19</b>	<b>Provisions and contingencies</b>
	<p>A provision is recognised when the Company has a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions (excluding retirement benefits) are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the Balance Sheet date. These are reviewed at each Balance Sheet date and adjusted to reflect the current best estimates.</p> <p>A contingent liability is disclosed where, as a result of past events, there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources. When there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made.</p>
<b>2.20</b>	<b>Leases</b>
	<b>a) Finance lease</b>
	i) Assets taken on finance lease are capitalised at fair value or net present value of the minimum lease payments, whichever is less.
	ii) Lease payments are apportioned between the finance charges and outstanding liability in respect of assets taken on lease.
	<b>b) Operating lease</b>
	i) Leases, where the lessor effectively retains substantially all the risks and benefits of ownership of the leased term are classified as operating lease. Lease rent are recognized as an expense in the Statement of Profit and Loss on a straight line basis over the lease term.
<b>2.21</b>	<b>Earning per share</b>

	Basic earnings per share is calculated by dividing the net profit or loss for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year. Partly paid equity shares are treated as a fraction of an equity share to the extent that they were entitled to participate in dividends relative to a fully paid equity share during the reporting year. For the purpose of calculating diluted earnings per share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.
2.22	<b>The Previous Year figures have been regrouped/rearranged wherever necessary to make them comparable.</b>

**Note 3 Equity Share capital**

Particulars	As at 31 March, 2022	As at 31 March, 2021
<b>(a) Authorised Share Capital</b>		
Equity shares of Rs. 10 each: 1,50,00,000 (March 31, 2021:2,00,000)	1,500.00	20.00
<b>Total Authorised Share Capital</b>		
<b>(b) Issued, Subscribed &amp; Fully Paid up Shares</b>		
Equity shares of Rs. 10 each: 1,01,11,192 (March 31, 2021:1,00,000)	1,011.12	10.00
<b>Total Issued, Subscribed &amp; Fully Paid up Shares</b>		
<b>(c) Issued, Subscribed but not Fully Paid up Shares</b>		
Equity shares of Rs. 10 each: Nil (March 31, 2021: 11,112)	-	0.14
<b>Total Issued, Subscribed but not Fully Paid up Shares</b>		
<b>Total (b+c)</b>	1,011.12	10.14

**(d) Reconciliation of shares outstanding at the beginning and at the end of the reporting period**

Particulars	As at 31 March, 2022		As at 31 March, 2021	
	No. of shares	Amount	No. of shares	Amount
<b>Equity shares</b>				
Balance at the beginning of the period/ year	1,11,112	10,13,890	1,00,000	10,00,000
Issued during the year	-	-	11,112	13,890
Call money receipts for shares issued during the previous years	-	97,230	-	-
Shares bought back	-	-	-	-
<b>Balance at the end of the reporting period/ year</b>	1,11,112	11,11,120	1,11,112	10,13,890

**(e) Terms/ rights attached to Equity Shares**

The Company has only one class of Equity Shares having a par value of Rs. 10 per share. Each holder of Equity Shares is entitled to one vote per share. In the event of liquidation, the Equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholding.

**(f) Details of shareholders holding more than 5% shares in the Company**

Name of Shareholder	As at 31 March, 2022		As at 31 March, 2021	
	No. of shares	% holding	No. of shares	% holding
<b>Equity shares of Rs. 10 each fully paid-up</b>				
Sh. Manish Grover	99,000	89.10%	99,000	97.64%
Smt. Bhavna Grover	1,000	0.90%	1,000	0.99%
Oregano Life Private Limited	11,112	10.00%	1,389	1.37%

**(g) Details of Promoter shareholding**

Name of Shareholder	As at 31 March, 2022		As at 31 March, 2021	
	No. of shares	% holding	No. of shares	% holding
<b>Equity shares of Rs. 10 each fully paid-up</b>				
Sh. Manish Grover	99,000	89.10%	99,000	97.64%
Smt. Bhavna Grover	1,000	0.90%	1,000	0.99%
<b>% change during the year/period</b>				
Sh. Manish Grover		-8.54%		-1.36%
Smt. Bhavna Grover		-0.09%		-0.01%

**Note 4 Reserves and surplus**

Particulars	As at 31 March, 2022	As at 31 March, 2021
<b>(a) Security Premium</b>	150.79	18.86
<b>(b) Statement of Profit and Loss</b>		
Balance as per last Balance Sheet	2,366.38	1,357.22
Add: Profit / (Loss) for the year	1,127.24	1,029.42
Less: Provision for CSR	-	(20.26)
Less: Bonus issue during the year	1,000.01	-
<b>Total</b>	2,493.61	2,366.38
<b>Total</b>	2,644.40	2,385.24

**Note 5 Long-term borrowings**

Particulars	As at 31 March, 2022	As at 31 March, 2021
<b>(a) Vehicles Loan - Secured</b>		
Loan from banks	80.80	15.32
<b>Total</b>	<b>80.80</b>	<b>15.32</b>

Vehicle loan from Banks is for a total of 4 vehicles (Loan from HDFC Bank for Ambulance, Fortuner and Honda WRV and loan from Axis Bank for Land Rover). The loan is secured by hypothecation of vehicles. These vehicle loans carries an interest from 8.9% to 9.25% p.a. The loans are repayable in 5 years.

**Note 6 Deferred Tax Liability**
**Balance Sheet**

Particulars	As at 31 March, 2022	As at 31 March, 2021
<b>Deferred tax liability</b>		
Property Plant and Equipment	33.37	28.67
<b>Tax effect of items constituting deferred tax liability</b>	<b>33.37</b>	<b>28.67</b>
<b>Deferred tax asset</b>		
Employee benefits	5.58	-
<b>Tax effect of items constituting deferred tax assets</b>	<b>5.58</b>	<b>-</b>
<b>Net deferred tax liability / (asset)</b>	<b>27.79</b>	<b>28.67</b>

**Impact on Statement of Profit & Loss**

Particulars	As at 31 March, 2022	As at 31 March, 2021
Property Plant and Equipment	4.70	7.42
Employee benefits	(5.58)	-
<b>Deferred tax expense/ (credit) charged in profit and loss</b>	<b>(0.88)</b>	<b>7.42</b>

**Note 7 Long Term Provisions**

Particulars	As at 31 March, 2022	As at 31 March, 2021
Provision for Employee benefits	8.27	47.76
<b>Total</b>	<b>8.27</b>	<b>47.76</b>

**Note 8 Short-term borrowings**

Particulars	As at 31 March, 2022	As at 31 March, 2021
<b>(a) Unsecured</b>		
<b>Loan from other parties ( Repayable on Demand)</b>		
DSG Investments Private Limited	229.00	229.00
Khosya Finlease Private Limited	216.00	336.00
Mourvinandan Traders & Consultants Ltd	-	200.00
SKP Leasing Limited	40.00	40.00
Acturial Learner Island P Ltd	40.00	40.00
Pawan Motor General Finance	-	200.00
White Diamond Media	110.00	135.00
<b>(b) Current maturities of long-term borrowings (Secured)</b>		
Vehicle loan	27.69	8.02
<b>Total</b>	<b>662.69</b>	<b>1,188.02</b>

**Terms of Loan:**

(b) Unsecured loan from other parties are repayable on demand and carries interest rate of 10%

**Note 9 Trade Payables**

Particulars	As at 31 March, 2022	As at 31 March, 2021
(i) total outstanding dues of micro enterprises and small enterprises	-	-
(ii) total outstanding dues for creditors other than micro enterprises and small enterprises	463.12	328.14
<b>Total</b>	<b>463.12</b>	<b>328.14</b>

**Trade Payables Ageing Schedule**

Particulars	As at 31 March, 2022	As at 31 March, 2021
<b>Undisputed</b>		
<b>Due to MSME</b>		
Less than one year	-	-
1-2 years	-	-
2-3 years	-	-
More than 3 years	-	-
<b>Total</b>	<b>-</b>	<b>-</b>
<b>Other</b>		
Less than one year	446.38	311.68
1-2 years	0.27	3.24
2-3 years	3.24	13.22
More than 3 years	13.22	-
<b>Total</b>	<b>463.12</b>	<b>328.14</b>

\* There are no vendors who have confirmed that they are covered under the Micro, Small and Medium Enterprises Development Act, 2006. Thus the disclosures relating to dues of Micro and Small enterprises under section 22 of "The Micro, Small and Medium Enterprises Development Act, 2006, are not provided.

\*\* There are no disputed dues for trade payable

**Note 10 Other current liabilities**

Particulars	As at 31 March, 2022	As at 31 March, 2021
Salary & Bonus Payable	279.65	230.87
Director's Remuneration Payable	153.26	18.26
Statutory dues	114.74	85.77
Interest accrued and due on unsecured borrowings	16.67	27.29
Interest accrued and not due on secured borrowings	0.46	-
Other expense payable	159.66	8.18
Advance from Customers	178.00	208.57
Security deposit for clinic	195.55	236.50
Other security deposit	58.09	75.87
<b>Total</b>	<b>1,156.08</b>	<b>891.31</b>

**Note 11 Short-term provisions**

Particulars	As at 31 March, 2022	As at 31 March, 2021
Provision for Income Tax (Net of advance tax)	66.66	-
Provision for employee benefits	13.89	0.14
Provision for Corporate Social Responsibility	20.39	20.26
<b>Total</b>	<b>100.94</b>	<b>20.40</b>

**Note 12 Property, Plant and Equipment**

Particular	Freehold Land	Building	Furniture & Fixtures	Office Equipment's	Computers	Electrical Installation	Motor Vehicles	Total
<b>Gross Block</b>								
As at March 31, 2020	253.35	642.94	435.93	170.64	337.64	39.91	99.74	1,980.15
Addition	211.72	257.84	79.76	129.73	153.24	8.25	30.90	871.44
Deletion	-	-	-	-	-	-	48.90	48.90
As at March 31, 2021	465.07	900.78	515.69	300.37	490.88	48.16	81.74	2,802.69
Addition	778.73	4.67	130.54	117.71	8.89	23.67	109.21	1,173.42
Deletion	-	331.66	8.36	5.94	6.63	1.00	-	352.79
As at March 31, 2022	1,243.80	573.79	637.87	412.94	493.14	70.83	190.95	3,623.32
<b>Depreciation</b>								
As at March 31, 2020	-	53.95	60.63	44.66	139.26	12.63	16.54	327.67
Addition	-	64.34	38.09	34.99	82.06	6.77	12.00	238.25
Deletion	-	-	-	-	-	-	12.80	12.80
As at March 31, 2021	-	118.29	98.72	79.65	221.32	19.40	15.74	553.12
Addition	-	19.06	51.84	66.11	155.75	9.75	17.10	319.60
Deletion	-	63.34	2.73	2.15	2.38	0.49	-	71.07
As at March 31, 2022	-	74.01	147.83	143.63	374.69	28.66	32.84	801.65
As at March 31, 2021	465.07	782.49	416.97	220.72	269.56	28.76	66.00	2,249.57
As at March 31, 2022	1,243.80	499.78	490.04	269.31	118.45	42.17	158.11	2,821.67

**Note 13 Intangible assets**

Particular	Software	Total
<b>Gross Block</b>		
As at March 31, 2020	18.32	18.32
Addition	11.83	11.83
Deletion	-	-
As at March 31, 2021	30.15	30.15
Addition	6.00	6.00
Deletion	-	-
As at March 31, 2022	36.15	36.15
<b>Depreciation</b>		
As at March 31, 2020	4.46	4.46
Addition	7.84	7.84
Deletion	-	-
As at March 31, 2021	12.30	12.30
Addition	10.99	10.99
Deletion	-	-
As at March 31, 2022	23.29	23.29
As at March 31, 2021	17.85	17.85
As at March 31, 2022	12.86	12.86

**\*\* Capital work in progress ageing schedule**

Particulars	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
<b>CWIP</b>					
Project in progress	504.10	-	-	-	504.10
Projects temporarily suspended	-	-	-	-	-
<b>Total</b>	504.10	-	-	-	504.10

**Note 14 Non current investment**

Particulars	As at 31 March, 2022	As at 31 March, 2021
<b>Non Trade Investment</b>		
<b>Investment in Equity Shares (unquoted):</b>		
<b>Subsidiary Company</b>		
Investment in subsidiary Company (Shuddhi Green Charcoal Private Limited (5100 shares (PY: Nil))	0.51	-
<b>Total</b>	<b>0.51</b>	<b>-</b>

**Note 15 Long-term loans and advances**

Particulars	As at 31 March, 2022	As at 31 March, 2021
Capital Advances	507.82	12.66
<b>Total</b>	<b>507.82</b>	<b>12.66</b>

**Note 16 Other Non Current Assets**

Particulars	As at 31 March, 2022	As at 31 March, 2021
Security Deposit	104.04	26.19
<b>Total</b>	<b>104.04</b>	<b>26.19</b>

**Note 17 Inventories**

Particulars	As at 31 March, 2022	As at 31 March, 2021
<b>Valued at lower of cost or net realizable value</b>		
Stock in trade	575.90	927.86
<b>Total</b>	<b>575.90</b>	<b>927.86</b>

**Note 18 Trade receivables**

Particulars	As at 31 March, 2022	As at 31 March, 2021
Secured, considered good	-	-
Unsecured, considered good	897.39	323.74
Doubtful	-	-
<b>Total</b>	<b>897.39</b>	<b>323.74</b>

**Trade Receivable Ageing Schedule**

Particulars	As at 31 March, 2022	As at 31 March, 2021
<b>Undisputed trade receivable</b>		
Less than six months	802.65	265.94
6 months - 1 year	36.93	14.36
1-2 years	14.36	28.12
2-3 years	28.12	15.33
More than 3 years	15.33	-
<b>Total</b>	<b>897.39</b>	<b>323.74</b>

\* There are no disputed trade receivables

**Note 19 Cash and cash equivalents**

Particulars	As at 31 March, 2022	As at 31 March, 2021
Cash in hand	72.82	42.73
Balances with banks		
Current Account With Banks	144.60	330.51
Bank deposits with original maturity of less than 3 months	39.50	523.06
<b>Total</b>	<b>256.92</b>	<b>896.30</b>

**Note 20 Short-term loans and advances**

Particulars	As at 31 March, 2022	As at 31 March, 2021
<b>unsecured, considered good;</b>		
Advance to suppliers	198.01	274.15
Advance to Staff	11.62	4.06
Advance to Others	173.24	42.68
<b>Total</b>	<b>382.87</b>	<b>320.89</b>

\* advances includes advance to related party for Rs. 138.50 Lakhs

**Note 21 Other current assets**

Particulars	As at 31 March, 2022	As at 31 March, 2021
Prepaid Expenses	29.36	0.11
Balance with government authority	57.96	121.52
Professional Tax Recoverable	-	0.34
Imprest Paid to Staff	1.56	10.73
Other receivables	-	5.77
Advance payment of Income-tax ( net of provisions )	-	1.43
Accrued interest	2.25	-
Other current assets	-	0.06
<b>Total</b>	<b>91.13</b>	<b>139.94</b>

**Note 22 Revenue from Operations**

Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
Sale of products	13,984.23	13,489.82
Sale of Services	661.09	91.00
<b>Total</b>	<b>14,645.32</b>	<b>13,580.82</b>

**Note 23 Other income**

Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
Interest Income	22.26	13.54
Rental Income	14.49	85.64
Profit on Sale of Fixed Assets	79.70	-
Other Misc. Income	30.84	4.60
Discount Income	1.61	2.85
<b>Total</b>	<b>148.90</b>	<b>106.63</b>

**Note 24 Purchase of Stock in Trade**

Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
Purchase of Stock in trade	1,159.16	1,492.04
<b>Total</b>	<b>1,159.16</b>	<b>1,492.04</b>

The purchase of stock in trade consist of ayurvedic medicine only thus, there is only one broad head i.e. Ayurvedic Medicine.

**Note 25 Changes in inventories of stock-in-trade**

Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
<b>Inventories at the end of the year/period:</b>		
Stock in trade	575.90	927.86
	575.90	927.86
<b>Inventories at the beginning of the year/period:</b>		
Stock in trade	927.86	1,055.54
	927.86	1,055.54
<b>Net (increase) / decrease in inventories of stock-in-trade</b>	<b>351.96</b>	<b>127.68</b>

**Note 26 Employee benefits expense**

Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
Salaries and wages	3,228.18	2,880.89
Contribution to provident and other funds	163.58	117.90
Gratuity Expenses	(25.73)	25.31
Staff Welfare Expenses	8.63	14.15
<b>Total</b>	<b>3,374.66</b>	<b>3,038.25</b>

**Note 27 Finance costs**

Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
<b>(a) Interest expense:</b>		
(i) Borrowings from Banks	5.80	4.69
(ii) Borrowings from Others	101.04	118.00
<b>(b) Other borrowing costs</b>	7.13	7.46
<b>Total</b>	<b>113.97</b>	<b>130.15</b>

**Note 28 Depreciation and amortisation expense**

Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
Depreciation on Property, Plant & Equipment	319.60	238.25
Depreciation on Intangible Assets	10.99	7.84
<b>Total</b>	<b>330.59</b>	<b>246.09</b>

**Note 29 Other expenses**

Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
Payments to the auditors *	10.00	0.30
Advertisement and business promotion expense	3,496.63	3,322.44
Corporate social responsibility expenses (Refer Note 32)	20.39	-
Consumable Expenses	128.13	68.20
Packing Material Expenses	34.74	9.08
Business Support Services	244.86	361.64
Freight Expenses	13.09	12.24
Annual Maintenance Charges	1.19	1.24
Call Centre Expenses	416.33	430.95
Discount Expenses	2.73	0.08
Camp Expenses	2.30	26.56
Clinic Expenses	33.28	19.45
Telephone Expenses	134.45	190.82
Postage & Courier	530.96	505.55
Printing and stationery	64.16	66.06
Office Expenses	129.75	62.18
Donation	4.78	0.27
Diwali Expenses	3.00	7.57
Bad Debts	-	1.16
Computer Expenses	47.45	53.28
Commission & Brokerage	1,611.91	1,441.21
Rent Expenses	179.60	135.80
Legal & Professional Charges	281.85	99.90
Loss on sale of Assets	-	13.28
Insurance expenses	2.47	4.66
Rate Fees & Taxes	20.00	2.62
Interest and penalties	4.27	6.01
Security Expenses	154.12	79.29
Uniform Expense	0.42	0.96
Hiring Charges	-	3.13
Repair & Maintenance	75.53	51.88
Food & Kitchen Expenses	40.37	-
Resort expenses	8.18	52.17
Vehicle Running & Maintenance	21.38	14.35
Travelling & Conveyance Expenses	68.55	55.75
Ineligible Input	43.39	9.76
Water and Electricity Charges	107.48	111.36
Miscellaneous Expenses	9.35	13.41
<b>Total</b>	<b>7,947.09</b>	<b>7,234.61</b>

**\* Payments to the auditors comprises:**

Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
For Statutory audit	8.00	0.25
For Tax Audit	2.00	0.05
<b>Total</b>	<b>10.00</b>	<b>0.30</b>

**Note 30 Earning Per Share**
**(A) Reconciliation Of Basic And Diluted Shares Used In Computing Earning Per Share**

Particulars	As at 31 March, 2022	As at 31 March, 2021
Basic earnings per equity share - weighted average number of equity shares outstanding (Nos) - Opening	1,01,389	1,00,000
Add: Impact of shares issued during the year (Receipts of share call money)	7,889	209
Add: Bonus shares issued	1,00,00,080	1,00,00,080
<b>Basic earnings per equity share - weighted average number of equity shares outstanding (Nos) - Closing</b>	<b>1,01,09,358</b>	<b>1,01,00,289</b>
Add/(Less): Effect of dilutive shares (Nos)	-	-
<b>Diluted earnings per equity share - weighted average number of equity shares outstanding (Nos)</b>	<b>1,01,09,358</b>	<b>1,01,00,289</b>

**(B) Computation of basic and diluted earning per share**

Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
<b>Basic earning per share</b>		
Profit after tax	1,127.24	1,029.42
Weighted average number of shares (For Basic EPS)	1,01,09,358	1,01,00,289
<b>Basic EPS</b>	<b>11.15</b>	<b>10.19</b>
<b>Diluted earning per share</b>		
Profit after tax	1,127.24	1,029.42
Add/(less): Effect of dilution on profit	-	-
Revised profit after tax	1,127.24	1,029.42
Weighted average number of shares (For Diluted EPS)	1,01,09,358	1,01,00,289
<b>Diluted EPS</b>	<b>11.15</b>	<b>10.19</b>

**Note 31: Employee benefit Plan**
**(A) Defined benefit Plan**

The defined benefit plan operated by the Company is as below:

**Retiring gratuity**

The Company has an obligation towards gratuity, a defined benefit retirement plan covering eligible employees. The plan provides for a lump-sum payment to vested employees at retirement, death while in employment or on termination of employment of an amount equivalent to 15 to 30 days salary payable for each completed year of service. Vesting occurs upon completion of five years of service. The Company does not make any contributions to gratuity funds and the plan is unfunded. The Company accounts for the liability for gratuity benefits payable in the future based on an actuarial valuation.

The defined benefit plans expose the Company to a number of actuarial risks as below:

(a) **Interest risk:** A decrease in the bond interest rate will increase the plan liability.

(b) **Salary risk:** The present value of the defined benefit plan liability is calculated by reference to the future salaries of plan participants. As such, an increase in the salary of the plan participants will increase the plan's liability.

(c) **Longevity risk:** The present value of the defined benefit plan liability is calculated by reference to the best estimate of the mortality of plan participants. An increase in the life expectancy of the plan participants will increase the plan's liability.

The following table sets out the amounts recognised in the financial statements in respect of retiring

**(i) Change in Defined Benefit Obligation (DBO) during the year**

Particulars	31.03.2022	31.03.2021
Present value of DBO at the beginning of the year	47.90	22.59
Current service cost	24.78	10.99
Interest cost	2.49	1.23
Actuarial (gain) / loss	(53.00)	13.09
Benefits paid	-	-
<b>Present value of DBO at the end of the year</b>	<b>22.17</b>	<b>47.90</b>

**(ii) Change in fair value of plan assets during the year**

Particulars	31.03.2022	31.03.2021
Fair value of plan assets at the beginning of the year	-	-
Interest income	-	-
Employer contributions	-	-
Benefits paid	-	-
<b>Fair value of plan assets at the end of the year</b>	<b>-</b>	<b>-</b>

**(iii) Amounts recognised in the Balance Sheet**

Particulars	31.03.2022	31.03.2021
Present value of DBO at the end of the year	22.17	47.90
Fair value of plan assets at the end of the year	-	-
<b>Net Liability recognised in the Balance Sheet</b>	<b>22.17</b>	<b>47.90</b>

**(iv) Components of employer expense**

Particulars	For the year ended 31st March 2022	For the year ended 31st March 2021
Current service cost	24.78	10.99
Interest cost	2.49	1.23
Actuarial (gain) / loss	(53.00)	13.09
<b>Expense recognised in Statement of Profit and Loss</b>	<b>(25.73)</b>	<b>25.31</b>

**(v) Nature and extent of investment details of the plan assets**

Particulars	For the year ended 31st March 2022	For the year ended 31st March 2021
State and Central Securities	0%	0%
Bonds	0%	0%
Special deposits	0%	0%
Insurer managed funds	0%	0%

**(vi) Assumptions**

Particulars	For the year ended 31st March 2022	For the year ended 31st March 2021
Discount Rate	4.60%	5.20%
Rate of increase in Compensation levels	5.00%	10.00%
Rate of Return on Plan Assets	NA	NA
Withdrawal rates	90.00% p.a at all ages	40.00% p.a at all ages

**(B) Defined Contribution Plan**

**Provident fund and pension**

In accordance with the Employee's Provident Fund and Miscellaneous Provisions Act, 1952, eligible employees of the Company are entitled to receive benefits in respect of provident fund, a defined contribution plan, in which both employees and the Company make monthly contributions at a specified percentage of the covered employees' salary. The contributions, as specified under the law, are made to the employee provident fund organization (EPFO).

The total expenses recognised in the statement of profit and loss during the year on account of defined contribution plans amounted to Rs. 96.46 Lakhs (YE 31.03.2021: Rs. 81.02 Lakhs)

**Note 32 Corporate social responsibility expenses**

<b>Particulars</b>	<b>For the year ended 31st March 2022</b>	<b>For the year ended 31st March 2021</b>
a) Gross amount required to be spent by the Company during the year/period	20.39	12.64
b) Gross amount provided for CSR activities	20.39	20.26
c) Amount spent during the period / year	-	20.26
d) shortfall at the end of the period / year	20.39	-
e) total of previous years shortfall,	20.39	-
f) reason for shortfall	Balance amount will be spended by AGM	NA
g) nature of CSR activities,		
<b>Eradicating Hunger, Poverty &amp; Malnutrition, Promoting preventive health care, education and sanitation and making available safe drinking water</b>		

**Note 33 Segment reporting**

The company operates only in one business segment viz "Trading of Ayurvedic Medicines ". Therefore, a separate segment wise reporting is not required.

**Note 34 Related party disclosures**
**A. Names of related parties and nature of relationship:**

Description of relationship	Names of related parties
Key Management Personnel (KMP)	Sh. Manish Grover (Director) Smt. Bhavna Grover (Director)
Entities in which KMP / Relatives of KMP can exercise significant influence	Divya Upchar Sansthan Finest Tech Solution Pvt Ltd
Subsidiary	Shuddhi Green Charcoal Private Limited

**B) Transactions with related parties are as follows:**

Particular	Key Management Personnel (KMP)	Entities in which KMP / Relatives of KMP can exercise significant influence	Subsidiary	Total
<b>(i) Salary, allowances and bonus</b>				
March 31, 2022	372.00	-	-	372.00
March 31, 2021	276.00	-	-	276.00
<b>(ii) Sale of goods</b>				
March 31, 2022	-	591.73	-	591.73
March 31, 2021	-	352.08	-	352.08
<b>(iii) Receiving of services</b>				
March 31, 2022	-	60.50	-	60.50
March 31, 2021	-	40.50	-	40.50
<b>(iv) Investment in subsidiary</b>				
March 31, 2022	-	-	0.51	0.51
March 31, 2021	-	-	-	-
<b>(v) Loans and advances given</b>				
March 31, 2022	-	-	138.50	138.50
March 31, 2021	-	-	-	-

**B) Balances outstanding are as follows:**

Particular	Key Management Personnel (KMP)	Entities in which KMP / Relatives of KMP can exercise significant influence	Subsidiary	Total
<b>(i) Salary, allowances and bonus payable</b>				
March 31, 2022	153.25	-	-	153.25
March 31, 2021	18.26	-	-	18.26
<b>(ii) Imprest</b>				
March 31, 2022	0.17	-	-	0.17
March 31, 2021	10.69	-	-	10.69
<b>(iii) Trade payables</b>				
March 31, 2022	-	6.96	-	6.96
March 31, 2021	-	7.91	-	7.91
<b>(iv) Trade receivable</b>				
March 31, 2022	-	9.18	-	9.18
March 31, 2021	-	-	-	-
<b>(v) Investment in subsidiary</b>				
March 31, 2022	-	-	0.51	0.51
March 31, 2021	-	-	-	-
<b>(vi) Loans and advances given</b>				
March 31, 2022	-	-	138.50	138.50
March 31, 2021	-	-	-	-

**Note 35 Disclosure on significant ratios**

	As at 31 March, 2022	As at 31 March, 2021	% Change
Current Ratio	0.93	1.07	-14%
Debt-Equity Ratio,	0.17	0.33	-49%
Debt Service Coverage Ratio	17.21	13.79	25%
Return on Equity Ratio	0.31	0.43	-28%
Inventory turnover ratio	2.01	1.61	25%
Trade Receivables turnover ratio	16.32	41.95	-61%
Trade payables turnover ratio	2.50	4.55	-45%
Net capital turnover ratio	-82.00	75.09	-209%
Net profit ratio	7.70%	7.58%	2%
Return on Capital employed	30.84%	42.98%	-28%

The Company has raised funds during the year by issue of equity shares through IPO, as a result there is a significant change in financial position during the year and the ratios have changed by more than 25%.

**Methodology:**

1. Current Ratio – Current Asset / Current Liability
2. Debt-Equity Ratio = Total Debt / (Total Debt + Equity)
3. Debt Service Coverage Ratio = EBITDA / Finance Cost
4. Return on Equity Ratio = Profit After Tax / Total Equity
5. Inventory Turnover Ratio = Purchase / Inventory
6. Trade Receivable Turnover Ratio = Revenue from Operations / Trade Receivable
7. Trade Payable Turnover Ratio = Purchase / Trade Payable
8. Net Capital Turnover Ratio = Revenue from Operations / (Current Asset - Current Liability)
9. Net Profit Ratio = Profit After Tax / Revenue from Operations
10. Return on Capital Employed = Profit After tax / Total Equity

**Note 36 Other Notes**

- (i) In the opinion of the Board of Directors and Management, all the assets other than, Property, Plant and Equipment, Intangible assets and non-current investments have a value on realisation in the ordinary course of business which is at least equal to the amount at which they are stated.
- (ii) Figures for the previous year have been re-grouped/ rearranged/ restated wherever necessary to make them comparable with those of the current year.

As per our report of even date

**For KRA & Co.**

Chartered Accountants

Firm Regd. No.020266N

**For and on behalf of the Board of Directors**

**JEENA SIKHO LIFECARE LIMITED**

**Saurabh Garg**

**(Partner)**

M.No. 510541

Place: New Delhi

UDIN: 22510541ANOJAG3579

Dated: 25/07/2022

Sd/-

**Manish Grover**

Managing Director

DIN: 07557886

Sd/-

**Bhavna Grover**

Whole-Time Director

DIN: 07557913

Sd/-

Nanak Chand

**(Chief Financial Officer)**

Sd/-

Nikita Juneja

**(Company Secretary)**

(M No. - A65160)

**INDEPENDENT AUDITOR'S REPORT  
TO THE MEMBERS OF JEENA SIKHO LIFECARE LIMITED**

**Report on the Audit of the Consolidated Financial Statements**

**Opinion**

We have audited the accompanying consolidated financial statements of **JEENA SIKHO LIFECARE LIMITED** ("hereinafter referred to as the 'Holding Company") and its subsidiary (Holding Company and its subsidiary together referred to as "the Group"), which comprise the consolidated balance sheet as at March 31, 2022, and the consolidated statement of profit and loss and the consolidated cash flow statement for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as "the consolidated financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Consolidated financial statements give the information required by the Companies Act, 2013 in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the consolidated state of affairs of the Group at March 31, 2022, and its consolidated profit and its consolidated cash flows for the year ended on that date.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the consolidated financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Key Audit Matters**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

<b>The Key Audit Matter</b>	<b>How the matter was addressed in our audit</b>
<p><b>Revenue Recognition</b> As the Group revenue is from trading of ayurvedic medicine consisting of large number of sales orders, there are risks related to completeness of revenue, improper sales cut</p>	<ul style="list-style-type: none"> <li>• Cut off procedures performed for year ended 31<sup>st</sup> March 2022.</li> <li>• Substantive verification of sales transactions.</li> <li>• Analytical review of sales transactions.</li> <li>• Debtors analysis to ensure that all sales reversal are recognized appropriately.</li> <li>• Review that the revenue has been recognized in accordance with the revenue recognition policy of the Company.</li> </ul>

off, timing of recognitions, out of period sales etc.	<ul style="list-style-type: none"> <li>• Review sales booked by Company for unusual items, if any.</li> <li>• Verification of existence and operating effectiveness of internal controls related to sales transactions.</li> </ul>
---	--



### Other Information

The Holding Company's Board of Directors is responsible for the other information. The other information comprises the information included in the annual report but does not include the consolidated financial statements and our auditor's report thereon. The annual report is expected to be made available to us after the date of this auditor's report.

Our opinion on the consolidated financial statements does not cover the other information and we will not express any form of assurance or conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

When we will read the annual report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance.

When we read the annual report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance.

### Responsibilities of management and those charged with governance for the Consolidated Financial Statements

The Holding Company's Management and Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these Consolidated financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Group in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act. The respective Management and Board of Directors of the Companies Included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the each Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Management and Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial statements, the respective Management and Board of Directors of the Companies included in the Group are responsible for assessing the ability of each company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors are also responsible for overseeing the Company's financial reporting process.

#### **Auditor's responsibilities for the audit of the Consolidated Financial Statements**

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of such entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial statements of which we are the independent auditors. For the other entities included in the consolidated financial statements, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in section titled 'Other Matters' in this audit report.

We believe that the audit evidence obtained by us along with the consideration of management certified accounts as referred to in Other Matters paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the consolidated financial statements.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated annual financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

#### **Other Matters**

The consolidated financial statement includes the unaudited financial results/financial information of one subsidiary, whose financial results/financial information reflects total assets of Rs. 137.89 Lakhs as at March 31, 2022, total revenue of Rs. 10.13 Lakhs, total net loss after tax of Rs. (7.86) Lakhs and net cash inflow of Rs. 2.07 Lakhs for the year ended on that date, as considered in the consolidated financial statements, which

have not been audited by its auditor. The subsidiary financial statements have been consolidated based on its management certified accounts.

Our opinion on the Consolidated Financial Statements above, and our report on Other Legal and Regulatory Requirements below, is not modified in respect of the above matter with respect to our reliance on the management certified financial statements for the subsidiary.

### **Report on Other Legal and Regulatory Requirements**

1. As required by Section 143(3) of the Act, we report that:
  - a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
  - b. In our opinion, proper books of account as required by law have been kept by the Holding Company so far as it appears from our examination of those books
  - c. The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss and the Consolidated Cash Flow Statement dealt with by this Report are in agreement with the books of account
  - d. In our opinion, the aforesaid consolidated financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
  - e. On the basis of the written representations received from the directors of the Holding Company as on March 31, 2022 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2022 from being appointed as a director in terms of Section 164(2) of the Act.
  - f. With respect to the adequacy of the internal financial controls over financial reporting of the Holding Company and subsidiary company and the operating effectiveness of such controls, refer to our separate Report in “Annexure A”.
  - g. With respect to the matter to be included in the Auditor’s Report under Section 197(16) of the Act:

In our opinion, the managerial remuneration for the year ended March 31, 2022 has been paid by the Holding Company to its directors in accordance with the provisions of section 197 read with Schedule V to the Act;
  - h. With respect to the other matters to be included in the Auditor’s Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
    - i. There are no pending litigations on the Group
    - ii. The Group did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
    - iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.
    - iv. (a) The management has represented that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been advanced

or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Holding Company to or in any other person or entity, including foreign entity (“Intermediaries”), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Holding Company (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(b) The Management has represented, that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the Holding Company from any person or entity, including foreign entity (“Funding Parties”), with the understanding, whether recorded in writing or otherwise, that the Holding Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(c), as provided under (a) and (b) above, contain any material misstatement.

**For KRA & Co.**  
**Chartered Accountants**  
**(Firm Registration No.020266N)**

**Saurabh Garg**  
**Partner**  
**Membership No.: 510541**  
**UDIN: 22510541ANOMXC1173**  
**Place: Delhi**  
**Date: July 25, 2022**

**ANNEXURE “A” TO THE INDEPENDENT AUDITORS’ REPORT OF EVEN DATE ON THE CONSOLIDATED FINANCIAL STATEMENTS OF JEENA SIKHO LIFECARE LIMITED (Referred to in Paragraph 1 point (f) under the heading of “Report on Other Legal and Regulatory Requirements” of our report of even date)**

**Report on the Internal Financial Controls Over Financial Reporting under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)**

In conjunction with our audit of the consolidated financial statements of **JEENA SIKHO LIFECARE LIMITED** (the ‘Holding Company’) and its subsidiary (the Holding Company and its subsidiary together referred to as the ‘Group’) as at and for the year ended 31 March 2022, we have audited the internal financial controls over financial reporting (‘IFCoFR’) of the Holding Company, which is the company covered under the Act, as at that date.

**Management’s Responsibility for Internal Financial Controls**

The Board of Directors of the Holding Company, which is the company covered under the Act, as at that date, is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the ‘Guidance Note’) issued by the Institute of Chartered Accountants of India (the ‘ICAI’). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of the company’s business, including adherence to the company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

**Auditors’ Responsibility**

Our responsibility is to express an opinion on the IFCoFR of the Holding Company, which is the company covered under the Act, as at that date, based on our audit. We conducted our audit in accordance with the Standards on Auditing issued by the ICAI and deemed to be prescribed under Section 143(10) of the Act, to the extent applicable to an audit of IFCoFR, and the Guidance Note issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate IFCoFR were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the IFCoFR and their operating effectiveness. Our audit of IFCoFR includes obtaining an understanding of IFCoFR, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our audit opinion on the IFCoFR of the Holding Company.

### **Meaning of Internal Financial Controls over Financial Reporting**

A company's IFCoFR is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's IFCoFR include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements

### **Inherent Limitations of Internal Financial Controls Over Financial Reporting**

Because of the inherent limitations of IFCoFR, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the IFCoFR to future periods are subject to the risk that the IFCoFR may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### **Opinion**

In our opinion, the Holding Company, which is the company covered under the Act, have in all material respects, adequate internal financial controls over financial reporting and such controls were operating effectively as at 31 March 2022, based on the internal control over financial reporting criteria established by the Holding Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India

**For KRA & Co.**  
**Chartered Accountants**  
**(Firm Registration No.020266N)**

**Saurabh Garg**  
**Partner**  
**Membership No.: 510541**  
**UDIN: 22510541ANOMXC1173**  
**Place: Delhi**  
**Date: July 25, 2022**

<b>Jeena Sikho Lifecare Limited</b> <b>CIN: U52601PB2017PLC046545</b> <b>Consolidated Balance Sheet as at 31.03.2022</b> <b>(All amounts in Indian Rupees in Lakhs, unless otherwise stated)</b>		
Particulars	Note No.	As at 31 March, 2022
<b>A</b>		
<b>EQUITY AND LIABILITIES</b>		
<b>1 Shareholders' funds</b>		
(a) Equity Share capital	3	1,011.12
(b) Reserves and surplus	4	2,640.40
<b>2 Minority interest</b>		(3.36)
<b>3 Non-current liabilities</b>		
(a) Long-term borrowings	5	80.80
(b) Deferred tax liabilities (net)	6	28.13
(c) Long-term provisions	7	8.27
<b>4 Current liabilities</b>		
(a) Short-term borrowings	8	662.69
(b) Trade payables	9	-
(i) total outstanding dues of micro enterprises and small enterprises; and		
(ii) total outstanding dues of creditors other than micro enterprises and small enterprises		465.98
(c) Other current liabilities	10	1,159.12
(d) Short-term provisions	11	100.94
<b>TOTAL</b>		<b>6,154.09</b>
<b>B</b>		
<b>ASSETS</b>		
<b>1 Non-current assets</b>		
(a) Property, Plant and Equipment and Intangible assets		
(i) Property, Plant and Equipment	12	2,846.05
(ii) Intangible assets	13	12.86
(iii) Capital work in progress		504.10
(b) Long-term loans and advances	14	534.51
(c) Other non-current assets	15	104.04
<b>2 Current assets</b>		
(a) Inventories	16	635.62
(b) Trade receivables	17	904.30
(c) Cash and cash equivalents	18	258.98
(d) Short-term loans and advances	19	262.50
(e) Other current assets	20	91.13
<b>TOTAL</b>		<b>6,154.09</b>
Notes to Consolidated Balance Sheet and Consolidated Statement of Profit and		
As per our report of even date		
<b>For KRA &amp; Co.</b> Chartered Accountants Firm Regd. No.020266N		<b>For and on behalf of the Board of Directors</b> <b>JEENA SIKHO LIFECARE LIMITED</b>
<b>Saurabh Garg</b> <b>(Partner)</b> M.No. 510541 Place: New Delhi UDIN: 22510541A.NOMXC1173 Dated: 25/07/2022	Sd/- <b>Manish Grover</b> Managing Director DIN: 07557886	Sd/- <b>Bhavna Grover</b> Whole-Time Director DIN: 07557913
	Sd/- <b>Nanak Chand</b> <b>(Chief Financial Officer)</b>	Sd/- <b>Nikita Juneja</b> <b>(Company Secretary)</b> (M No. - A65160)

<b>Jeena Sikho Lifecare Limited</b>			
<b>CIN: U52601PB2017PLC046545</b>			
<b>Consolidated Statement of Profit and Loss</b>			
<b>(All amounts in Indian Rupees in Lakhs, unless otherwise stated)</b>			
<b>Particulars</b>		<b>Note No.</b>	<b>For the year ended 31 March, 2022</b>
<b>I</b>	Revenue from Operations	21	14,655.44
<b>II</b>	Other Income	22	148.91
<b>III</b>	<b>Total Income (I + II)</b>		<b>14,804.35</b>
<b>IV</b>	<b>Expenses</b>		
	(a) Purchases of stock-in-trade	23	1,226.97
	(b) Change in inventories of stock-in-trade	24	292.24
	(c) Employee benefits expenses	25	3,379.64
	(d) Finance costs	26	113.97
	(e) Depreciation and amortisation expenses	27	331.09
	(f) Other expenses	28	7,951.16
	<b>Total expenses</b>		<b>13,295.07</b>
<b>V</b>	<b>Profit before exceptional and extraordinary items and tax (III - IV)</b>		<b>1,509.28</b>
<b>VI</b>	Exceptional items & Extraordinary items		-
<b>VII</b>	<b>Profit before tax (V + VI)</b>		<b>1,509.28</b>
<b>VIII</b>	<b>Tax expense:</b>		
	(a) Current tax		386.83
	(b) Taxation for earlier years		3.60
	(c) Deferred tax		(0.54)
	<b>Total tax expense</b>		<b>389.89</b>
<b>IX</b>	<b>Profit for the year (VII - VIII)</b>		<b>1,119.39</b>
<b>X</b>	<b>Less: Minority interest</b>		<b>(3.85)</b>
<b>XI</b>	<b>Profit for the year attributable to the owner of the Company (IX - X)</b>		<b>1,123.24</b>
<b>XII</b>	<b>Earnings per share (of Rs. 10 each):</b>		
	(a) Basic	29	11.11
	(b) Diluted	29	11.11
<b>Notes to Consolidated Balance Sheet and Consolidated Statement of Profit and Loss</b>			
As per our report of even date <b>For KRA &amp; Co.</b> Chartered Accountants Firm Regd. No.020266N		<b>For and on behalf of the Board of Directors</b> <b>JEENA SIKHO LIFECARE LIMITED</b>	
<b>Saurabh Garg</b> <b>(Partner)</b> M.No. 510541 Place: New Delhi UDIN:22510541ANOMXC:1173 Dated: 25/07/2022		Sd/- <b>Manish Grover</b> Managing Director DIN: 07557886	Sd/- <b>Bhavna Grover</b> Whole-Time Director DIN: 07557913
		Sd/- Nanak Chand <b>(Chief Financial Officer)</b>	Sd/- Nikita Juneja <b>(Company Secretary)</b> (M.No. - A65160)

<b>Jeena Sikho Lifecare Limited</b> <b>CIN: U52601PB2017PLC046545</b> <b>Consolidated Statement of cash flow</b> <b>(All amounts in Indian Rupees in Lakhs, unless otherwise stated)</b>		
Particulars		For the year ended 31 March, 2022
<b>Profit before tax</b>		<b>1,509.28</b>
<b>Adjustments for:</b>		
Depreciation & amortization expense		330.59
Net (gain)/ loss on sale of Property Plant & Equipment		(79.70)
Interest expense on borrowings		113.97
Interest income		(22.26)
Minority interest		0.49
<b>Operating Profit before working capital changes</b>		<b>1,852.37</b>
<b>Changes in operating assets and liabilities:</b>		
Increase/(decrease) in provisions		41.05
Increase/(decrease) in trade payables		137.85
Increase/(decrease) in other current liabilities		278.00
Decrease/(increase) in loans and advances		31.72
Decrease/(increase) in trade receivables		(580.56)
Decrease/(increase) in inventories		292.24
Decrease/(increase) in other non current assets		(77.86)
Decrease/(increase) in other current assets		51.06
<b>Cash generated from operations</b>		<b>2,025.87</b>
Income taxes refunded/ (paid)		(390.43)
<b>Net cash flow from operations (A)</b>		<b>1,635.44</b>
<b>Cash flow from investing activities</b>		
Purchase of property, plant & equipment and Intangible assets		(1,707.95)
Increase in capital advances		(495.16)
Advance to related party		-
Sale of property, plant & equipment		361.42
Interest received		20.01
<b>Net cash used in investing activities (B)</b>		<b>(1,821.68)</b>
<b>Cash flow from financing activities</b>		
Proceeds/(Repayment) of Short Term Borrowings		(525.33)
Proceeds from issue of equity shares		132.90
Repayment of Long Term Borrowings		65.48
Interest paid		(124.13)
<b>Net cash flow from/ (used in) financing activities (C)</b>		<b>(451.08)</b>
Net increase/(decrease) in cash and cash equivalents (A+B+C)		<b>(637.32)</b>
Cash and cash equivalents at the beginning of the year		896.30
<b>Cash and cash equivalents at the closing of the year</b>		<b>258.98</b>
a) Cash and Cash Equivalents included in Cash Flow Statement comprise of following (Refer Note 18):		
Particulars		As at 31 March, 2022
Cash in hand		72.82
Balances with banks		
Current Account With Banks		146.66
Bank deposits with original maturity of less than 3 months		39.50
		<b>258.98</b>
Notes to Consolidated Balance Sheet and Consolidated Statement of Profit and Loss		
As per our report of even date		
<b>For KRA &amp; Co.</b>		<b>For and on behalf of the Board of Directors</b>
Chartered Accountants		<b>JEENA SIKHO LIFECARE LIMITED</b>
Firm Regd. No.020266N		
<b>Saurabh Garg</b>	Sd/-	Sd/-
<b>(Partner)</b>	<b>Manish Grover</b>	<b>Bhavna Grover</b>
M.No. 510541	Managing Director	Whole-Time Director
Place: New Delhi	DIN: 07557886	DIN: 07557913
UDIN:22510541A.NOMXC1173		
Dated:25/07/2022	Sd/-	Sd/-
	Nanak Chand	Nikita Juneja
	<b>(Chief Financial Officer)</b>	<b>(Company Secretary)</b>
		(M No. - A65160)

<b>Notes to consolidated financial statement for the year ended March 31, 2022</b>	
<b>(All amounts in Indian Rupees in Lakhs, unless otherwise stated)</b>	
<b>1</b>	<b>Corporate information</b>
	Jeena Sikho Lifecare limited was incorporated in 2017. The Company is a trading concern. The company deals in trading of Ayurvedic Medicines across the PAN India basis.
<b>2</b>	<b>Basis of Preparation of financial statements (Significant Accounting Policies &amp; other explanatory Notes)</b>
<b>2.1</b>	<b>Basis of Preparation</b>
	The consolidated financial statements of the Company have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP), including the Accounting Standards notified under section 133 of the Companies Act, 2013. The financial statements have been prepared on accrual basis under the historical cost convention.
	The consolidated financial statements have been prepared on the following basis: i) The financial statements of the Company and its subsidiary are combined on a line-by-line basis by adding together the book values of like items of assets, liabilities, income and expenses, after fully eliminating intra-group balances and intra-group transactions in accordance with Accounting Standard (AS) 21 - "Consolidated Financial Statements".  ii) The consolidated financial statements are prepared using uniform accounting policies for like transactions and other events in similar circumstances and are presented in the same manner as the Company's separate financial statements.
<b>2.2</b>	<b>Current versus non-current classification</b>
	The Company presents assets and liabilities in the balance sheet based on current/non-current classification. An asset is treated as current when it is: - Expected to be realized or intended to be sold or consumed in normal operating cycle - Held primarily for purpose of trading - Expected to be realized within twelve months after the reporting period, or - cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period All other assets are classified as non-current. A liability is current when: - It is expected to be settled in normal operating cycle - It is held primarily for purpose of trading - It is due to be settled within twelve months after the reporting period, or - There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period All other liabilities are classified as non current. Deferred tax assets and deferred tax liabilities are classified as non-current assets and liabilities. The operating cycle is the time between the acquisition of assets for processing and their realization in cash and cash equivalents. The Company has identified twelve months as its operating cycle.
<b>2.3</b>	<b>Use of estimates</b>
	The preparation of the financial statements requires the Management to make estimates and assumptions considered in the reported amounts of assets and liabilities (including contingent liabilities) and the reported income and expenses during the year. The Management believes that the estimates used in preparation of the financial statements are prudent and reasonable. Future results could differ due to these estimates and the differences between the actual results and the estimates are recognised in the periods in which the results are known / materialise.
<b>2.4</b>	<b>Inventories</b>
	The inventory are valued at lower of cost or net realizable value. The inventory costs are based on first in first out method. Cost includes all charges in bringing the goods to the point of sale, including octroi and other levies, transit insurance and receiving charges. Finished goods include appropriate proportion of overheads.
<b>2.5</b>	<b>Cash and cash equivalents</b>

	Cash and cash equivalents in the balance sheet comprise of cash at bank and in hand and short term investments with an original maturity of three months or less. Earmarked balances with bank, margin money or security against borrowings, guarantees and other commitments ,if any shall be treated separately from cash and cash equivalent														
<b>2.6</b>	<b>Cash flow statement</b>														
	Cash flows are reported using the indirect method, whereby profit / (loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated based on the available information.														
<b>2.7</b>	<b>Property, plant and equipment</b>														
	Property, Plant and equipment including capital work in progress are stated at cost, less accumulated depreciation and accumulated impairment losses, if any. The cost comprises of purchase price, taxes, duties, freight and other incidental expenses directly attributable and related to acquisition and installation of the concerned assets and are further adjusted by the amount of input tax credit availed wherever applicable. Subsequent costs are included in asset's carrying amount or recognised as separate assets, as appropriate, only when it is probable that future economic benefit associated with the item will flow to the Company and the cost of item can be measured reliably.														
<b>2.8</b>	<b>Depreciation and amortisation</b>														
	Depreciation on property, plant and equipment is provided on prorata basis on straight line method using the useful lives of the assets estimated by the management and in the manner prescribed in Schedule II of the Companies Act 2013. The estimated life of various assets is as follows:														
	<table border="1"> <tr> <td>Building</td> <td>30 Years</td> </tr> <tr> <td>Motor Cycle</td> <td>10 Years</td> </tr> <tr> <td>Electrical equipment's</td> <td>10 Years</td> </tr> <tr> <td>Furniture and Fixture</td> <td>10 Years</td> </tr> <tr> <td>Motor Car</td> <td>8 Years</td> </tr> <tr> <td>Office Equipment</td> <td>5 Years</td> </tr> <tr> <td>Computer and Software</td> <td>3 Years</td> </tr> </table>	Building	30 Years	Motor Cycle	10 Years	Electrical equipment's	10 Years	Furniture and Fixture	10 Years	Motor Car	8 Years	Office Equipment	5 Years	Computer and Software	3 Years
Building	30 Years														
Motor Cycle	10 Years														
Electrical equipment's	10 Years														
Furniture and Fixture	10 Years														
Motor Car	8 Years														
Office Equipment	5 Years														
Computer and Software	3 Years														
<b>2.9</b>	<b>Intangible assets</b>														
	<b>Separately acquired intangible assets</b> Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less accumulated amortization and accumulated impairment losses, if any. Internally generated intangibles, excluding capitalized development cost, are not capitalized and the related expenditure is reflected in statement of Profit and Loss in the period in which the expenditure is incurred. Cost comprises the purchase price and any attributable cost of bringing the asset to its working condition for its intended use.														
<b>2.10</b>	<b>Revenue recognition</b>														
	<b>Sale of goods</b>														
	Sales are recognised, net of returns and trade discounts, on transfer of significant risks and rewards of ownership to the buyer, which generally coincides with the delivery of goods to customers. Sales exclude GST. The company follows the mercantile system of accounting and recognizes the income and expenditures on accrual basis except in case of significant uncertainties.														
<b>2.11</b>	<b>Other income</b>														
	Interest income is recognised on time proportion basis. Rental income is recognized on accrual basis														
<b>2.12</b>	<b>Foreign currency transactions and translations</b>														
	<b>Initial recognition</b>														

	Transactions in foreign currencies entered into by the Company are accounted at the exchange rates prevailing on the date of the transaction or at rates that closely approximate the rate at the date of the transaction.
	<b>Measurement of foreign currency monetary items at the Balance Sheet date</b>
	Foreign currency monetary items (other than derivative contracts) of the Company outstanding at the Balance Sheet date are restated at the year-end rates. Exchange differences arising out of these translations are charged to the Statement of Profit and Loss.
<b>2.13</b>	<b>Investments</b>
	Long-term investments, are carried individually at cost less provision for diminution, other than temporary, in the value of such investments. Current investments are carried individually, at the lower of cost and fair value. Cost of investments include acquisition charges such as brokerage, fees and duties.
<b>2.14</b>	<b>Employee benefits</b>
	The Company has adopted the Accounting Standard 15- Employee Benefits prescribed under the Companies (Accounting Standards) Rules, 2006. Employee benefits include provident fund, bonus and gratuity benefits. The Company's obligation towards various employee benefits has been recognized as follows:
	<b>Short Term Employee Benefits</b>
	All employee benefits payable wholly within twelve months of rendering the service are short-term employee benefits. Benefits such as salaries, wages and bonus wages, etc, are recognized in the Profit and Loss statement in the period in which the employee renders the related service.
	<b>Defined contribution plans</b>
	The Company's contribution to provident fund are considered as defined contribution plans and are charged as an expense as they fall due based on the amount of contribution required to be made.
	<b>Defined benefits plans</b>
	(i) For defined-benefit plans, the amount recognised in the Balance Sheet is the present value of the defined-benefit obligation less the fair value of any plan assets and any past service costs not yet recognised. The present value of the defined-benefit obligation is the present value of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. The discount rate used is the market yields on government bonds at the Balance Sheet date with remaining terms to maturity approximating those of the Company's obligations.
	(ii) Actuarial gains and losses in respect of post employment and other long-term benefits are charged to the Statement of Profit and Loss.
<b>2.15</b>	<b>Borrowing costs</b>
	Borrowing costs include interest, amortisation of ancillary costs incurred and exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost. Costs in connection with the borrowing of funds to the extent not directly related to the acquisition of qualifying assets are charged to the Statement of Profit and Loss over the tenure of the loan. Borrowing costs, allocated to and utilised for qualifying assets, pertaining to the period from commencement of activities relating to construction / development of the qualifying asset up to the date of capitalisation of such asset is added to the cost of the assets. Borrowing cost attributable to the fixed assets during construction/ exploration, renovation and modernization are capitalized. Such borrowing costs are apportioned on the average balance of capital work in progress for the year. Other borrowing costs are recognized as an expense in the period in which they are incurred.
<b>2.16</b>	<b>Segment reporting</b>
	The Company identifies primary segments based on the dominant source, nature of risks and returns and the internal organisation and management structure. The operating segments are the segments for which separate financial information is available and for which operating profit/loss amounts are evaluated regularly by the executive
<b>2.17</b>	<b>Taxes on income</b>

	<p>Tax expense comprises current and deferred tax. Current income tax is measured at the amount expected to be paid to the tax authorities in accordance with Income Tax Act, 1961. Deferred income tax reflects the impact of current year timing differences between taxable income that originates in one period and are capable of reversal in one or more subsequent periods</p> <p>Minimum Alternate Tax (MAT) paid in accordance with the tax laws, which gives future economic benefits in the form of adjustment to future income tax liability, is considered as an asset if there is convincing evidence that the Company will pay normal income tax. Accordingly, MAT is recognised as an asset in the Balance Sheet when it is probable that future economic benefit associated with it will flow to the Company.</p> <p>Deferred tax is recognised on timing differences, being the differences between the taxable income and the accounting income that originate in one period and are capable of reversal in one or more subsequent periods. Deferred tax is measured using the tax rates and the tax laws enacted or substantially enacted as at the reporting date. Deferred tax liabilities are recognised for all timing differences. Deferred tax assets in respect of unabsorbed depreciation and carry forward of losses are recognised only if there is virtual certainty that there will be sufficient future taxable income available to realise such assets. Deferred tax assets are recognised for timing differences of other items only to the extent that reasonable certainty exists that sufficient future taxable income will be available against which these can be realised. Deferred tax assets and liabilities are offset if such items relate to taxes on income levied by the same governing tax laws and the Company has a legally enforceable right for such set off. Deferred tax assets are reviewed at each Balance Sheet date for their realisability.</p>
<b>2.18</b>	<b>Impairment of assets</b>
	<p>The carrying values of assets / cash generating units are reviewed at each Balance Sheet date for impairment. If any indication of impairment exists, the recoverable amount of such assets is estimated and impairment is recognised if the carrying amount of these assets exceeds their recoverable amount. The recoverable amount is the greater of the net selling price and their value in use. Value in use is arrived at by discounting the future cash flows to their present value based on an appropriate discount factor. When there is indication that an impairment loss recognised for an asset in earlier accounting periods no longer exists or may have decreased, such reversal of impairment loss is recognised in the Statement of Profit and Loss.</p>
<b>2.19</b>	<b>Provisions and contingencies</b>
	<p>A provision is recognised when the Company has a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions (excluding retirement benefits) are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the Balance Sheet date. These are reviewed at each Balance Sheet date and adjusted to reflect the current best estimates.</p> <p>A contingent liability is disclosed where, as a result of past events, there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources. When there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made.</p>
<b>2.20</b>	<b>Leases</b>
<b>a)</b>	<b>Finance lease</b>
i)	Assets taken on finance lease are capitalised at fair value or net present value of the minimum lease payments, whichever is less.
ii)	Lease payments are apportioned between the finance charges and outstanding liability in respect of assets taken on lease.
<b>b)</b>	<b>Operating lease</b>
i)	Leases, where the lessor effectively retains substantially all the risks and benefits of ownership of the leased term are classified as operating lease. Lease rent are recognized as an expense in the Statement of Profit and Loss on a straight line basis over the lease term.
<b>2.21</b>	<b>Earning per share</b>

	Basic earnings per share is calculated by dividing the net profit or loss for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year. Partly paid equity shares are treated as a fraction of an equity share to the extent that they were entitled to participate in dividends relative to a fully paid equity share during the reporting year. For the purpose of calculating diluted earnings per share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.
2.22	<b>The Previous Year figures have been regrouped/rearranged wherever necessary to make them comparable.</b>

**Note 3 Equity Share capital**

Particulars	As at 31 March, 2022
<b>(a) Authorised Share Capital</b> Equity shares of Rs.10 each: 1,50,00,000	1,500.00
<b>Total Authorised Share Capital</b>	
<b>(b) Issued, Subscribed &amp; Fully Paid up Shares</b> Equity shares of Rs.10 each: 1,01,11,192	1,011.12
<b>Total Issued, Subscribed &amp; Fully Paid up Shares</b>	
<b>(c) Issued, Subscribed but not Fully Paid up Shares</b> Equity shares of Rs.10 each: Nil	-
<b>Total Issued, Subscribed but not Fully Paid up Shares</b>	
<b>Total (b+c)</b>	1,011.12

**(d) Reconciliation of shares outstanding at the beginning and at the**

Particulars	As at 31 March, 2022	
	No. of shares	Amount
<b>Equity shares</b>		
<b>Balance at the beginning of the period/ year</b>	1,11,112	10,13,890
Issued during the year	-	-
Call money receipts for shares issued during the previous years	-	97,230
Shares bought back	-	-
<b>Balance at the end of the reporting period/ year</b>	1,11,112	11,11,120

**(e) Terms/ rights attached to Equity Shares**

The Company has only one class of Equity Shares having a par value of Rs. 10 per share. Each holder of Equity Shares is entitled to one

**(f) Details of shareholders holding more than 5% shares in the**

Name of Shareholder	As at 31 March, 2022	
	No. of shares	% holding
<b>Equity shares of Rs. 10 each fully paid-up</b>		
Sh. Manish Grover	99,000	89.10%
Smt. Bhavna Grover	1,000	0.90%
Oregano Life Private Limited	11,112	10.00%

**(g) Details of Promoter shareholding**

Name of Shareholder	As at 31 March, 2022	
	No. of shares	% holding
<b>Equity shares of Rs. 10 each fully paid-up</b>		
Sh. Manish Grover	99,000	89.10%
Smt. Bhavna Grover	1,000	0.90%
<b>% change during the year/period</b>		
Sh. Manish Grover		-8.54%
Smt. Bhavna Grover		-0.09%

**Note 12 Property, Plant and Equipment**

Particular	Freehold Land	Building	Furniture & Fixtures	Office Equipment's	Computers	Electrical Installation	Motor Vehicles	Plant and Machinery	Total
<b>Gross Block</b>									
As at March 31, 2020	253.35	642.94	435.93	170.64	337.64	39.91	99.74	-	1,980.15
Addition	211.72	257.84	79.76	129.73	153.24	8.25	30.90		871.44
Deletion	-	-	-	-	-	-	48.90		48.90
As at March 31, 2021	465.07	900.78	515.69	300.37	490.88	48.16	81.74	-	2,802.69
Addition	778.73	4.67	130.54	117.71	8.89	23.67	109.21	24.88	1,198.30
Deletion	-	331.66	8.36	5.14	6.63	1.00	-		352.79
As at March 31, 2022	1,243.80	573.79	637.87	412.94	493.14	70.83	190.95	24.88	3,648.20
<b>Depreciation</b>									
As at March 31, 2020	-	53.95	60.63	44.66	139.26	12.63	16.54	-	327.67
Addition	-	64.34	38.09	34.99	82.06	6.77	12.00		238.25
Deletion	-	-	-	-	-	-	12.80		12.80
As at March 31, 2021	-	118.29	98.72	79.65	221.32	19.40	15.74	-	553.12
Addition	-	19.06	51.84	66.11	155.75	9.75	17.10	0.50	320.10
Deletion	-	63.34	2.73	2.13	2.38	0.49	-		71.07
As at March 31, 2022	-	74.01	147.83	143.63	374.69	28.66	32.84	0.50	802.15
As at March 31, 2021	465.07	782.49	416.97	220.72	269.56	28.76	66.00	-	2,249.57
As at March 31, 2022	1,243.80	499.78	490.04	269.31	118.45	42.17	158.11	24.38	2,846.05

**Note 13 Intangible assets**

Particular	Software	Total
<b>Gross Block</b>		
As at March 31, 2020	18.32	18.32
Addition	11.83	11.83
Deletion	-	-
As at March 31, 2021	30.15	30.15
Addition	6.00	6.00
Deletion	-	-
As at March 31, 2022	36.15	36.15
<b>Depreciation</b>		
As at March 31, 2020	4.46	4.46
Addition	7.84	7.84
Deletion	-	-
As at March 31, 2021	12.30	12.30
Addition	10.99	10.99
Deletion	-	-
As at March 31, 2022	23.29	23.29
As at March 31, 2021	17.85	17.85
As at March 31, 2022	12.86	12.86

**## Capital work in progress ageing schedule**

Particulars	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
<b>CWIP</b>					
Project in progress	504.10	-	-	-	504.10
Projects temporarily	-	-	-	-	-
<b>Total</b>	504.10	-	-	-	504.10

**Note 4 Reserves and surplus**

Particulars	As at 31 March, 2022
<b>(a) Security Premium</b>	150.79
<b>(b) Statement of Profit and Loss</b>	
<b>Balance as per last Balance Sheet</b>	2,366.38
Add: Profit / (Loss) for the year	1,123.24
Less: Provision for CSR	-
Less: Bonus issue during the year	1,000.01
<b>Total</b>	<b>2,489.61</b>
<b>Total</b>	<b>2,640.40</b>

**Note 5 Long-term borrowings**

Particulars	As at 31 March, 2022
<b>(a) Vehicles Loan - Secured</b>	
Loan from banks	80.80
	-
<b>Total</b>	<b>80.80</b>

Vehicle loan from Banks is for a total of 4 vehicles (Loan from HDFC Bank for Ambulance, Fortuner and Honda WRV and loan from Axis Bank for Land Rover). The loan is secured by hypothecation of vehicles. These vehicle loans carries an interest from 8.9% to 9.25% p.a. The loans are repayable in 5 years.

**Note 6 Deferred Tax Liability**
**Balance Sheet**

Particulars	As at 31 March, 2022
<b>Deferred tax liability</b>	
Property Plant and Equipment	33.71
<b>Tax effect of items constituting deferred tax liability</b>	33.71
<b>Deferred tax asset</b>	
Employee benefits	5.58
<b>Tax effect of items constituting deferred tax assets</b>	5.58
<b>Net deferred tax liability / (asset)</b>	<b>28.13</b>

**Impact on Statement of Profit & Loss**

Particulars	As at 31 March, 2022
Property Plant and Equipment	5.04
Employee benefits	(5.58)
<b>Deferred tax expense/ (credit) charged in profit and loss</b>	<b>(0.54)</b>

**Note 7 Long Term Provisions**

Particulars	As at 31 March, 2022
Provision for Employee benefits	8.27
<b>Total</b>	<b>8.27</b>

**Note 8 Short-term borrowings**

Particulars	As at 31 March, 2022
<b>(a) Unsecured</b>	
<b>Loan from other parties ( Repayable on Demand)</b>	
DSG Investments Private Limited	229.00
Khosya Finlease Private Limited	216.00
Mourvinandan Traders & Consultants Ltd	-
SKP Leasing Limited	40.00
Acturial Leamer Island P Ltd	40.00
Pawan Motor General Finance	-
White Diamond Media	110.00
<b>(b) Current maturities of long-term borrowings (Secured)</b>	
Vehicle loan	27.69
<b>Total</b>	<b>662.69</b>

**Terms of Loan:**

(i) Unsecured loan from other parties are repayable on demand and carries interest rate of 10%

**Note 9 Trade Payables**

Particulars	As at 31 March, 2022
(i) total outstanding dues of micro enterprises and small enterprises	-
(ii) total outstanding dues for creditors other than micro enterprises and small enterprises	465.98
<b>Total</b>	<b>465.98</b>

**Trade Payables Ageing Schedule**

Particulars	As at 31 March, 2022
<b>Undisputed</b>	
<b>Due to MSME</b>	
Less than one year	-
1-2 years	-
2-3 years	-
More than 3 years	-
<b>Total</b>	
<b>Other</b>	
Less than one year	449.24
1-2 years	0.27
2-3 years	3.24
More than 3 years	13.22
<b>Total</b>	<b>465.98</b>

\* There are no vendors who have confirmed that they are covered under the Micro, Small and Medium Enterprises Development Act, 2006. Thus the disclosures relating to dues of Micro and Small enterprises under section 22 of 'The Micro, Small and Medium Enterprises Development Act, 2006, are not provided.

\*\* There are no disputed dues for trade payable

**Note 10 Other current liabilities**

Particulars	As at 31 March, 2022
Salary & Bonus Payable	281.35
Director's Remuneration Payable	153.26
Statutory dues	114.74
Interest accrued and due on unsecured borrowings	16.67
Interest accrued but not due on secured borrowings	0.46
Other expense payable	159.99
Advance from Customers	179.00
Security deposit for clinic	195.55
Other security deposit	58.10
<b>Total</b>	<b>1,159.12</b>

**Note 11 Short-term provisions**

Particulars	As at 31 March, 2022
Provision for Income Tax (Net of advance tax)	66.66
Provision for employee benefits	13.89
Provision for Corporate Social Responsibility	20.39
<b>Total</b>	<b>100.94</b>

**Note 14 Long-term loans and advances**

Particulars	As at 31 March, 2022
Capital Advances	534.51
<b>Total</b>	<b>534.51</b>

**Note 15 Other Non Current Assets**

Particulars	As at 31 March, 2022
Security Deposit	104.04
<b>Total</b>	<b>104.04</b>

**Note 16 Inventories**

Particulars	As at 31 March, 2022
<b>Valued at lower of cost or net realizable value</b>	
Stock in trade	635.62
<b>Total</b>	<b>635.62</b>

**Note 17 Trade receivables**

Particulars	As at 31 March, 2022
Secured, considered good	-
Unsecured, considered good	904.30
Doubtful	-
<b>Total</b>	<b>904.30</b>

**Trade Receivable Ageing Schedule**

Particulars	As at 31 March, 2022
<b>Undisputed trade receivable</b>	-
Less than six months	809.56
6 months - 1 year	36.93
1-2 years	14.36
2-3 years	28.12
More than 3 years	15.33
<b>Total</b>	<b>904.30</b>

\* There are no disputed trade receivables

**Note 18 Cash and cash equivalents**

Particulars	As at 31 March, 2022
Cash in hand	72.82
Balances with banks	
Current Account With Banks	146.66
Bank deposits with original maturity of less than 3 months	39.50
<b>Total</b>	<b>258.98</b>

**Note 19 Short-term loans and advances**

Particulars	As at 31 March, 2022
<b>Secured, considered good;</b>	
Advance to suppliers	216.12
Advance to Staff	11.62
Advance to Others	34.76
<b>Total</b>	<b>262.50</b>

**Note 20 Other current assets**

Particulars	As at 31 March, 2022
Prepaid Expenses	29.36
Balance with government authority	57.96
Imprest Paid to Staff	1.56
Accrued interest	2.25
<b>Total</b>	<b>91.13</b>

**Note 21 Revenue from Operations**

Particulars	For the year ended 31 March, 2022
Sale of products	13,994.35
Sale of Services	661.09
<b>Total</b>	<b>14,655.44</b>

**Note 22 Other income**

Particulars	For the year ended 31 March, 2022
Interest Income	22.26
Rental Income	14.49
Profit on Sale of Fixed Assets	79.70
Other Misc. Income	30.85
Discount Income	1.61
<b>Total</b>	<b>148.91</b>

**Note 23 Purchase of Stock in Trade**

Particulars	For the year ended 31 March, 2022
Purchase of Stock in trade	1,226.97
<b>Total</b>	<b>1,226.97</b>

The purchase of stock in trade primarily consist of ayurvedic medicine only thus, there is only one broad head i.e. Ayurvedic Medicine.

**Note 24 Changes in inventories of stock-in-trade**

Particulars	For the year ended 31 March, 2022
<b>Inventories at the end of the year/period:</b>	
Stock in trade	635.62
	635.62
<b>Inventories at the beginning of the year/period:</b>	
Stock in trade	927.86
	927.86
<b>Net (increase) / decrease in inventories of stock-in-trade</b>	<b>292.24</b>

**Note 25 Employee benefits expense**

Particulars	For the year ended 31 March, 2022
Salaries and wages	3,233.16
Contribution to provident and other funds	163.58
Gratuity Expenses	(25.73)
Staff Welfare Expenses	8.63
<b>Total</b>	<b>3,379.64</b>

**Note 26 Finance costs**

Particulars	For the year ended 31 March, 2022
<b>(a) Interest expense:</b>	
(i) Borrowings from Banks	5.80
(ii) Borrowings from Others	101.04
<b>(b) Other borrowing costs</b>	7.13
<b>Total</b>	<b>113.97</b>

**Note 27 Depreciation and amortisation expense**

Particulars	For the year ended 31 March, 2022
Depreciation on Property, Plant & Equipment	320.10
Depreciation on Intangible Assets	10.99
<b>Total</b>	<b>331.09</b>

**Note 28 Other expenses**

Particulars	For the year ended 31 March, 2022
Payments to the auditors *	10.25
Advertisement and business promotion expense	3,496.63
Corporate social responsibility expenses (Refer Note 31)	20.39
Consumable Expenses	128.13
Packing Material Expenses	37.10
Business Support Services	244.86
Freight Expenses	13.92
Annual Maintenance Charges	1.19
Call Centre Expenses	416.33
Discount Expenses	2.73
Camp Expenses	2.30
Clinic Expenses	33.28
Telephone Expenses	134.45
Postage & Courier	530.99
Printing and stationery	64.19
Office Expenses	129.75
Donation	4.78
Diwali Expenses	3.00
Bad Debts	-
Computer Expenses	47.45
Commission & Brokerage	1,611.92
Rent Expenses	179.60
Legal & Professional Charges	281.95
Loss on sale of Assets	-
Insurance expenses	2.47
Rate Fees & Taxes	20.00
Interest and penalties	4.27
Security Expenses	154.12
Uniform Expense	0.42
Hiring Charges	-
Repair & Maintenance	75.53
Food & Kitchen Expenses	40.37
Resort expenses	8.18
Vehicle Running & Maintenance	21.38
Travelling & Conveyance Expenses	68.55
Ineligible Input	43.39
Water and Electricity Charges	107.57
Miscellaneous Expenses	9.72
<b>Total</b>	<b>7,951.16</b>

**\*Payments to the auditors comprises:**

Particulars	For the year ended 31 March, 2022
As auditors - statutory audit	8.25
For taxation matters	2.00
<b>Total</b>	<b>10.25</b>

**Note 29 Earning Per Share**

**(A) Reconciliation Of Basic And Diluted Shares Used In Computing Earning Per Share**

Particulars	As at 31 March, 2022
Basic earnings per equity share - weighted average number of equity shares outstanding (Nos) - Opening	1,01,389
Add: Impact of shares issued during the year (Receipts of share call money)	7,889
Add: Bonus shares issued	1,00,00,080
<b>Basic earnings per equity share - weighted average number of equity shares outstanding (Nos) - Closing</b>	<b>1,01,09,358</b>
Add/(Less): Effect of dilutive shares (Nos)	-
<b>Diluted earnings per equity share - weighted average number of equity shares outstanding (Nos)</b>	<b>1,01,09,358</b>

**(B) Computation of basic and diluted earning per share**

Particulars	For the year ended 31 March, 2022
<b>Basic earning per share</b>	
Profit after tax	1,123.24
Weighted average number of shares (For Basic EPS)	1,01,09,358
<b>Basic EPS</b>	<b>11.11</b>
<b>Diluted earning per share</b>	
Profit after tax	1,123.24
Add/(less): Effect of dilution on profit	-
Revised profit after tax	1,123.24
Weighted average number of shares (For Diluted EPS)	1,01,09,358
<b>Diluted EPS</b>	<b>11.11</b>

**Note 30: Employee benefit Plan**

**(A) Defined benefit Plan**

The defined benefit plan operated by the Company is as below:

**Retiring gratuity**

The Company has an obligation towards gratuity, a defined benefit retirement plan covering eligible employees. The plan provides for a lump-sum payment to vested employees at retirement, death while in employment or on termination of employment of an amount equivalent to 15 to 30 days salary payable for each completed year of service. Vesting occurs upon completion of five years of service. The Company does not make any contributions to gratuity funds and the plan is unfunded. The Company accounts for the liability for gratuity benefits payable in the future based on an actuarial valuation.

The defined benefit plans expose the Company to a number of actuarial risks as below:

- (a) **Interest risk:** A decrease in the bond interest rate will increase the plan liability.
- (b) **Salary risk:** The present value of the defined benefit plan liability is calculated by reference to the future salaries of plan participants. As such, an increase in the salary of the plan participants will increase the plan's liability.
- (c) **Longevity risk:** The present value of the defined benefit plan liability is calculated by reference to the best estimate of the mortality of plan participants. An increase in the life expectancy of the plan participants will increase the plan's liability.

The following table sets out the amounts recognised in the financial statements in respect of retiring

**(i) Change in Defined Benefit Obligation (DBO) during the year**

Particulars	31.03.2022
Present value of DBO at the beginning of the year	47.90
Current service cost	24.78
Interest cost	2.49
Actuarial (gain) / loss	(53.00)
Benefits paid	-
<b>Present value of DBO at the end of the year</b>	<b>22.17</b>

**(ii) Change in fair value of plant assets during the year**

Particulars	31.03.2022
Fair value of plan assets at the beginning of the year	-
Interest income	-
Employer contributions	-
Benefits paid	-
<b>Fair value of plan assets at the end of the year</b>	<b>-</b>

**(iii) Amounts recognised in the Balance Sheet**

Particulars	31.03.2022
Present value of DBO at the end of the year	22.17
Fair value of plan assets at the end of the year	-
<b>Net Liability recognised in the Balance Sheet</b>	<b>22.17</b>

**(iv) Components of employer expense**

<b>Particulars</b>	<b>For the year ended 31st March 2022</b>
Current service cost	24.78
Interest cost	2.49
Actuarial (gain) / loss	(53.00)
<b>Expense recognised in Statement of Profit and Loss</b>	<b>(25.73)</b>

**(v) Nature and extent of investment details of the plan assets**

<b>Particulars</b>	<b>For the year ended 31st March 2022</b>
State and Central Securities	0%
Bonds	0%
Special deposits	0%
Insurer managed funds	0%

**(vi) Assumptions**

<b>Particulars</b>	<b>For the year ended 31st March 2022</b>
Discount Rate	4.60%
Rate of increase in Compensation levels	5.00%
Rate of Return on Plan Assets	NA
Withdrawal rates	90.00% p.a at all ages

**(B) Defined Contribution Plan**

**Provident fund and pension**

In accordance with the Employee's Provident Fund and Miscellaneous Provisions Act, 1952, eligible employees of the Company are entitled to receive benefits in respect of provident fund, a defined contribution plan, in which both employees and the Company make monthly contributions at a specified percentage of the covered employees' salary. The contributions, as specified under the law, are made to the employee provident fund organization (EPFO).

The total expenses recognised in the statement of profit and loss during the year on account of defined contribution plans amounted to Rs. 96.46 Lakhs

**Note 31 Corporate social responsibility expenses**

Particulars	For the year ended 31st March 2022
a) Gross amount required to be spent by the Company during the year/period	20.39
b) Gross amount provided for CSR activities	20.39
c) Amount spent during the period / year	-
d) shortfall at the end of the period / year	20.39
e) total of previous years shortfall,	20.39
f) reason for shortfall	Balance amount will be spended by AGM
g) nature of CSR activities,	
<b>Eradicating Hunger, Poverty &amp; Malnutrition, Promoting preventive health care, education and sanitation and making available safe drinking water</b>	

**Note 32 Segment reporting**

The company operates only in one business segment viz "Trading of Ayurvedic Medicines ". Therefore, a separate segment wise reporting is not required.

**Note 33 Related party disclosures**

**A. Names of related parties and nature of relationship :**

Description of relationship	Names of related parties
Key Management Personnel (KMP)	Sh. Manish Grover (Director) Smt. Bhavna Grover (Director)
Entities in which KMP / Relatives of KMP can exercise significant influence	Divya Upchar Sansthan

**B) Transactions with related parties are as follows :**

Particular	Key Management Personnel (KMP)	Entities in which KMP / Relatives of KMP can exercise significant influence	Total
<b>(i) Salary, allowances and bonus</b>			
March 31, 2022	372.00		372.00
March 31, 2021	276.00	-	276.00
<b>(ii) Sale of goods</b>			
March 31, 2022		591.73	591.73
March 31, 2021	-	352.08	352.08
<b>(iii) Receiving of services</b>			
March 31, 2022	-	60.50	60.50
March 31, 2021	-	40.50	40.50

**B) Balances outstanding are as follows:**

Particular	Key Management Personnel (KMP)	Entities in which KMP / Relatives of KMP can exercise significant influence	Total
<b>(i) Salary, allowances and bonus</b>			
March 31, 2022	153.25		153.25
March 31, 2021	18.26	-	18.26
<b>(ii) Imprest</b>			
March 31, 2022	0.17	-	0.17
March 31, 2021	10.69	-	10.69
<b>(iii) Trade payables</b>			
March 31, 2022	-	6.96	6.96
March 31, 2021	-	7.91	7.91
<b>(iv) Trade receivable</b>			
March 31, 2022		9.18	9.18
March 31, 2021	-	-	-

**Note 34 Disclosure on significant ratios**

	As at 31 March, 2022
Current Ratio	0.90
Debt-Equity Ratio,	0.17
Debt Service Coverage Ratio	17.15
Return on Equity Ratio	0.31
Inventory turnover ratio	1.93
Trade Receivables turnover ratio	16.21
Trade payables turnover ratio	2.63
Net capital turnover ratio	-62.05
Net profit ratio	7.66%
Return on Capital employed	30.76%

# Not annualized

As there are no comparative figures, the % change from year to year has not been calculated

**Methodology:**

1. Current Ratio = Current Asset / Current Liability
2. Debt-Equity Ratio = Total Debt / (Total Debt + Equity)
3. Debt Service Coverage Ratio = EBITDA / Finance Cost
4. Return on Equity Ratio = Profit After Tax / Total Equity
5. Inventory Turnover Ratio = Purchase / Inventory
6. Trade Receivable Turnover Ratio = Revenue from Operations / Trade Receivable
7. Trade Payable Turnover Ratio = Purchase / Trade Payable
8. Net Capital Turnover Ratio = Revenue from Operations / (Current Asset - Current Liability)
9. Net Profit Ratio = Profit After Tax / Revenue from Operations
10. Return on Capital Employed = Profit After tax / Total Equity

**Note 35 Information on share of net asset and profit and loss**

Name of the entity	Net Asset		Share in profit or loss	
	As % of consolidated net assets	Amount	As % of consolidated profit or loss	Amount
Jeena Sikho Lifecare Limited (Parent Company)	100%	3,655.53	100%	1,127.24
Minority Interest	0%	(4.01)	0%	(4.01)
		<b>3,651.52</b>		<b>1,123.24</b>

**Note 36 Information on subsidiary**

Particular	
Name of subsidiary	Shuddhi Green Charcoal Private Limited
Reporting currency	INR
Share Capital	1 Lakh
Reserve	(7.86 Lakhs)
Total Asset	137.89 Lakhs
Total Liability	144.75 Lakhs
Turnover	10.12 Lakhs
Loss before taxation	(7.52 Lakhs)
Tax expense	(0.34 Lakhs)
% of shareholding	51%

**Note 37 Other Notes**

- (i) In the opinion of the Board of Directors and Management, all the assets other than, Property, Plant and Equipment, Intangible assets and non-current investments have a value on realisation in the ordinary course of business which is at least equal to the amount at which they are stated.
- (ii) This is the first year when company has prepared the Consolidated Financial Statements as the subsidiary company was acquired in FY 2021-22 itself. Therefore, there are no consolidated financial statements for YE 31.03.2021
- (iii) Figures for the previous year have been re-grouped/ rearranged/ restated wherever necessary to make them comparable with those of the current year.

As per our report of even date

**For KRA & Co.**  
Chartered Accountants  
Firm Regd. No.020266N

**For and on behalf of the Board of Directors**  
**JEENA SIKHO LIFECARE LIMITED**

**Saurabh Garg**  
**(Partner)**  
M.No. 510541  
Place: New Delhi  
UDIN: 22510541ANOMXC1173  
Dated: 25/07/2022

Sd/-  
**Manish Grover**  
Managing Director  
DIN: 07557886

Sd/-  
**Bhavna Grover**  
Whole-Time Director  
DIN: 07557913

Sd/-  
Nanak Chand  
**(Chief Financial Officer)**

Sd/-  
Nikita Juneja  
**(Company Secretary)**  
(M No. - A65160)